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1. Introduction 
 
1.1. Biological sources of ROS and its role in diverse biological 
processes 
 
Reactive oxygen species (ROS) is a collective term and includes superoxide anion (O2–), 
hydrogen peroxide (H2O2), hydroxyl radical (HO•), hydroperoxy radical (HO2•), peroxyl radical 
(RO2•) and alkoxyl radical (RO•). Among them, hydrogen peroxide (H2O2) is the most 
extensively studied one. Most biological sources of H2O2 involve the spontaneous or catalytic 
breakdown of superoxide anion (O2−), generated by the partial reduction of oxygen during 
mitochondrial respiration (Boveris, 1984) . Also, exposure of cells to a variety of physical, 
chemical, and biological agents causes ROS accumulation. For instance, immune cells 
activate the NADPH oxidase complex to generate superoxide and hydrogen peroxide as a 
cytotoxic agent during microbial defence. Furthermore, UV light and ionising radiation causes 
oxidative stress as well. There is increasing evidence that cells produce H2O2 transiently in 
response to the activation of various cell-surface receptors. Various growth factors and 
cytokines, including PDGF, EGF, insulin, angiotensin II, and TNFα, generate hydrogen 
peroxide in target cells (D'Autreaux and Toledano, 2007; Geiszt and Leto, 2004; Park et al., 
2004a) . Thus, beyond its toxic effects H2O2 has been recognized as an important 
intracellular messenger that modifies protein function through the oxidation of critical cysteine 
residues of many proteins including protein tyrosine phosphatases (Choi et al., 2005; 
DeYulia et al., 2005; Finkel, 1998; Rhee, 1999; Rhee et al., 2000; Rhee et al., 2005). If the 
physiological threshold level of H2O2 is not exceeded, it will have an affirmative effect on the 
cell processes, such as receptor-mediated cell signalling pathways, normal cell proliferation, 
and transcriptional activation. On the contrary, the chronic presence of peroxides and oxygen 
radicals is a risk factor to cells because they may damage cellular components, which is 
often associated with the initiation and progression of many degenerative diseases. 
Therefore, it is no surprise that the generation of H2O2 and other reactive oxygen species 
(ROS) is a tightly regulated process. 
 
In addition to non-enzymatic antioxidants, among which glutathione (GSH), cysteine, vitamin 
C and E are well known, cells contain a variety of antioxidant enzymes which contribute to 
controlling the level of cellular ROS. The major antioxidant enzymes involved in the catalytic 
breakdown of ROS are superoxide dismutase (SOD), catalase, thioredoxin reductase 
(Txnrd), peroxiredoxins (Prx) and glutathione peroxidase (GPx). Catalase is a highly efficient 
enzyme that utilizes a heme prosthetic group, while the catalytic reduction of hydrogen 
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peroxide by thioredoxin peroxidases involves the oxidation of catalytic cysteine residues. The 
catalytic mechanism of thioredoxin reductases and glutathione peroxidases involves the 
cyclic oxidation/reduction of catalytic cysteine and selenocysteine residues. 
 
1.2. Selenoproteins 
 
Selenium (Se) is an essential trace element whose deficiency in mammals interferes with 
normal embryonic development and fertility or may even favour the development of certain 
cancers (Beck and Levander, 1998). Evidence for a molecular link between selenium 
deficiency and biological disorders was provided by knock-out mouse studies. Targeted 
disruption of the mouse selenocysteine-specific tRNA gene, Trsp, leads to early embryonic 
lethality, confirming that selenoprotein synthesis is essential for mammals (Bosl et al., 1997). 
Further studies carried out with knock-out mice for individual selenoproteins underlined the 
long-discussed protective role of selenium in form of selenocysteine against free radicals and 
different pathologies (Bondareva et al., 2007; Brigelius-Flohe and Banning, 2006; Conrad et 
al., 2004; Crack et al., 2001; Hill et al., 2007; Jakupoglu et al., 2005; Rohrbach et al., 2006; 
Rundlof and Arner, 2004; Schneider et al., 2009; Schweizer et al., 2004; Seiler et al., 2008; 
Soerensen et al., 2008; Yamamoto et al., 1993; Yoshida et al., 1997). The amino acid 
selenocysteine (Sec) is the major biological form of selenium in bacteria and animals. It is 
normally found in the active site of selenoproteins and is directly involved in the catalytic 
reaction. In this regard, the capacity of the selenol group (-SeH) to become ionized at 
physiological pH is higher than that for the cysteine thiol group (-SH), which usually requires 
a higher pH. This fact has been considered to account for the higher rate of selenoenzyme 
catalysis (Stadtman, 1991). Few selenoprotein families have been characterized so far in 
mammals. Thioredoxin reductase and glutathione peroxidase families are crucially involved 
in the scavenging of ROS and maintaining the redox status of the cell. The iodothyronine 
deiodinases (DIOs) family consists of three Sec-containing oxidoreductases (DIO1, DIO2, 
DIO3) that catalyze the activation (DIO1 and DIO2) and inactivation (DIO3) of the thyroid 
hormones thyroxine (T4), triiodothyronine (T3) and reverse-triiodothyronine (rT3) by 
removing distinct iodine moieties. Mammals express various other selenoproteins whose 
functions are still widely unknown; likewise, knowledge on structural data is still very limited 
(SelH, SelI, SelO, SelT, SelV-function unknown; SelK, SelR, SelW-antioxidant enzymes; 
SelM, SelN, SelS-protein folding and SelP has a function of transport and storage of 
selenium). The reason for the lack of knowledge is either their very recent discovery or 
general technical difficulties in the analysis of selenoprotein function due to their relatively 
low abundance in cells and tissues. 
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1.2.1. Incorporation of selenium  
 
Available evidence suggests that the principle of selenoprotein synthesis has been 
conserved during evolution (Atkins and Gesteland, 2000; Birringer et al., 2002; Driscoll and 
Copeland, 2003; Hirosawa-Takamori et al., 2004; Hirosawa-Takamori et al., 2000; Low and 
Berry, 1996). Sec is encoded by an in-frame UGA codon (opal codon), implying the 
existence of a machinery capable of distinguishing the UGA codon from a translational stop. 
Decoding UGA as Sec requires the presence of a Sec-specific tRNA, the Sec insertion 
sequence (SECIS) element and several protein factors acting in trans (Figure 1). 
 
The Sec-specific tRNA is designated as tRNA[Ser]Sec. In contrast to the other 20 amino acids, 
the 21st proteinogenic amino Sec is synthesised directly on the tRNA by incorporation of 
selenium into the amino acid serine. Seryl-tRNA synthetase attaches serine to tRNA[Ser]Sec to 
yield seryl-tRNA[Ser]Sec. The phosphoseryl-tRNA kinase phosphorylates this complex to give 
phosphoseryl-tRNA[Ser]Sec. It is believed that the phosphate of phosphoseryl-tRNA[Ser]Sec is 
replaced by the selenium donor selenide (H2Se-P) which is activated by selenophosphate 
synthetase. The resulting selenocysteyl-tRNA[Ser]Sec provides the Sec for the growing 
polypeptide chain (Xu et al., 2007). 
 
One more essential factor for Sec incorporation is the SECIS element, a stem-loop-like 
secondary structure located in the 3'-untranslated region of selenoprotein mRNAs (Low and 
Berry, 1996). SECIS elements from different selenoproteins in general display low sequence 
similarities; however, their secondary structures are very similar and they contain consensus 
sequences that are necessary for Sec incorporation (Krol, 2002). 
 
Besides these two elements, Sec-decoding requires the concerted action of several factors 
acting in trans. In mammals these are: the SECIS-binding protein 2 (SBP2) (Copeland and 
Driscoll, 1999; Copeland et al., 2000), the Sec-specific elongation factor (EFSec) (Fomenko 
and Gladyshev, 2003; Tujebajeva et al., 2000), ribosomal protein L30 (rpL30) (Chavatte et 
al., 2005), the 43-kDa RNA-binding protein (Secp43) and the soluble liver antigen protein 
(SLA) or Sec synthase (Figure 1) (Xu et al., 2005). Of these, SBP2 is the best characterised 
component of the UGA decoding machinery. SBP2 itself is a selenoprotein in organisms 
which do express selenoproteins. It is ubiquitously expressed in tissues and may be encoded 
by several transcripts (Copeland et al., 2000). SBP2 contains an RNA-binding domain 
(RBD), through which it binds to one of the consensus sequences within the SECIS elements 
(Fletcher et al., 2001; Walczak et al., 1998) and thereby interacts with the 28s ribosomal 
RNA (Copeland et al., 2001). Moreover, SBP2 contains a few other functional motifs: an 
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N-terminal nuclear localization signal (NLS) (Papp et al., 2006), a C-terminal NLS (de Jesus 
et al., 2006), two C-terminal nuclear export signals (NESs) (Papp et al., 2006), a functional 
domain dispensable for SECIS binding but required for Sec incorporation activity (Copeland 
et al., 2001), and a ribosomal interaction domain (Copeland et al., 2001; Kinzy et al., 2005). 
EFSec is the Sec-specific elongation factor that simultaneously interacts with Sec-tRNA[Ser]Sec 
and SBP2 (Fagegaltier et al., 2000; Tujebajeva et al., 2000). The role of Sec-tRNA[Ser]Sec has 
a stabilizing effect on the elongation factor in building the SBP2-EFSec complex (Zavacki et 
al., 2003), which might form in the nucleus as well as in the cytoplasm (Small-Howard et al., 
2006). 
 
Another trans-acting factor of the UGA translation machinery is the ribosomal protein L30. 
This element has an RNA-binding motif (Chen et al., 2003), which belongs to the same RBD  
type as the RBD of SPS2. Recent molecular and biochemical studies with rpL30 revealed 
that it binds specifically to the SECIS element, and thereby stimulates UGA codon read-
through (Chavatte et al., 2005). It seems, however, that rpL30 and SBP2 do not bind to the 
SECIS element simultaneously. Rather, they mutually bind the SECIS element in a 
competitive manner and are able to displace each other from the SECIS element (Chavatte 
et al., 2005). RpL30 appears to bind preferentially to a conformationally altered SECIS 
element. A model has been proposed, in which rpL30-binding to the SECIS element leads to 
a conformational change, inducing SBP2 release and thus promoting the delivery of Sec-
tRNA[Ser]Sec to the ribosomal A site (Figure 1). 
 
The roles for SECp43 and SLA in selenoprotein synthesis were recently characterized. 
Soluble liver antigen (SLA) was isolated by autoantibody precipitation (Gelpi et al., 1992) and 
the protein was found to be associated with a Sec-tRNA[Ser]Sec. SECp43 was identified 
independently, based on its ability to specifically precipitate Sec-tRNA[Ser]Sec from mammalian 
cell lysates. One of the identified SECp43 binding partners was a 48-kDa protein (Ding and 
Grabowski, 1999) now referred to as SLA (Xu et al., 2007; Xu et al., 2005). SECp43 has two 
ribonucleoprotein-binding domains (RNPs). Like SLA and Sec tRNA[Ser]Sec, SECp43 form a 
complex in cell lysates, and depletion of either SECp43 or SLA decreases the binding of the 
remaining protein to the Sec-tRNA[Ser]Sec (Xu et al., 2005). SECp43 normally resides in the 
nuclear compartment and is able to sequester SLA from the cytoplasm. Combined depletion 
of both proteins causes a global decrease in selenoprotein synthesis (Xu et al., 2005). 
Another study has shown that SECp43 plays an important role in the formation or 
stabilization of the EFSec–SBP2–Sec tRNA[Ser]Sec complex (Small-Howard et al., 2006). All 
these studies suggest that SECp43 and SLA are involved in the mechanism of Sec 
biosynthesis and Sec incorporation. 
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Figure 1. Mechanism of co-translational Sec incorporation. The tRNA (red), carrying Sec (yellow) is depicted in 
the complex required for co-translational Sec incorporation: EFsec (light green), SBP2 (blue), SLA (dark green), 
SECp43 (pink) and rpL30 (grey) and the SECIS element (black hairpin loop). Only when these factors are present 
and arranged in this manner, the opal codon (UGA) serves as a Sec codon, and Sec can be co-translationally 
incorporated into the nascent polypeptide chain. Translational start and stop codons of the mRNA are indicated by 
green and red arrows, respectively. The ribosome (large green) contains three RNA binding sites, designated as A, 
P, and E. The A site binds a tRNA bound to an amino acid; the P site binds a tRNA bound to the peptide being 
synthesized; and the E site binds a free tRNA before it exits the ribosome.  
 
1.2.2. Family of thioredoxin reductases 
 
The three members of the mammalian thioredoxin reductase family are homodimeric 
flavoproteins in which each monomer binds FAD as a prosthetic group. Each monomer has 
one NADPH binding site, an interface for dimerization, and two catalytic sites localised at the 
N- and C- termini (Holmgren, 1989). 
 
Thioredoxin reductases differ fundamentally between lower and higher organisms. The 
enzyme in eukaryotic organisms is more closely related to glutathione reductase (GR) than 
to bacterial thioredoxin reductase, being larger, having broader substrate specificity and an 
additional redox-active motif, which, at least in mammals, contains Sec (Gladyshev et al., 
1996; Papp et al., 2006). 
 
The main substrates of thioredoxin reductases are oxidized thioredoxins (Trx) (Figure 2). 
There are two major thioredoxins in mammals, one primarily localised in the cytosol (Trx1) 
and one in mitochondria (Trx2). The expression of these relatively small (12 kDa), 
redox-active proteins is essential for embryonic development as knock-out for both Trx1 and 
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Trx2 is embryonic lethal at E6.5 and E10.5, respectively (Matsui et al., 1996; Nonn et al., 
2003b). Thioredoxins are characterised by a conserved -Trp-Cys-Gly-Pro-Cys-Lys- catalytic 
site that undergoes reversible oxidation/reduction of the two Cys residues. The redox activity 
of this catalytic site is necessary for the biological activity of Trx (Freemerman et al., 1999; 
Gasdaska et al., 1994). 
 
 
 
Figure 2. The thioredoxin/thioredoxin reductase system. The figure schematically depicts the reduction of the 
active site disulfide in oxidized thioredoxin (Trx-S2) to a dithiol of reduced thioredoxin (Trx-(SH)2) by mitochondrial 
thioredoxin reductase (Txnrd2) and NADPH. Trx-(SH)2 reduces protein disulfides by its oxidoreductase activity, 
whereby it becomes oxidised (Trx-S2). Mammalian thioredoxin reductases have various substrates other than 
thioredoxins (Arner and Holmgren, 2000).  
 
The major functions of Trx are the supply of reducing equivalents to enzymes, including 
thioredoxin peroxidases (Chae et al., 1994; Rhee et al., 2005; Watabe et al., 1997). 
Moreover thioredoxin was initially described in E.coli as an essential co-factor for 
ribonucleotide reductase which converts NTPs into dNTPs (Laurent et al., 1964). Through 
thiol-disulphide exchange reactions, thioredoxins reduce key Cys residues in certain 
transcription factors, resulting in their increased binding to DNA and altered gene 
transcription (Nordberg and Arner, 2001). Mammalian Trxs have also been shown to function 
as cell growth factors and to inhibit apoptosis (Baker et al., 1997; Gasdaska et al., 1995a). 
Since thioredoxin reductases are the only class of enzymes known to reduce oxidized Trx, it 
is very likely that alterations in reductase activity may compromise Trx activities. Besides 
thioredoxins, a large number of small molecules have been shown to be substrates of Txnrds 
(Figure 2). These include lipoic acid (Arner et al., 1996), H2O2, lipid hydroperoxides 
(Bjornstedt et al., 1995), cytotoxic peptide NK-lysin (Andersson et al., 1996), vitamin K3 
(Holmgren, 1985), dehydroascorbic acid (May et al., 1998), the ascorbyl free radical (May et 
al., 1998) and many selenium-containing molecules, such as selenite, selenodiglutathione, 
methyseleninate, selenocystine, and ebselen (Bjornstedt et al., 1995; Gromer and Gross, 
2002; Kumar et al., 1992; Park et al., 2004b; Persson-Moschos et al., 2000). However, the 
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physiological relevance in the reduction of most of these substrates by thioredoxin reductase 
is not known. 
 
Three distinct mammalian thioredoxin reductases have been identified: cytosolic thioredoxin 
reductase (Txnrd1) (Tamura and Stadtman, 1996), mitochondrial thioredoxin reductase 
(Txnrd2) (Gasdaska et al., 1999b; Lee et al., 1999; Miranda-Vizuete et al., 1999; Watabe et 
al., 1999) and a testis-specific enzyme thioredoxin-glutathione reductase (Txnrd3/TGR) (Sun 
et al., 2001a; Sun et al., 1999). Mammalian thioredoxin reductases are encoded by three 
distinctive genes; yet, they share general domain organization (Figure 3).  
 
Both Txnrd1 and Txnrd2 express various isoforms some of which are well characterised. An 
evolutionary conserved genetic mechanism contributes to the heterogeneity of Txnrds and 
suggests the existence of a greater variety of Txrnd species with different regulation and 
cellular functions (Rundlof and Arner, 2004; Rundlof et al., 2000; Rundlof et al., 2007; Su and 
Gladyshev, 2004; Sun et al., 2001b; Turanov et al., 2006). Both cytosolic and mitochondrial 
Txnrd are essential for murine embryogenesis. The genetic deletion of either gene was 
shown to cause embryonic lethality (Bondareva et al., 2007; Conrad et al., 2004; Jakupoglu 
et al., 2005). 
 
1.2.3 Mammalian thioredoxin system 
 
1.2.3.1. Cytosolic thioredoxin reductase (Txnrd1) 
 
Txnrd1 is the most studied enzyme of the thioredoxin reductase family. Predominantly 
localised in cytosol, this enzyme has a wide range of functions in cells, including the 
regulation of cell proliferation and differentiation, modulation of the immune system, 
antioxidant defence, redox control of transcription factors, and in the development of cancer 
(Arner and Holmgren, 2006; Gromer et al., 2004). 
 
Transcription of cytosolic thioredoxin reductase involves complex alternative splicing and 
transcription initiation leading to a large number of different isoforms that differ from each 
other at their N-termini (Rundlof et al., 2007; Su and Gladyshev, 2004; Sun et al., 2001b). A 
study by Sun QA and colleagues provided evidence for first alternative exon splicing, thus 
yielding various different forms of mouse and rat Txnrd1 mRNA. Three alternative forms of 
Txnrd1 mRNA were described from a single Txnrd1 gene by transcription initiation at exons 
1, 2, or 3 (Sun et al., 2001b). The next study identified six human TXNRD1 isoforms that 
were derived from a large number of transcripts and differed in their N-terminal sequences 
(Su and Gladyshev, 2004). Similarly, the study by Rundlof AK et al., provided evidence for a 
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core promoter region of TXNRD1 in A549 and HeLa cells. This study identified several 
TXNRD1 transcripts in the 5′-region using cDNA derived from different tissues. The results 
show that the core promoter governs transcription of the majority of TXNRD1 transcripts but 
also shows that alternative promoters may be activated under rare conditions or in specific 
cell types. Furthermore, extensive alternative splicing occurred in the 5′ region of TXNRD1. 
In total, 21 different transcripts were identified, potentially encoding five isoforms of TXNRD1 
carrying alternative N-terminal domains (Rundlof et al., 2007).  
 
1.2.3.2. Txnrd3  
 
The thioredoxin reductase isoenzyme TGR, encoded by the Txnrd3 gene, is similar to the 
two other reductases, although Txnrd3 appears to be evolutionary more distant than Txnrd1 
and Txnrd2. At the N-terminus it contains a monothiol Grx extension conferring both 
glutathione and glutaredoxin reductase activity (Sun et al., 2001a; Sun et al., 1999). The 
Txnrd3 enzyme is mainly expressed in early spermatids, and is suggested to participate in 
redox reactions required during sperm maturation (Su et al., 2005; Sun et al., 2001a; Sun et 
al., 2005).  
 
1.2.3.3. Mitochondrial thioredoxin reductase (Txnrd2) 
 
1.2.3.3.1. The molecular structure and catalytic mechanism of Txnrd2 
 
For the time being, four papers describing mouse, human, rat and bovine mitochondrial 
thioredoxin reductase, have been reported (Gasdaska et al., 1999a; Gasdaska et al., 1999b; 
Lee et al., 1999; Miranda-Vizuete et al., 1999; Watabe et al., 1999). When it was cloned, it 
was shown that Txnrd2 has more than 50% sequence identity to both rat (Zhong et al., 1998) 
and human (Gasdaska et al., 1995b) Txnrd1 (Lee et al., 1999). However, Txnrd2 contains 36 
additional amino acid residues at its N-terminus, which displays features typical of a 
mitochondrial leader sequences. Furthermore, rat Txnrd2 shows 50% similarity to the human 
glutathione reductase  (Lee et al., 1999; Watabe et al., 1999; Zhong et al., 2000)(Figure 3). 
Several biochemical and computational studies have been performed to elucidate the 
catalytic mechanisms of Txnrd2 and other family members. Structural analyses confirmed 
the ‘‘head-to-tail’’ arrangement with the redox-active C-terminal center of one subunit 
interacting with the active N-terminal site of the opposing subunit (Figure 3) (Sandalova et 
al., 2001; Zhong et al., 2000). More specifically, each Txnrd2 subunit is comprised of three 
domains: an FAD-binding domain (residues 35–190 and 322–392), an NADPH-binding 
domain (residues 191–321) and an interface domain (residues 393–524) (Biterova et al., 
2005; Sandalova et al., 2001). 
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Figure 3. Model of mammalian Txnrd structure. The structure of mammalian Txnrd is based on the homology 
to GR. Model of Txnrd with FAD (light green), NADPH (purple) and interface domains (green) (adapted from 
(Zhong et al., 2000). Active-site cysteines and the Sec (filled circles) are indicated. FAD is represented only with 
isoalloxazine ring and NADPH with the adenosine structure. 
 
Txnrd1 was the first thioredoxin reductase to be discovered; considering the high structural 
homology between Txnrds, the proposed basic mechanism by which Txnrd1 reduces its 
substrates is most likely the same for Txnrd2. Hence, electrons are first transferred from 
NADPH to FAD, which then leads to the reduction of the cysteines of the N-terminal 
conserved redox-active catalytic site -Cys-Val-Asn-Val-Gly-Cys-  (Gasdaska et al., 1999b; 
Sandalova et al., 2001)(Figure 4). The electrons are further passed on to the highly flexible 
C-terminal catalytic site -Gly-Cys-Sec-Gly of the adjacent subunit (Gladyshev et al., 1996; 
Lee et al., 1999; Miranda-Vizuete et al., 1999; Sandalova et al., 2001; Tamura and 
Stadtman, 1996; Watabe et al., 1999; Williams et al., 2000; Zhong et al., 2000). The 
C-terminal catalytic site eventually reduces its substrates including oxidised thioredoxin. 
Once reduced, the enzyme catalyzes a selenenylsulfide exchange between the reduced 
C-terminus and oxidized thioredoxin (Arner and Holmgren, 2000; Bauer et al., 2003; Brandt 
and Wessjohann, 2005; Gilberger et al., 1997; Gromer et al., 1998; Sun et al., 2001a; 
Williams et al., 2000). 
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Figure 4. Postulated mechanism of Trx reduction. (1) The catalytic reaction starts by reduction of the 
selenenylsulfide to yield the selenolate (Se−) anion. The selenenylsulfide receives electrons from NADPH via FAD 
and the N-terminal redox-active dithiol of the first subunit to generate 2) a sulfhydryl and a selenol (-SeH) or 
selenolate anion (-Se−) at the C-terminus of the second subunit. The selenolate anion (-Se−) performs a 
nucleophilic attack of the disulfide of Trx. The resulting enzyme-substrate mixed selenenylsulfide 3) is attacked by 
the neighbouring “releasing” Cys to release fully reduce Trx, thereby forming the selenenylsulfide. The latter 4) is 
then reduced by the N-terminal active-site thiolate from the other subunit. During the catalytic reaction cycle, the 
active-site dithiol maintains the selenol in the reduced state. The selenolate anion is both a better nucleophile and 
a better leaving group than the thiolate anion. Because of the low pKa of the selenol, the selenolate anion is 
considered to be the predominant form under physiological conditions (adopted from (Zhong et al., 2000) 
 
The expression of multiple Txnrds isoforms was first described for Txnrd1 (Gladyshev et al., 
1996; Sun et al., 2001a; Tamura and Stadtman, 1996). Later on, some splicing variants were 
also predicted for Txnrd2 (Lescure et al., 1999; Miranda-Vizuete and Spyrou, 2002; Sun et 
al., 2001a), and shortly after confirmed and further characterised (Turanov et al., 2006) 
(Figure 5). 
 
 
 
Figure 5. Structural organisation of the 5´region of the mouse, rat and human Txnrd2 genes. Only the first 
four exons of a total of 18 exons are shown. Alternative transcription initiation determines which Txnrd2 transcript 
is generated in cells. The three forms utilize alternative first exons 1–3, followed by the common exons 4 to 18. 
Exon 2a encodes only for three amino acids (in mice and rats), exon 2b encodes 12 amino acids (in mice and 
humans), while the classical exon 1 encodes 36 amino acids, including the mitochondrial leader sequence. 
(adapted from (Turanov et al., 2006). 
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The three Txnrd2 isoforms are generated by alternative transcription initiation at the 5´ 
region. Hence, the Txnrd2 variants differ in their N-termini (Turanov et al., 2006). The same 
genomic organisation and the same Txnrd2 variants were also detected in mouse, human 
and rat, suggesting a high conservation of alternative splicing among the different organisms. 
The predominant form of Txnrd2 contains a N-terminal signal peptide necessary for 
mitochondrial targeting (mitochondrial leader sequence, MLS) (Figure 5, mitochondrial 
Txnrd2) (Lee et al., 1999; Watabe et al., 1999; Zhong et al., 2000). The two other isoforms 
(Figure 5, cytoplasmatic Txnrd2 2b and 2a) have shorter N-terminal sequences and are 
localised in cytosol. Additionally, it was shown that the protein Txnrd2 2b resides neither in 
the endoplasmic reticulum nor in lysosomes (Turanov et al., 2006). 
 
1.2.3.3.2. Cellular functions of Trx2 and Txnrd2 
 
Eukaryotic mitochondria are equipped with a thioredoxin system, composed of mitochondrial 
thioredoxin (Trx2) and mitochondrial thioredoxin reductase (Txnrd2). Both enzymes are 
essential in mammals (Conrad et al., 2004; Nonn et al., 2003b); however the physiological 
functions of Trx2 and Txnrd2 are far less understood than that for the cytoplasmatic 
thioredoxin system, consisting of Txnrd1 and Trx1. 
 
In fact, it has been proposed that the main function of the mitochondrial thioredoxin-
dependent system is to act as the major antioxidant device, controlling the level of ROS in 
mitochondria. The antioxidant function of mitochondrial thioredoxin either relies on its direct 
scavenging properties (Tanaka et al., 2002) or by reducing the mitochondrial thioredoxin-
dependent peroxidases (Araki et al., 1999; Pedrajas et al., 2000; Watabe et al., 1995; 
Watabe et al., 1997). Nalvarte et al. showed ex vivo, that cytochrome c is reduced by Txnrd2 
(Nalvarte et al., 2004b). Thus it was proposed that in vivo Trx2 may recruit cytochrome c to 
keep it in closer proximity to Txnrd2, which would allow electrons to bypass complex III 
during cytochrome c reduction. This hypothesis might be valuable in understanding the 
pathophysiology of diseases induced by dysfunctional mitochondrial respiration, such as 
cardiomyopathies and encephalomyopathies (Keightley et al., 2000; Lerman-Sagie et al., 
2001). Moreover, Txnrd2 may also be involved in the redox regulation of the mitochondrial 
estrogen receptor (Nalvarte et al., 2004b). 
 
Furthermore, using a Tet-off expression system for an alternative splicing variant of TXNRD2 
it was found that this form impaired Txnrd2 activity altered cellular ROS levels and increased 
apoptosis (Chang et al., 2005). By using a very similar system, when cells were expressing a 
dominant-negative form of TXNRD2 (DNTXNRD2) were stimulated with epidermal growth 
factor (EGF), they were found to produce more H2O2 than normal cells (Kim et al., 2003b). 
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Overexpression of dominant-negative Txnrd2 was shown to perturb proper electron flow from 
NADPH via Trx2 to Prx III, thus impinging on cellular redox imbalance. Stimulation of these 
cells with EGF then alters the cellular redox status and affects signalling pathways mediated 
through tyrosine phosphorylation of ERKs (extracellular signal-regulated kinases). 
Furthermore, another laboratory reported that overexpressing either Trx2 or Txnrd2 reduces 
p42/p44 MAPK signalling (Zhou et al., 2008). Collectively, these results indicate that the 
forced expression of Trx2 and Txnrd2 decreases intracellular ROS, leading to reduced cell 
growth. Contrary, the overexpression of DNTXNRD2 accelerates transition of the cells from 
G1 to S phase and expression of some cyclins (A, B, D3), CDKs (2, 4), and p27 (Kim et al., 
2003b). 
 
1.2.3.3.3. Knock-out mouse model for Txnrd2 
 
Mice with spatiotemporal inactivation of Txnrd2 were established in our laboratory (Conrad et 
al., 2004). To this end, the last four exons of Txnrd2 gene were flanked by loxP sites. 
Cre-mediated deletion leads to removal of the C-terminal catalytic site including the Sec 
codon, which is encoded by exon 17, the SECIS element and the polyA termination signal, 
both encoded by the last exon (Figure 6). In the same work, it was shown that ubiquitous 
deletions of both Txnrd2 alleles leads to embryonic lethality around E13.5 most likely due to 
severe defects in foetal haematopoiesis and improper heart development. More specifically, 
Txnrd2−/− embryos displayed an increased number of apoptotic cells in the foetal 
haematopoietic compartment and an impaired proliferative capacity of isolated 
haematopoietic stem cells isolated from foetal liver. Moreover, heart-specific Txnrd2 
knock-out animals died just after birth. The knock-out mice showed thinning of the ventricular 
walls, and a perturbation in the heart muscle architecture. On the cellular level, 
cardiomyocytes showed swelling of mitochondria along with a destruction of mitochondrial 
cristae of cardiomyocytes. All these phenotypes are hallmarks of dilated cardiomyopathy 
(DCM). This suggests that Txnrd2 plays a pivotal role in both foetal haematopoiesis and 
cardiac development and function. To bypass postnatal lethality of heart-specific Txnrd2−/− 
mice, mice with Tamoxifen (Tam) inducible, cardiac tissue-restricted disruption of Txnrd2 
(Figure 6) were generated (Kiermayer et al., 2007). Interestingly, inducible adult 
heart-specific Txnrd2 null mice are fully viable, and cardiac tissue did not display any signs of 
severe histopathological abnormalities in induced knock-out mice, at least in young animals. 
Additionally, a conditional Txnrd2 knock-out mouse (Figure 6) lacking Txnrd2 expression in 
CD4−- and CD19-positive T- and B-lymphocytes were generated using CD4−- and CD19- Cre 
transgenic mice, respectively. However, the development and differentiation of both cell 
types in thymus and bone marrow was not impaired. In addition, B-cell proliferation and 
activation in response to CD40 and IL-4 was unaltered in Txnrd2-deficient B-cells 
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(Geisberger et al., 2007). These findings, however, do not rule out that Txnrd2 inactivation in 
the myeloid compartment may provoke yet-unrecognized abnormalities in adult 
myelopoiesis. 
 
In order to examine whether proliferation and/or cell death are affected in Txnrd2−/− cells, 
primary mouse embryonic fibroblasts (MEFs) were established from E12.5 embryos and 
used as a cellular model system (Conrad et al., 2004). Although MEF cultures could be 
established from Txnrd2−/− embryos, proliferation and survival of ex vivo cultured mouse 
embryonic fibroblasts (MEFs) is clearly compromised. The difference between wild-type and 
knock-out embryonic fibroblasts is even more pronounced when the de-novo synthesis of 
GSH is inhibited by BSO. GSH depletion rapidly induces apoptosis in Txnrd2−/− cells, but not 
in wild-type cells. Treatment of cells with the antioxidant NAC rescued Txnrd2−/− MEFs from 
BSO-induced cell death (Conrad et al., 2004). Taken together, these results suggest that 
Txnrd2 is involved in the defence against oxidative stress in vitro and in vivo, although it 
remains to be formally demonstrated.  
 
 
 
Figure 6. The conditional knock-out strategy for Txnrd2. The 3’ region of Txnrd2 gene is shown in the upper 
line. For conditional gene targeting, exons 15 to 18 were flanked by loxP sites (yellow triangles). Neomycin 
phosphotransferase gene (neoR) removal was achieved by Flp recombinase (violet triangles). Deletion of the 
C-terminally located redox-center is mediated by Cre. The Sec codon (red asterisk) encoded by exon 17 and the 
SECIS element (green asterisk) located on exon 18 are both deleted in these mice. For gene targeting the 
thymidine kinase gene (TK) was placed downstream from the 3’ arm for negative selection (adopted from Conrad 
et al., 2004). 
 
1.3. Peroxiredoxins 
 
Mammals express 6 peroxiredoxins, which can be subdivided according to structural 
similarities or catalytic mechanism in the reduction of their substrates (Wood et al., 2003). 
The localisation of peroxiredoxins in different compartments, including the extracellular space 
(Haridas et al., 1998; Okado-Matsumoto et al., 2000), suggests that it is important that these 
enzymes are present at compartments where H2O2 is generated, as H2O2 is essentially 
involved in cell signalling and even able to cross membranes. 
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Previously, peroxiredoxins were named thioredoxin peroxidases (TPx), since Trx and Txnrd 
were initially considered to be the sole reducing systems for peroxiredoxins. But later on it 
was shown that mammalian cells express peroxiredoxins with only one conserved 
peroxidatic cysteine, capable of reducing peroxides in the presence of DTT (dithiothreitol) but 
not in the presence of Trx. For this reason thioredoxin peroxidases (TPx) were then 
redefined and named peroxiredoxins (Prx). All peroxiredoxins act as “head-to-tail” dimers, in 
which the larger N-terminal domain of one subunit folds over the smaller C-terminal domain 
of the other subunit to form an active site (Choi et al., 1998; Hirotsu et al., 1999). 
 
Prxs I–IV belong to the category of 2-Cys Prxs and they share high sequence homology 
(60-80%). Prx VI is a member of the 1-Cys group. Peroxiredoxin V, for now, is the only 
representative of an atypical 2-Cys protein (Seo et al., 2000). Also, Prx I-IV belong to the 
thioredoxin peroxidase subfamily (TPx) and require thioredoxin (Trx) as an electron source, 
while Prx V and VI can use other cellular reducing agents, such as GSH or DTT (Fisher et 
al., 1999; Seo et al., 2000). Prx I, Prx II, and Prx VI are localised in the cytoplasm and in the 
nucleus (Kinnula et al., 2002; Mizusawa et al., 2000; Oberley et al., 2001). Other than these, 
Prx VI displays other cellular localisations including lysosomes and cytoplasmic vesicles. Prx 
IV has an N-terminal secretion signal sequence and is found in the endoplasmic reticulum as 
well as in the extracellular space (Okado-Matsumoto et al., 2000). Prx III and V are both 
expressed in the mitochondrion, although Prx V is additionally detected as a short form in 
peroxisomes (Seo et al., 2000) and in nuclei (Kinnula et al., 2002). Prx III and Prx V use the 
mitochondrial thioredoxin system (Trx2 and Txnrd2) as the main electron source for its 
peroxidase activity (Watabe et al., 1995; Watabe et al., 1997), but they may also use 
electrons from DTT in vitro. The specific localization of Prx III in mitochondria, along with the 
mitochondria-specific reducing system Trx2 and Txnrd2, suggests that these three proteins 
possibly together with Prx V provide a primary line of defence against H2O2 produced by the 
mitochondrial respiratory chain. The precise in vivo roles of Prx III and Prx V and their 
contribution to the maintenance of normal mitochondrial and cellular function are, however, 
still sparely investigated. Specific inactivation of both Prxs has been reported to increase 
their sensitivity to apoptosis (Araki et al., 1999; Chang et al., 2004b; Watabe et al., 1995; 
Watabe et al., 1997; Zhou et al., 2000). Lowering Prx III expression increases the sensitivity 
of cells to TNFα- or staurosporine-induced apoptosis (Chang et al., 2004b). Studies with Prx 
III knock-out mice revealed that Prx III is not required for embryonic development; rather the 
knock-out mice were more sensitive to LPS-induced severe lung injury due to augmented 
levels of intracellular ROS. Thus, it has been proposed that Prx III acts as an important ROS 
scavenger, particularly under stress–inducing conditions (Li et al., 2007). Mice 
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overexpressing Prx III were shown to have decreased left ventricular remodelling and cardiac 
failure in response to myocardial infarction due to reduced mitochondrial oxidative stress 
(Matsushima et al., 2006; Tsutsui et al., 2009). Furthermore, overexpression of Prx III in 
thymoma cells was shown to dampen cellular H2O2 levels, leading to decreased growth rates 
and increased resistance to apoptosis induced either by high H2O2, hypoxia, t-
butylhydroperoxide and the anticancer drug imexon (Nonn et al., 2003a). Overexpression of 
Prx III has been reported to protect rat hippocampal neurons from excitotoxic injury (Hattori et 
al., 2005b). Up-regulation of Prx VI and Prx III within skeletal muscles of neuronal nitric oxide 
synthase (nNOS) knock-out mice functionally compensates for the absence of nNOS in 
superoxide scavenging (Da Silva-Azevedo et al., 2009). Increased expression of Prx V in 
Chinese hamster ovary cells was found to decrease mtDNA damages caused by 
exogenously added hydrogen peroxide (Banmeyer et al., 2005). Furthermore, Prx I and Prx II 
are prime candidates to regulate H2O2 signalling of cell-surface receptors after activation with 
platelet-derived growth factor (PDGF) or tumor necrosis factor (TNF) (Choi et al., 2005; Egler 
et al., 2005; Jin et al., 1997; Kang et al., 1998b; Kang et al., 2004; Kim et al., 2008; Kwon et 
al., 2004; Veal et al., 2004; Zhang et al., 1997; Zhao et al., 2009). 
 
Furthermore, Prx expression is increased in several human cancers. Prx I levels are 
increased relative to normal tissue in oral cancer (Yanagawa et al., 2000), in follicular 
(Yanagawa et al., 2000), in breast cancer (Noh et al., 2001), and in lung cancer (Kim et al., 
2003a). Noh DY et al. have shown that Prx II and III are increased in breast cancer (Noh et 
al., 2001), while increased expression of all peroxiredoxins has been observed in 
mesothelioma (Kinnula et al., 2002). 
 
1.3.1. The catalytic mechanisms of peroxiredoxins  
 
The catalytic mechanisms by which 2-Cys and 1-Cys Prx enzymes remove peroxides 
diverge (Kang et al., 1998a). In case of 2-Cys Prx (Figure 7), the N-terminal thiol group 
(Cys-SH) is oxidized by peroxides to sulfenic acid (Cys-SOH), which immediately reacts with 
the C-terminal Cys-SH of the other subunit to form an intermolecular disulfide. This disulfide 
is subsequently reduced by Trx and Txnrd (Seo et al., 2000). Kang et al showed that mutant 
2-Cys Prx proteins that lack either the N-terminal or C-terminal Cys residues do not exhibit 
Trx-dependent peroxidase activity (Kang et al., 1998a). 
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Figure 7. The catalytic mechanism by which 2-Cys peroxiredoxins reduce peroxides. In case of 2-Cys Prx, 
the N-terminal Cys thiol group (Cys-SH) is oxidized by peroxides to sulfenic acid (Cys-SOH), which immediately 
reacts with the C-terminal Cys-SH of the other subunit to form an intermolecular disulfide. This disulfide is 
subsequently reduced by Trx and Txnrd (adapted from (Seo et al., 2000). 
 
 
 
Figure 8. 1-Cys Prx catalytic mechanism. The N-terminal Cys-SH of 1-Cys Prx is oxidised by peroxides. The 
resulting Cys-SOH does not form a disulfide because of the unavailability of another nearby Cys-SH. The Cys-
SOH of oxidized 1-Cys Prx can be reduced by non-physiological thiols such as DTT and GSH but not by Trx. 
 
The N-terminal Cys-SH of 1-Cys Prx is also the site of oxidation by peroxides. However, the 
resulting Cys-SOH does not form a disulfide because of the unavailability of another nearby 
Cys-SH (Figure 8). The electron donor used to reduce the sulfenic acid of 1-Cys 
peroxiredoxins might be GSH (Fisher et al., 1999); however in in vitro experiments it was 
shown that DTT is able to effectively reduce the active site Cys (Kwon et al., 2004; Rhee et 
al., 2005; Rhee et al., 2001). 
 
Prx V is an atypical 2-Cys peroxidase. Mutant analyses of human Prx V revealed that the 
N-terminal cysteine (Cys48) and the C-terminal cysteine (Cys152) are essential for 
Trx-dependent activity and that the oxidized intermediate is a monomer containing the 
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Cys48–Cys152 disulfide (as shown in Figure 9). The C48S mutant of Prx V is inactive, 
regardless of whether the reducing equivalents are provided by DTT, or by Trx, whereas the 
C152S mutant is active in the presence of DTT, but not in the presence of the Trx system. 
These results suggest that Cys48 is the catalytically active peroxidatic cysteine and that this 
is directly oxidized by H2O2 to yield H2O and Cys48-SOH; Cys48-SOH then reacts with 
Cys152-SH to form an intramolecular disulfide, which is subsequently reduced by Trx. In this 
model, Cys48-SOH would react with one thiol of DTT to form a mixed disulfide in the 
absence of Cys152, whereas the second thiol of DTT would attack the disulfide to produce 
Cys48-SH and oxidized DTT (Figure 9) (Seo et al., 2000). 
 
 
 
Figure 9. The catalytic mechanism of 2-Cys atypical Prx. Analysis of Prx V revealed that both Cys48 and 
Cys152 are essential for Trx-dependent activity. Cys48 is the site of peroxide oxidation by H2O2 resulting in 
Cys48-SOH; this reacts with Cys152-SH to form an intramolecular disulfide, which is subsequently reduced by 
Trx. Cys48-SOH would react with one thiol of DTT to form a mixed disulfide in the absence of Cys152, whereas 
the second thiol of DTT would attack the disulfide to produce Cys48-SH and oxidized DTT (adapted from(Seo et 
al., 2000)  
 
1.3.2. The role of sulfiredoxin (Srx) 
 
The disulfide-forming cysteine residues of 2-Cys Prx enzymes are positioned far apart 
(Schroder et al., 2000), which significantly slows down the process of disulfide formation 
(Figure 7). Under strongly oxidizing conditions, the sulfenic acid intermediate (Cys-SOH) can 
be further oxidized to sulfinic acid (Cys-SO2H), which cannot be directly reduced to the 
ground state. Neither Trx nor other cellular reductants, such as GSH, are able to reduce the 
sulfinic acid moiety of Prx. Therefore, the overoxidation was thought to result in permanent 
inactivation of Prx peroxidase activity (Chae et al., 1994; Rabilloud et al., 2002; Yang et al., 
2002). Additionally, it was shown that H2O2 causes hyperoxidation of Prx I in different cells 
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which was gradually reduced to the catalytically active thiol form (Woo et al., 2003a; Woo et 
al., 2003b). This implied that in cells there must be a system demonstrated the ability of 
mammalian cells to reduce protein sulfinic acid. Subsequently, Toledano’s laboratory 
identified sulfiredoxin (Srx) in yeast capable of reducing sulfinylated Prx and thus returning it 
into its fully reduced ground state (Biteau et al., 2003). Srx was initially identified as its 
expression is rapidly induced by high H2O2 concentrations. These studies further showed that 
Prx reduction requires a conserved cysteine residue in Srx, ATP or GTP hydrolysis, Mg2+ and 
a thiol group as an electron donor (Trx or DTT) (Biteau et al., 2003). The reductase activity of 
rat Srx was shown to be equally efficient with GSH or Trx as electron source (Chang et al., 
2004c). Reduction of sulfinic acid by mammalian Srx is specific to 2-Cys Prx isoforms (Woo 
et al., 2005). Thus, the cycle of thiol to sulfinic acid might represent a redox switch by which 
the function of a wide variety of proteins is regulated in response to a strongly changing 
intracellular redox status. It was also shown that the conserved cysteine of Srx from various 
species is essential for enzyme activity. The catalytically active cysteine is thought to serve 
as the phosphate carrier in the reducing reaction (Roussel et al., 2008): 
 
Prx-SO2H + ATP → Prx-SO2-PO3-2 + ADP 
 
or as the removing site for phosphate in the thiol-transferase reaction: 
 
Prx-SO2-PO32- + Srx-S → Prx-S(O)-S-Srx + PO43- 
 
Even when cells are exposed to high H2O2 concentrations Srx is not inactivated. Srx is able 
to keep peroxiredoxins in their reduced states, because Srx turnover by ATP is highly 
efficient, similar to the reduction of Trx by Txnrd2 (Chang et al., 2004c). It has been 
speculated that the slow rate of Prx reactivation via Srx-dependent reduction has been 
evolved to regulate the basal levels H2O2 so that it can confer its intracellular second 
messenger-like function (Bondareva et al., 2007; Chang et al., 2004c; Woo et al., 2003a; 
Woo et al., 2003b). Rapid reactivation of the inactivated Prx enzymes would reduce the time 
window needed for H2O2 accumulation and thus propagating the signal. Although sulfiredoxin 
is mainly localised in the cytoplasm, it was shown that in vitro Srx reduces not only sulfinic 
acids of cytosolic Prxs (I and II) but also sulfinic acid of mitochondrial Prx III (Noh et al., 
2009; Woo et al., 2005). In response to oxidative stress, sulfiredoxin was shown to 
translocate from the cytosol to mitochondria. Moreover, overexpression of mitochondrion-
targeted Srx promotes the regeneration of overoxidised Prx III and results in cellular 
resistance to apoptosis, accompanied by enhanced elimination of mitochondrial H2O2 and 
decreased rates of mitochondrial membrane breakdown. Therefore, Srx appear to play a 
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crucial role in maintaining the balance between mitochondrial H2O2 production and 
elimination (Noh et al., 2009). 
 
1.4. System xC− 
 
Cysteine is an essential amino acid and as such is indispensable for normal cell proliferation, 
including cultured cells. Moreover, cysteine (Cys) is unstable in the extracellular environment 
and becomes readily oxidised to yield cystine, (Cys)2 (Toohey, 1975).  
 
 
 
Figure 10. The Cys/(Cys)2 circuit. Cysteine (CySH) is unstable in the extracellular environment and is readily 
oxidised to cystine (Cys)2. Cysteine transport is mediated by the neutral amino acid transport system ASC, while 
the transport of cystine is mediated by system xC−. System xC− is an antiporter for cystine and glutamate. Cystine, 
taken up via system xC−, is rapidly reduced to cysteine in the intracellular reducing environment, which is then 
used for protein synthesis or GSH biosynthesis. The driving force of this circuit that actually reduces cystine to 
cysteine is considered to be GSH, by forming mixed disulfides; yet experimental proof is still lacking. 
 
Cysteine transport is mediated by the neutral amino acid transport system ASC, whereas the 
transport of cystine, the predominant form of cysteine in the extracellular space and body 
fluids, is accomplished by system xC− (Bannai and Kasuga, 1985; Sato et al., 2000). System 
xC− is a member of the glycoprotein-associated amino acid transporters (gpAATs) (Shih and 
Murphy, 2001). gpAAT functions as heterodimeric transmembrane proteins consisting of a 
highly glycosylated heavy chain (4F2hc/CD98) that is common to all gpAATs, and a light 
chain. The light chain component of system xC− is xCT which confers high substrate 
specificity for cystine (Bannai, 1986; Bannai and Ishii, 1982; Sato et al., 2000). System xC− 
carries one mole of cysteine and at the same time releases one mole of glutamate. Upon 
uptake, cystine is rapidly reduced to cysteine inside cells, which is subsequently used for the 
synthesis of GSH or proteins (Bannai and Ishii, 1982). Since intracellular cysteine 
concentrations are the substrate-limiting step in GSH biosynthesis, the intracellular GSH 
level is considered to be coupled to systems xC− activity, at least in cell culture. 
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Figure 11. Schematic representation of system xC−. xCT light chain of system xC− is embedded in the plasma 
membrane via 12 transmembrane domains. The N- and C-termini reside in the cytosol. Cys 158 is involved in the 
formation of a disulfide bridge with heavy chain (4F2hc/CD98). Proper folding of xCT requires the presence of the 
heavy subunit (Gasol et al., 2004).  
 
The driving force for intracellular reduction of cystine to cysteine is thought to be GSH by 
forming mixed disulfides, thus releasing cysteine. Since system xC− provides Cys for 
intracellular GSH levels, it is classified to the category of the stress proteins that are required 
for the metabolic response to oxidative stress (Sasaki et al., 2002). In fact, the activity of 
system xC− is strongly induced by electrophilic agents (Bannai, 1984; Bannai et al., 1991), 
LPS (Sato et al., 1991), oxygen (Sato et al., 2000) and even HIV infection (Bridges et al., 
2004). Moreover, the expression of xCT is partly up-regulated by an electrophile response 
element (EpER), which is recognized by the oxidative stress-activated transcription factor 
NF-E2-related factor 2 (Nrf2). The electrophile response element (EpRE) is a gene 
regulatory sequence which is present in the promoter region of a variety of genes that are 
involved in the defence against xenobiotics (Sasaki et al., 2002). In the brain, system xC− is 
predominantly expressed in regions that are in contact with the cerebrospinal fluid, indicating 
that relatively high levels of ROS in these regions are counteracted by augmented cysteine 
supply (Burdo et al., 2006; Sato et al., 2002). 
 
In addition, xCT has also been studied in the context of high glutamate levels in the brain 
(Massie et al., 2008). The latest hypothesis is that neuronal injury might be caused by high 
extracellular glutamate levels ultimately leading to cell damage. It has also been shown that 
cystine/glutamate antiporter contributes to the pathogenesis of Parkinson's disease (Massie 
et al., 2008). The striatal xCT protein expression level was investigated in a hemi-Parkinson 
rat model, using comparative western blotting. Time-dependent changes were observed after 
a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway with increased expression 
levels in the deafferented striatum. These data suggest for the first time an involvement of 
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the cystine/glutamate antiporter in determining the aberrant glutamate neurotransmission in 
the striatum of a parkinsonian brain (Massie et al., 2008). 
 
On the other hand, high xCT expression levels have been shown to negatively correlate with 
the potency of the anti-tumor drug cisplatin, as shown in cisplatin-resistant human ovarian 
cancer cell line (Okuno et al., 2003). Accordingly, the inhibition of system xC− abolished the 
growth of primary brain tumours (Chung et al., 2005; Savaskan et al., 2008). Enforced 
expression of xCT protects Burkitt’s lymphoma cells from cell death induced by oxidative 
stress and GSH depletion (Banjac et al., 2008). The studies by Banjac et al. provided strong 
evidence that the cystine/cysteine redox couple represents an efficient redox system, which 
may also act independently from intracellular GSH (Banjac et al., 2008).  
 
It is noteworthy, that mice lacking xCT are born at the Mendelian ratio and are healthy in 
appearance (Sato et al., 2005). Most interestingly, xCT-deficient MEFs rapidly die in normal 
cell culture, if not supplemented with thiol-containing compounds, such as GSH or NAC 
(Qiao et al., 2008; Sato et al., 2005). This is a perfect example that one has to be extremely 
careful when conclusions are drawn from in vitro experiments, particularly when dealing with 
oxidative stress and redox signalling - very often in vitro results do not really reflect the in 
vivo situation, which calls for more specific transgenic mouse models for redox enzymes.  
 
1.5. Objectives  
 
The importance of the overall cellular redox balance on many cell processes has been 
recognized in recent years. However, the redox control of distinct cellular pathways is still 
poorly understood and still at its infancy. This is also supported by the fact, that interacting 
partners, as well as substrates of redox enzymes, are widely unknown. 
 
To date, in ex vivo studies investigating the role of peroxiredoxins (Prx) in cellular redox 
system, the focus was placed on the biochemical characterisation of reactions which 
included Trx2 and Txnrd2. It was found that Trx2 is needed for maintenance of Prx in the 
active state. Also, form these experiments it is known that this reaction was possible only in 
the presence of Txnrd2. Given that a confirmation of these results in vivo is lacking, one of 
our research aims was to demonstrate that the mechanisms proposed are also operable in 
the cells. 
 
Furthermore, in order to dissect the contribution of the thioredoxin 2 dependent system on 
the redox balance and effect on the overall physiology and pathophysiology of tissues and 
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organs, a mice with targeted deficiencies in mitochondrial thioredoxin reductase (Txnrd2) 
were created (Conrad et al., 2004). Ubiquitous inactivation of Txnrd2 revealed that 
mitochondrial thioredoxin reductase is essential for embryonic development, increased 
apoptosis of haematopoietic cells and perturbed cardiac development. Additionally, heart-
specific Txnrd2 ablation shows perturbed myocyte organisation and leads to fatal cardiac 
insufficiency (Conrad et al., 2004). Hence, unbalanced levels of ROS due to Txnrd2 absence 
are probably a cause for the failing myocardium and lethality among ubiquitous and heart-
specific Txnrd2 knock-out mice. The use of cells isolated from the embryos lacking Txnrd2 
(MEFs and eEPCs) would therefore help us reveal the mechanisms behind cell and tissue 
pathological modifications caused by absence of Txnrd2. The next aim of the present study 
was to clone the tagged mitochondrial and cytoplasmatic isoforms of Txnrd2 and to confirm 
their function in vivo, by using the cells which lack respective enzymes. Furthermore, we 
have used the constructs to investigate more in detail cellular localisation of Txnrd2 isoforms, 
since the data on their subcellular arrangement is sparse. Moreover, it was interesting to see 
whether there is in vitro functional overlap between Txnrd1 and Txnrd2. In order to elucidate 
biological implications of mutation in mitochondrial Txnrd2 found in DCM patients, we have 
designed two different mutants and performed a functional analysis in transfected cells, as 
well as the repercussions of introduced changes on the protein localisation. 
 
Over recent decades genetically manipulated mouse models have proven themselves as 
valuable tools to study human disease and as models to study disease mechanisms. 
Cystine/glutamate transporter, designated as system xc−, mediates cystine entry in exchange 
for intracellular glutamate in mammalian cells. Overexpression of xCT plays a role in 
maintaining the GSH intracellular levels (Bannai, 1986). As shown by Banjac et al, 
overexpression of xCT in vitro in Burkit lymphoma cells protects them from BSO-induced cell 
death (Banjac et al., 2008). Moreover, it is suggested that Cys/(Cys)2 biochemical system 
functions independently and could be induced by oxidative stress, mediated by electrophilic 
agents and by oxygen (Bannai et al., 1989; Hattori et al., 2005a) surmounting the effects of 
oxidative stress. In this work our aim was to extend the study of Banjac et al and to clarify the 
physiological roles of xCT transporter in vivo. Thus, we successfully generated mice 
overexpressing xCT. For that purpose Rosa26 locus was used. This is a mouse locus 
commonly used to knock-in different constructs for ubiquitous or conditional gene expression 
in transgenic mice. Also, since, molecular mechanisms of potential cross-talk between 
system xC− and Txnrd2 remain obscure, we sought to perform a comprehensive analysis of 
Txnrd-deficient cells and a putative overlap between Txnrd2 and system xC− seeking for the 
truly driving force of the Cys/(Cys)2 circuit. 
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2. Materials and Methods 
 
2.1. Materials 
 
Chemicals     Company   Catalog-No. 
4-Hydroxytamoxifen (Tam)  Sigma-Aldrich GmbH, Taufkirchen, Germany   H7904 
Acrylamide   Roth Carl GmbH & Co., Karlsruhe, Germany   3426 
Agarose    Invitrogen, Karlsruhe, Germany    15510-027 
Agarose, low melting point  Fermentas GmbH, St. Leon-Rot, Germany   R0801 
Albumin Fraction V  Roth Carl GmbH & Co., Karlsruhe, Germany   2923225 
Ammonia (30%)    Merck KGaA, Darmstadt, Germany    1054231000 
Ammonium persulfate  Sigma-Aldrich GmbH, Taufkirchen, Germany   A3678 
Ampicillin sodium salt   Sigma-Aldrich GmbH, Taufkirchen, Germany   A9518 
ANTI-FLAG M2 Affinity Gel Sigma-Aldrich GmbH, Taufkirchen, Germany   A2220 
Antimycin A   Sigma-Aldrich GmbH, Taufkirchen, Germany   A0274 
Bacto yeast extracts  Difco Laboratories, Michigan, USA  
BODIPY581/591 C11  Invitrogen, Karlsruhe, Germany    D-3861 
Boric acid   Merck KGaA, Darmstadt, Germany    203667 
Bromophenol Blue sodium salt Sigma-Aldrich GmbH, Taufkirchen, Germany   B8026 
L-Buthionine Sulfoximine (BSO) Sigma-Aldrich GmbH, Taufkirchen, Germany   B2640 
Calcium chloride   Sigma-Aldrich GmbH, Taufkirchen, Germany   C7902 
Chloroquine diphosphate salt Sigma-Aldrich GmbH, Taufkirchen, Germany   C6628 
cis-Platinum(II) dichloride  Sigma-Aldrich GmbH, Taufkirchen, Germany   P4394 
Citric acid   Sigma-Aldrich GmbH, Taufkirchen, Germany   C4540 
DAPI    Invitrogen, Karlsruhe, Germany    D1306 
DCF, DCFDA   Invitrogen, Karlsruhe, Germany    C-13293 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich GmbH, Taufkirchen, Germany   D2650 
Disodium hydrogen ortophosphat Merck KGaA, Darmstadt, Germany    1065855000 
Dithiothreitol (DTT)  Sigma-Aldrich GmbH, Taufkirchen, Germany   D8161 
dNTP/dUTP Mix   Fermentas GmbH, St. Leon-Rot, Germany   R0241 
Doxorubicin hydrochloride  Sigma-Aldrich GmbH, Taufkirchen, Germany   D1515 
ECL    GE Healthcare, Freiburg, Germany    RPN2106 
Ethanol p.a   Merck KGaA, Darmstadt, Germany    1.00983.2500 
Ethidium bromide   Merck KGaA, Darmstadt, Germany    70257083 
EDTA    Sigma-Aldrich GmbH, Taufkirchen, Germany   E9884 
Foetal Bovine Serum (FCS) PAA, Pasching, Austria     A15-043 
Formaldehyde (38%)  Sigma-Aldrich GmbH, Taufkirchen, Germany   F8775 
Formamide   Merck KGaA, Darmstadt, Germany    344205 
Gelatine from porcine skin  Sigma-Aldrich GmbH, Taufkirchen, Germany   G2500 
Glacial acetic acid  Merck KGaA, Darmstadt, Germany    8187552500 
Glutaraldehyd (25%)  Merck KGaA, Darmstadt, Germany    354400 
Glutathione (GSH)  Sigma-Aldrich GmbH, Taufkirchen, Germany   G6013 
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Chemicals   Company     Catalog-No. 
Glycerol    Sigma-Aldrich GmbH, Taufkirchen, Germany   G8773 
Glycine    Merck KGaA, Darmstadt, Germany    2002722 
HEPES    Invitrogen, Karlsruhe, Germany    15630-080 
Hydroperoxide   Sigma-Aldrich GmbH, Taufkirchen, Germany   H1009 
Iodoacetamide   Sigma-Aldrich GmbH, Taufkirchen, Germany   I6125 
Isopropanol p.a.   Merck KGaA, Darmstadt, Germany    1.09634.2511 
LIF (ESGRO)   Millipore, Billerica, MA, USA    ESG1107 
Luria Broth Base   Invitrogen, Karlsruhe, Germany    12795-019 
Magnesium sulfate  Merck KGaA, Darmstadt, Germany    105886 
Mounting medium  Dako Cytomation, Hamburg, Germany   S3023 
N-Acetyl-L-cysteine (NAC)  Sigma-Aldrich GmbH, Taufkirchen, Germany   A9165 
Oligonucleotides   Metabion international AD, Martinsried, Germany 
Paraformaldehyde (PFA)  Roth Carl GmbH & Co., Karlsruhe, Germany   0335.3 
Penicillin-Streptomycin solution Invitrogen, Karlsruhe, Germany    15140-122 
Perchloric acid (70%)  Merck KGaA, Darmstadt, Germany    1005191001 
Phenethyl isothiocyanate (PEITC) Fluka Chemie GmbH, Buchs, Switzerland   77972 
Phenol/Chloroform/Isoamyl alcohol Roth Carl GmbH & Co., Karlsruhe, Germany   A156 
Ponceau S   Sigma-Aldrich GmbH, Taufkirchen, Germany   P3504 
Potassium acetate  Merck KGaA, Darmstadt, Germany    1048201000 
Potassium dihydrogen phosphate Merck KGaA, Darmstadt, Germany    104873 
Propidium iodide (PI)  Sigma-Aldrich GmbH, Taufkirchen, Germany   P4170 
Puromycin dihydrochloride  Sigma-Aldrich GmbH, Taufkirchen, Germany   P7255 
RPMI 1640 medium  Invitrogen, Karlsruhe, Germany     31870025 
Rubidium chloride  Sigma-Aldrich GmbH, Taufkirchen, Germany   215260 
Silver nitrate   Sigma-Aldrich GmbH, Taufkirchen, Germany   S8157 
Skim Milk Powder  Fluka Chemie GmbH, Buchs, Switzerland   70166 
Sodium acetate   Sigma-Aldrich GmbH, Taufkirchen, Germany   S8750 
Sodium chloride   MP Biomedicals, Eschwege, Germany   194848 
Sodium deoxycholate  Sigma-Aldrich GmbH, Taufkirchen, Germany   D6750 
Sodium dodecyl sulfate (SDS) Fluka Chemie GmbH, Buchs, Switzerland   71729 
Sodium hydroxide  Roth Carl GmbH & Co., Karlsruhe, Germany   2151855 
Sodium phosphate  Merck KGaA, Darmstadt, Germany    567550 
Sodium pyrophosphate tetrabasic Sigma-Aldrich GmbH, Taufkirchen, Germany   S6422 
Sodium selenite   Sigma-Aldrich GmbH, Taufkirchen, Germany   S5261 
Tetramethylethylenediamine (TEMED)Fluka Chemie GmbH, Buchs, Switzerland   87689 
Trichloroacetic acid  Sigma-Aldrich GmbH, Taufkirchen, Germany   T8657 
Tris(hydroxymethyl)aminomethane  Merck KGaA, Darmstadt, Germany    108382 
Tris-sodium citrate  Merck KGaA, Darmstadt, Germany    1110371000  
Triton X-100   GE Healthcare, Freiburg, Germany    17-1315-01 
Trypan Blue (0.4%)  Sigma-Aldrich GmbH, Taufkirchen, Germany   T8154 
Trypsin-EDTA   Invitrogen, Karlsruhe, Germany    25300 
Tryptone   Difco Laboratories, Michigan, USA 
Tween 20   Sigma-Aldrich GmbH, Taufkirchen, Germany   P5927 
ß-Mercaptoethanol (2-ME)  Invitrogen, Karlsruhe, Germany    31350-010 
α-Tocopherol (Toc)  Sigma-Aldrich GmbH, Taufkirchen, Germany   T3251 
 24
  Materials & Methods 
Radioactive Isotopes  Company     Catalog-No. 
[gamma-32P]-dCTP  GE Healthcare, Freiburg, Germany    PT10165 
L-[14C (U)] Cystine  Perkin Elmer Life Sciences Inc., Boston, USA  NEC465050UC 
 
Bacteria   Company__        
TOP 10 E.coli cells  Invitrogen, Karlsruhe, Germany 
 
Enzymes   Company     Catalog-No. 
DNA Polymerase I (Klenow) New England Biolabs GmbH, Frankfurt, Germany  M0210S 
Pfx DNA Polymerase  Invitrogen, Karlsruhe, Germany    11708-013 
Phosphatase, alkaline  Roche Diagnostics, Mannheim, Germany   713 023 
Protease Inhibitor Cocktail Tablets Roche Diagnostics, Mannheim, Germany   1 697 498 
Proteinase K   Roth Carl GmbH & Co., Karlsruhe, Germany   7528.1 
Restriction Endonucleases  MBI Fermentas GmbH, St. Leon-Rot, Germany 
Restriction Endonucleases  New England Biolabs GmbH, Frankfurt, Germany 
RNAse A   QIAGEN GmbH, Hilden, Germany    19101 
T4 DNA Ligase   Promega GmbH, Mannheim, Germany   M180A 
Taq DNA Polymerase  Invitrogen, Karlsruhe, Germany    18038-026 
 
Antibodies   Company     Catalog-No. 
anti-actin   Santa Cruz Biotechnology, Heidelberg, Germany  sc-58679 
anti-FLAG   Sigma-Aldrich GmbH, Taufkirchen, Germany   F2555 
anti-mause-HRP conjugate Santa Cruz Biotechnology, Heidelberg, Germany  sc-2354 
anti-mouse-Alexa Fluor 488 Invitrogen, Karlsruhe, Germany    A-11001 
anti-peroxiredoxin-III  LabFrontier, Seoul Korea     LP-PA0030 
anti-peroxiredoxin-SO3  LabFrontier, Seoul Korea     LF-PA0004 
anti-rabbit-HRP conjugate  Santa Cruz Biotechnology, Heidelberg, Germany  sc-2768 
anti-rat-HRP conjugat  Santa Cruz Biotechnology, Heidelberg, Germany  sc-2006 
anti-Txnrd1 polyclonal antisera Dr. Vladim Gladyshev, University of Nebraska, Lincoln, USA 
anti-Txnrd2 monoclonal antisera Dr. Elisabeth Kremmer, Helmholtz Zentrum München, Germany 
anti-Txnrd2 polyclonal antisera Dr. Vladim Gladyshev, University of Nebraska, Lincoln, USA 
anti-xCT monoclonal antisera Dr. Elisabeth Kremmer, Helmholtz Zentrum München, Germany 
anti-α-tubulin   Sigma-Aldrich GmbH, Taufkirchen, Germany   T6199 
 
Disposables and Kits  Company     Catalog-No. 
CEA RP NEW   CEA AB, Martinsried, Germany    C011824 
DC Protein Assay   Bio-Rad, Munich, Germany    500-0112 
DMEM lacking L-cystine  Invitrogen, Karlsruhe, Germany    21013 
DMEM    Invitrogen, Karlsruhe, Germany    41966 
Gel Extraction Kit   QIAGEN GmbH, Hilden, Germany    28704 
Hybond-C super membrane GE Healthcare, Freiburg, Germany    RPN203G 
Illustra MicroSpin™ Columnx GE Healthcare, Freiburg, Germany     27-3565-01 
Immobilon-Ny+   Millipore, Schwalbach, Germany    HAHY13750 
JETstar Plasmid purification system Genomed GmbH, Loehne, Germany   220020 
LightCycler Capillaries  Roche Diagnostics, Mannheim, Germany   11 909339 001 
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Disposables and Kits  Company     Catalog-No. 
LightCycler FastStart DNA MasterPLUSRoche Diagnostics, Mannheim, Germany   03515869001 
LS 5000 TA Scintillation Counter Beckman Coulter GmbH, Krefeld, Germany 
Parafilm M®    Pechiney Plastic Packaging Company 
PCR Cloning Kit   QIAGEN GmbH, Hilden, Germany    231122 
Plasmid Maxi Kit   QIAGEN GmbH, Hilden, Germany    12163 
Random Prime DNA Labeling Kit Roche Diagnostics, Manheim, Germany   11 004 760 001 
Reverse Transcription System Promega GmbH, Mannheim, Germany   A3500 
RNase-Free DNase Set  QIAGEN GmbH, Hilden, Germany    79254 
RNeasy Mini Kit   QIAGEN GmbH, Hilden, Germany    74104 
 
Equipment   Company     Catalog-No. 
250/SE 260 Mini-Vertical Gel Unit  GE Healthcare Europe GmbH, Freiburg, Germany 
Axiovert 200M   Carl Zeiss, Jena GmbH, Germany 
Bench-top radioisotope counter Bioscan, Washington D.C., USA 
Eurostar RW16, IKA-Labortechnik IKA Werke GmbH, Staufen, Germany   2572100 
FACS Calibur   BD GmbH, Heidelberg, Germany 
GenAmp PCR system 2700 Applied Biosystems, Darmstadt, Germany 
Gene Pulser II System  Bio-Rad, Munich, Germany 
GenPulser Cuvettes, 0.4 cm gap Bio-Rad, Munich, Germany  
Heraeus Incubator, Modell B 5060 Heraeus Holding GmbH, Hanau, Germany 
Leica DM IRBE confocal microscopeLeica Microsystems GmbH, Wetzlar, Germany 
Leica TCS SP2 scanner  Leica Microsystems GmbH, Wetzlar, Germany 
Light-Cycler 1.5   Roche Diagnostics, Mannheim, Germany 
Microscope Axiovert 135  Carl Zeiss Jena GmbH, Germany  
Mini-PROTEAN 3 Electrophoresis CellBio-Rad, Munich, Germany 
Mini-Sub Cell GT Electrophoresis CellBio-Rad, Munich, Germany 
OTD Combi Ultracentrifuge Sorvall, Langenselbold, Germany 
Overhead stirrer   Eurostar RW, IKA-Labortechnik, Staufen, Germany  2572100 
Photometer Bio   Eppendorf, Hamburg, Germany 
PowerPac 200 Power Supply Bio-Rad, Munich, Germany 
RF-10A XL Spectrophotometer Shimadzu, Duisburg, Germany 
Sephadex G-50 columns  GE Healthcare, Freiburg, Germany     27-5330-01 
Spectrophotometer DU-64  Beckman Coulter GmbH, Krefeld, Germany 
Stereomicroscope   Nikon, Tokyo, Japan 
Supelclean LC-18 columns Sigma-Aldrich, Stockholm, Sweden    57012 
Trans-Blot Semi-Dry  Bio-Rad, Munich, Germany 
UZ-PA-38,5-1 Ultracentrifuge TubesKisker GbR, Steinfurt, Germany 
X-ray film   GE Healthcare, Freiburg, Germany   RPN16778K 
 
Oligonucleotides  Sequence        
Genotyping 
Cre D    5’-CACGACCAAGTGACAGCAATGCTG-3’ 
Cre E    5’-CAGGTAGTTATTCGGATCATCAGC-3’ 
TR2_Del_for   5’-TGCTTCCAGGCCCAGTGCTCTGACTGG-3’ 
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Oligonucleotides  Sequence        
Genotyping 
TR2_Del_rev   5’-CAGGCTCCTGTAGGCCCATTAAGGTGC-3' 
TR2_flox_for   5’-CAGGTCACTAGGCTGTAGAGTTTGC-3’ 
TR2_flox_rev   5’-ATGTCCCAGTGTACTTATGATGAATC-3’ 
TrxR2E15   5’-TTCACGGTGGCGGATAGGGATGC-3’ 
TrxR2E18   5’-TGCCCAGGCCATCATCATCTGACG-3’ 
xCT for    5’-CCTGAAACATAGAATGAATGCA-3’ 
xCT for1    5’-GGCACCGTCATCGGATCAGGCATC-3’ 
xCT KO for I   5’-TCACGACCGAACAGTGATCAGTC-3’ 
xCT KO rev I   5’-ATCCGATGACGGTGCCGATGATG-3’ 
xCT KO rev II   5’-GCTCATATTGCCCTGCAGGTAAC-3’ 
xCT rev    5’-CCTTTGGAGATGGTGGCCA-3’ 
xCT rev1   5’-CACGAGCTTGATTGCAAGTTCAGG-3’ 
 
Cloning 
Olig_SECI_BglII_for  5’-TCTCAGAGATCTGAGAAGATGTGGATGGAAC-3’ 
Oligo TR2 A59T for  5’-AGCGGGAATCGATTATAAAGAT-3’ 
Oligo TR2 A59T rev  5’-GCCAGAAGCTTTCTTGCCTTGATAGC-3’ 
Oligo TR2 G375R for  5’-GCTATCAAGGCAAGAAAGCTTCTGGC-3’ 
Oligo TR2 G375R rev  5’-GCCAGAAGCTTTCTTGCCTTGATAGC-3’ 
Oligo_ClaI_for   5’-TCGCCGCCACCATCGATTATAAAGATGA-3’ 
Oligo_ClaI_rev   5’-TCATCTTTATAATCGATGGTGGCGGCGA-3’ 
Oligo_KpnI_for   5’-CAGCCAGAAGATGTCGTCACTTGTGAT-3’ 
Oligo_mTxnrd2_Cla I  5’-ATTGAATTCCATGGCGGCGATGGTGGCGGCGA-3’ 
Oligo_SECIS_rev   5’-GTTTGAACCCCTGGCATTTCTAGAGCACT-3’ 
Oligo_TR2_NheI_&_SacI_rev 5’-ATGAGCTCGCTAGCAGATCAAAGCTCTGCTGCCC-3’ 
Oligo_Txnrd2_ATG_MLS_EcoRI 5’-ATTGAATTCCATGGCGGCGATGGTGGCGGCGA-3’ 
 
RT-PCR 
18s RNA for   5’-GGACAGGATTGACAGATTGATAG-3’ 
18s RNA rev   5’-CTCGTTCGTTATCGGAATTAAC-3’ 
Prx I for    5’-GGGAATTGAACCTGGGTCTT-3’ 
Prx I rev    5’-CGAAAAACAAAAGGCCAACT-3’ 
Prx II for    5’-TTGACTGTGATCTGGCGAAGG-3’ 
Prx II rev   5’-CTCTTGCTCACGCAGTCATGG-3’ 
Prx III fov   5’-GTCTGCCTCTGCCCAAGGAAA-3’ 
Prx III rev   5’-CTTGGTGTGTTGATCCAGGCA-3’ 
Prx IV for   5’-CACAAAGGTCAAATCCAGTGGG-3’ 
Prx IV rev   5’-TTAGCTGGCTGCCTGGCGGAGG-3’ 
Prx V for    5’-AATCTCATCAAAGTTCCTGCCC-3’ 
Prx V rev   5’-ACCACAGAACTTGGCAGAGCTGC-3’ 
Prx VI for   5’-CCGATCAAGGTGGGAGATGCC-3’ 
Prx VI rev   5’-TCTGGCTCCACGTTCAGTGCC-3’ 
TrxR2E15   5’-TTCACGGTGGCGGATAGGGATGC3’ 
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Oligonucleotides  Sequence        
RT-PCR 
TrxR2E18   5’-TGCCCAGGCCATCATCATCTGACG-3’ 
xCT for1    5’-GGCACCGTCATCGGATCAGGCATC-3’ 
xCT rev1   5’-CACGAGCTTGATTGCAAGTTCAGG-3’ 
Srx fov    5’-AGACACGGGGTTTTTCTGTG-3’ 
Srx rev    5’-ACGAACTGACCAACGGAAAC-3’ 
 
Sequencing 
Cter    5’-TCTGAGAGGCAGCAAGGCCTTC-3’ 
IRES rev1   5’-CTTCGGCCAGTAACGTTAGG-3’ 
LTR 3’-for1   5’-GCTCACAACCCCTCACTC-3’ 
ROSA26 flox for   5’-CCCAAGTGGTTCAGACGATTA-3’ 
ROSA26 flox rev   5’-GGTGGCCACAACTGGCTT-3’ 
Sp6 promoter   5’-ATTTAGGTGACACTATAGAA-3’ 
T7 promoter   5’-TAATACGACTCACTATAGGG-3’ 
TR2 mid    5’-GTCATCTTTGGTCACAGAG-3’ 
 
All DNA-oligonucleotides were obtained from Metabion GmbH, Martinsried, Germany. 
 
Expression and Targeting Vectors         
Depicted are the expression vectors pCAG-3SIP (Figure 12), the lentiviral vector p442 
(Figure 13), and the targeting vectors pTVRosa26-mxCT (Figure 14) and pMB-mxCT (Figure 
15). 
 
 
Figure 12. Map of the expression vector pCAG-3SIP. Abbreviations: SV40 (early SV-40 promoter), hCMVieE 
(human cytomegalovirus immediate early-enhancer modified chicken ß-actin promoter), EcoRI (unique restriction 
site used for cloning), 3 x stop (three stop codons in all three open reading frames), IRES (internal ribosomal 
entry site), PuroR (puromycin N-acetyltransferase gene), globin pA (globin poly A signal), SV40 ori (simian virus 
40 origin of replication), ampR (ß-lactamase: ampicillin resistance gene), Py ori (Polyoma origin of replication). 
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Figure13. Map of the lentiviral vector p442L1. Abbreviations: ampR (ß-lactamase), RU5 (HIV 5’ LTR splice donor 
site, necessary for the integration of gene in to host genome), RRE (Rev responsive element, splice acceptor 
site), SFFVp (spleen focus forming virus promoter), EcoRI/XhoI (restriction sites used for cloning), IRES (internal 
ribosome entry site), VENUSnucmem (fluorescent protein with nuclear membrane anchor), PRE (post regulatory 
element), SIN (self-inactivating 3’ LTR). 
 
 
 
Figure 14. Map of the targeting vector pTVRosa26-mxCT. Abbreviations: SA (splice acceptor), RFP (red 
fluorescence protein), neoR (neomycin phosphotransferase), FRT (34 bp palindromic sequence, which allows 
Flp-mediated removal of neoR), pA (bidirectional polyA signal), loxP (34 bp palindromic sequence, which is the 
target for Cre recombinase), mxCT (murine xCT cDNA), pA (polyA signal), SD (splice donor), KpnI restriction 
unique site used for linearization of the plasmid. 
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Figure 15. Map of the HPRT targeting vector. hCMVeiE (human CMV early immediate enhancer/CAG chicken ß-
actin promoter), loxP (34 bp palindromic sequence, which is the target for Cre recombinase), RFP (red 
fluorescence protein), FRT sequence (34 bp palindromic sequence, which allows Flp-mediated removal of neoR), 
pA (three polyA signals), mxCT (murine xCT cDNA), FseI/AsiSI (restriction sites used for linearization of the 
plasmid), bla (ampicillin resistance gene). 
 
Cell lines            
 
Primary mouse embryonic fibroblasts (MEFs) were isolated from E12.5 mouse embryos 
arising from breeding pairs that were heterozygous for Txnrd2 (wt/ko). Isolated MEFs were 
stably transfected with the pCAG-3SIP-mxCT and pCAG-3SIP-EGFP expressing vectors 
yielding the respective cell lines. 
 
Murine E14tg2a embryonic stem (ES) cells were a kind gift from Dr. W. Wurst’s laboratory 
(Helmholtz Zentrum München). E14tg2a 129/Ola-derived HPRT-negative ES cells were used 
for the generation of the transgenic mouse line R26mxCT flSTOP. 
 
HH514 is a human, EBV-positive Burkitt’s lymphoma cell line (Y163H + frame shift: 
E287stop). This cell line was already stably transfected with the expression constructs 
pCAG-3SIP-mxCT and pCAG-3SIP by Ana Banjac (Banjac, 2005). 
 
HEK293 T cells were used for the production of lentiviral particles, based on the third 
generation lentiviral vector p442L1 (kind gift from Dr. T. Schroeder, Helmholtz Zentrum 
München). 
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Probes for Southern Blot analysis        
 
The Rosa26-Probe was a kind gift from Dr. Cornelia Hoemig (Hömig, 2005). A 550 bp long 
fragment encompassing the first intron of the Rosa26 locus was cloned via EcoR und PacI 
sites into the plasmid pBSIIKS.  
 
The Neo-Probe was a kind gift from Dr. Cornelia Hoemig (Hömig, 2005).The probe (466 bp) 
was isolated with RsrII and PstI from the pBSIIKS-Neo plasmid. 
 
Probes for Northern Blot analysis         
 
The mxCT-Probe was amplified by PCR using the pCAG-mxCT plasmid as template and 
xCT for1/xCT rev1 as primer pair. 
2.2. Methods 
 
2.2.1. Cell culture 
 
Bacterial cells 
 
The bacterial strain TOP10 was cultured either on LB agar plates or in LB liquid medium, in 
an incubator at 37°C over night. Selection of transformed bacteria on agar plates or in liquid 
medium was achieved by use of the corresponding antibiotics. 
 
LB medium: 20 mM MgSO4, 10 mM KCl, 1% (w/v) Tryptone, 0.5% (w/v) Bacto yeast extracts, 0.5% 
(w/v) NaCl 
LB agar: 20 mM MgSO4, 10 mM KCl, 1% (w/v) Tryptone, 0.5% (w/v) Bacto yeast extracts, 0.5% (w/v) 
NaCl, 1.2% (w/v) Bacto-agar 
 
Murine embryonic fibroblasts (MEFs) 
 
Hemizygous Txnrd2 knock-out mice were mated and females were checked daily for vaginal 
mucous plugs. A vaginal mucous plug was considered as embryonic day 0.5 (E0.5). 
Pregnant mice were sacrificed at E12.5 by cervical dislocation. Uterine horns were dissected 
under sterile conditions and placed into a Petri dish containing PBS. Each embryo was 
separated from its placenta and surrounding membranes. The body trunk was dissected from 
the organs and washed with fresh PBS to remove blood and other tissue debris. Embryo tails 
were used for determination of the genotype by using TR2_Del_for/TR2_Del_rev and 
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TR2_flox_for/TR2_flox_rev primer pairs. Only when the floxed allele is deleted by Cre 
recombinase, the distance between TR2_Del_for/TR2_Del_rev primer binding sites is small 
enough to be amplified by standard PCR. The second primer pair, 
TR2_flox_for/TR2_flox_rev, was used to detect the wt allele, and thus to determine genotype 
(either Txnrd2−/− or Txnrd2+/−) of the cells. By using two forceps embryo trunks were minced, 
suspended in trypsin-EDTA and incubated at 37°C for 15 min. The suspension was 
homogenized by vigorous pipetting, the cells were collected by centrifugation (1,200 rpm/5 
min) and washed in Standard DMEM to remove trypsin. After washing, the cells were plated 
in 6 cm diameter cell culture dishes (referred to as passage No. 0). Cells were cultured at 
37°C in a 5% O2, 5% CO2 water-saturated atmosphere. After the cell lines reached 
confluency, they were split at a ratio of 1:3 on to a larger cell culture dishes. Cells from early 
passage numbers were harvested by trypsinization and aliquots were stored by 
cryo-conservation in liquid nitrogen. Primary cells cultured in Standard DMEM were routinely 
split by trypsinization at a ratio of 1:3 every 4th to 5th day. 
 
PBS: 80.0 g NaCl, 2.0 g KCL, 14.4 g Na2HPO4, 2.4 g KH2PO4 in 1 l H2O, pH 7.4 
Standard DMEM: DMEM, 10% FCS, 1% glutamine, 50 U/ml penicillin G, 50 µg/ml streptomycin 
 
HH514 Burkitt’s lymphoma cell line 
 
The Burkitt’s lymphoma cell line HH514 was cultured at 37°C and 6% CO2 under water-
saturated atmosphere. Cells were grown in Standard RPMI medium and routinely split at a 
ratio of 1:3 every 3rd day. 
 
Standard RPMI: RPMI 1640-medium, 10% FCS, 1% glutamine, 50 U/ml penicillin G, 
50 µg/ml streptomycin 
 
HEK293 T cells  
 
Cells were cultured at 37°C in a 5% O2, 5% CO2 water-saturated atmosphere in Standard 
DMEM. HEK293 T cells were routinely split by trypsinization at a ratio of 1:5 every 2nd or 3rd 
day. 
 
Determination of cell number 
 
Cells were detached from cell culture dishes by trypsinization and suspended by adding 
2.5 volumes of Standard DMEM. Thereafter, 30 µl of the cell suspension was mixed with an 
equal volume of 0.4% trypan blue solution, and cells were counted using the 
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Fuchs-Rosenthal haemocytometer. Trypan blue is excluded from viable cells, whereas dead 
cells stain blue due to plasma membrane disruption. 
 
Cryo-conservation and thawing of cells 
 
Cells were grown in 10 cm diameter culture dishes until they reached approximately 80% 
confluency, trypsinized, and collected by centrifugation. The cell pellets were resuspended in 
FCS containing 10% DMSO, transferred to cryo-vials in 1 ml aliquots and frozen in propanol 
containers at −80°C over night. On the following day, vials were transferred to a liquid 
nitrogen tank. Stocks of all cell lines were stored in liquid nitrogen. 
When needed, frozen cells were defrosted in a water bath at 37°C, immediately transferred 
to 5 ml Standard DMEM and collected by centrifugation. Cell pellets were resuspended in 
10 ml Standard DMEM and plated in 10 cm diameter cell culture dish. 
 
Cell fractionation by digitonin method 
 
For the purpose of cell fractioning, cells were collected from 15 cm cell culture dishes. The 
medium was aspirated and cells were washed two times with ice cold PBS. Cells were 
scraped off with a cell scraper and were resuspended in Digi-buffer. For plasma membrane 
rupture digitonin was added in Digi-buffer in the final concentration of 0,007%. Cells were 
incubated on ice for 15-30 min. Plasma membrane rupture was followed by staining cells 
with Trypan Blue. When the majority of cells (> 95%) were Trypan Blue-positive, they were 
centrifuged for 15 min/4°C/15,000 rpm. The supernatant (cytoplasmic fraction) was stored at 
−20°C until needed. The cell pellet containing plasma membranes and organelles was 
washed in ~200 µl of Digi-buffer and centrifuged once more at 4°C/15,000 rpm. The resulting 
supernatant was discarded, and the cell pellet was lysed in 50-100 µl of LCW and stored at 
−20°C until further needed. 
 
Digi-buffer: 100 mM HEPES (pH 7.4), 250 mM Saccarose, protease inhibitor 
100X digitonin: 0.7% in DMSO (freshly prepared) 
LCW: 0.5% TritonX-100, 0.5% Sodium Deoxocholate Salt, 150 mM NaCl, 20 mM Tris, 10 mM EDTA, 
30 mM Na-Pyrophosphate, pH 7.5 
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2.2.2.Gene-transfer methods 
 
Electroporation of MEFs 
 
Cells were grown on 15 cm cell culture dishes to ~80% confluency, harvested by 
trypsinization, washed in PBS and resuspended in 800 µl DMEM. Primary MEFs were 
electroporated with a Gene Pulser II (Bio Rad, Munich, Germany) at 240 V, 1,000 μF in 
cuvettes with 0.4 cm gap width. For each transfection, ~20 µg plasmid DNA was used. 
Immediately after the pulse, FCS (500 µl) was applied to the cells. The cell suspension was 
plated in a 10 cm diameter cell culture dish in Standard DMEM. Selection for antibiotic 
resistance was initiated 24 h after electroporation with 0.5 µg/ml puromycin, gradually 
increasing to 2 µg/ml over a period of one to three weeks. 
 
Lentiviral infection 
 
Lentiviruses are retroviruses capable of integrating DNA into the target cells. Lentiviruses 
enter the nucleus of dividing and resting cells and are therefore one of the most efficient 
methods for gene delivery into cells. Lentiviral particles were produced in HEK293 T cells 
using a third generation lentiviral packaging system, which provides maximal biosafety. For 
lentivirus production, four different plasmids were co-transfected into the producer cell line 
(HEK293 T). Three plasmids encode all necessary and structural proteins for lentivirus 
production: (i) pEcoEnv-IRES-puro expresses the structural gen env, which encodes the 
surface and transmembrane glycoprotein; (ii) plasmid pMDLg_pRRE expresses the structural 
gene gag that encodes for capsid and matrix proteins and also the enzyme cluster Pol which 
encodes for provirus-integrase, reverse transcriptase, as well as the protease indispensable 
for post-translational modification of the fusion proteins; and (iii) pRSV_Rev plasmid which 
expresses rev (regulator of virion), which promotes the cytoplasmic accumulation of 
unspliced and single spliced viral transcripts. Third generation packaging systems are 
Tat-independent, as the transfer vector pRRL.PPT.SF.IRES-VENUSnucmem (p442L1) 
contains an additional SFFV promoter. 
 
For the generation of lentiviruses, 5 x 106 human embryonic kidney cells (HEK293 T) were 
plated in Standard DMEM in 10 cm diameter cell culture dishes and incubated for 24 h. 
Plasmids (2 µg pEcoEnv-IRES-puro, 5 µg pMDLg_pRRE, 10 µg pRSV_Rev, 5 µg 
p442-based vector) were diluted in 450 µl 12.5 mM CaCl2 and mixed with 500 µl HBS by 
air-bubbling. Cell culture medium was replaced with TF medium, in which chloroquine was 
added to a final concentration of 25 µM. For calcium phosphate transfection, the plasmid mix 
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was vortexed, incubated for 20 min at room temperature and applied drop wise onto the 
HEK293 T cells. Cells were incubated for another 8-12 h. The transfection medium was 
replaced with fresh TF medium, and the transfected packaging cells were incubated for 
further 36 h. Virus-enriched TF medium was recovered from the cell culture dish, filtrated 
through a 0.22 µm sterile filter and ultracentrifuged in a swing rotor for at least 16 h at 
10,000 x g. The virus-containing pellet was resuspended in 200 µl Standard DMEM and 
stored at −80°C until used. 
 
1 x 105 MEFs were transduced in a 3.5 cm diameter cell culture dish by adding 30 µl of the 
virus concentrate, followed by another incubation period for 48 h. Infection efficiency was 
monitored by flow cytometry (BD FACSCalibur), with excitation wavelength at 488 nm and 
analysed using CellQuestTM software (Becton Dickinson). In experiments where the 
p442L1-based vectors, which contain an IRES-puromycin N-acetyl-transferase cassette, 
were used, infected cells were selected with 0.5 µg/ml puromycin 24 h after infection, 
gradually increasing from 0.5 µg/ml puromycin to 1 µg/ml over a period of one to two weeks. 
 
1000X chloroquine : 25 mM chloroquine in PBS  
2X HBS: 50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.05 adjusted with NaOH 
TF medium: Standard DMEM, 20 mM HEPES 
 
2.2.3. Molecular biology techniques 
 
Cloning 
 
Preparation of competent bacterial cells 
 
The E.coli TOP10 bacterial strain (Invitrogen) was grown on LB plates at 37°C overnight. A 
single colony from the plate was used to inoculate 2.5 ml medium in a loose-capped vessel 
with constant shaking. An overnight culture was diluted 1:100 (250 ml) in LB medium 
containing 100 mM KCl and 200 mM MgCl2. Bacterial cells were grown in 1 l flasks until A600 
reached 0.4-0.6. Bacteria were harvested by centrifugation (4,000 rpm/10 min/4°C). The 
pellet was resuspended in ~40% of the original volume of ice cold TFB1. For the remaining 
steps the cells were kept on ice. Finally, bacterial cells were concentrated in 0.04 original 
volume of ice-cold TFB2. Aliquots of 100 µl of the bacterial suspension were snap-frozen in 
liquid nitrogen and stored at −80°C until further use. 
 
TFB1: 15% (w/v) glycerol, 100 mM RbCl, 10 mM CaCl2, 50 mM MgCl2, 30 mM KAc. Adjust pH to 5.8 
with acetic acid. Filter-sterilize (0.45 µm) and store at room temperature.  
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TFB2: 10 mM MOPS or PIPES (pH 6.5), 75 mM CaCl2, 10 mM RbCl, 15% glycerol. Adjust pH to 6.5 
with 1 M KOH. Filter-sterilize (0.45 μm) and store at room temperature. 
 
Transformation of bacteria by heat shock 
 
Aliquots of frozen competent cells were removed from –80°C and thawed on ice. The cells 
were gently mixed by flicking the tube. For transformation, 100 μl of competent cells were 
transferred to pre-chilled sterile polypropylene tubes and either 10 µl of the ligation mixture 
(see below) or 1-10 pg purified plasmid DNA was added to the cell suspension. After 
incubation on ice for 15-20 min, cells were heated to 42°C for 1-2 min and placed on ice for 
10 min. 1 ml of LB medium was added to the cell suspension and incubated with shaking 
(~750 rpm) for 45 min at 37°C. Cells were harvested by centrifugation (4,500 rpm for 5 min), 
and LB excess was discarded. The transformation mixture was resuspended in 200 µl of LB 
and plated on an LB plate containing 50 µg/ml ampicillin (all plasmids used in this study 
expressed ß-lactamase for selection). Plates were incubated for 12-16 h at 37°C until single 
cell colonies became visible. 
 
Preparation of plasmids by the alkaline lysis method 
 
After transformation, single colonies were inoculated in 2.5 ml LB medium, containing 
100 µg/ml ampicillin. The inoculum was incubated with vigorous shaking (~200 rpm) at 37°C 
for 5-7 h or overnight. The volume of 2 ml of the bacterial suspension was centrifuged at 
4,500 rpm for 5 min. The remaining cell suspension (~500 µl) was stored at 4°C until needed. 
The cell pellet was resuspended in 200 µl E1 resuspension buffer by vortexing. E2 lysis 
buffer (200 µl) was added to the cell suspension, mixed by inverting the tubes and incubated 
no longer than 5 min at room temperature. 200 µl of neutralisation buffer E3 was added, 
mixed by inverting the tubes and centrifuged for 8 min at 15,000 rpm. For DNA precipitation 
0.7 volumes of isopropanol was added to the supernatant, and the plasmid DNA was 
recovered by centrifugation (15,000 rpm) for 15 min at 4°C. The DNA pellet was washed with 
70% ethanol, air-dried at room temperature and resuspended in 30 µl TE. 
 
The isolated plasmids were subjected to analytic restriction digestions to identify the correct 
construct and orientation of the insert. After identification of positive clones, the amount of 
plasmid DNA was augmented using the Qiagen Plasmid Maxi Kit. Plasmid concentrations 
were quantified by measuring the absorbance at 260 nm in a spectrophotometer 
(Spectrophotometer DU-64, Beckman Coulter GmbH, Krefeld, Germany). 
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E1 (resuspension buffer): 50 mM Tris, 10 mM EDTA, pH 8.0 
E2 (lysis buffer): 200 mM NaOH, 10% w/v SDS, RNAseA 7,000 U/ml 
E3 (neutralisation buffer): 3.1 M potassium acetate, adjust to pH 5.5 with acetic acid 
TE: 10 mM Tris pH 7.5; 1 mM EDTA 
 
Restriction digestion 
 
DNA restriction digestion was performed with respective endonucleases according to 
manufacturer’s instructions (New England Biolabs GmbH or MBI Fermentas GmbH).  
For cloning, DNA fragments were separated and visualised by electrophoresis in a 0.8% low 
melting point (LMP) agarose gel, stained with ethidium bromide, at 50 V in 1X TAE buffer. 
The desired fragment was isolated from the gel with a scalpel and processed with a Qiagen 
Gel Extraction Kit, according to the manufacturers’ instructions. For analytical purposes, 
digested DNA was separated and visualised by electrophoresis in a 1-2% agarose gel at 
80 V in 1X TAE buffer.  
 
50X TAE: 2 M Tris-acetate (2 M Tris and 5.71% v/v acetic acid); 50 mM EDTA/NaOH pH 8.0 
 
Phenol/chloroform extraction and precipitation of DNA 
 
DNA fragments, obtained from enzyme digestions or other modifications, such as 
dephosporylation reactions or fill-in reactions by Klenow DNA polymerase, were purified by 
phenol/chloroform/isoamylalcohol treatment and ethanol precipitation. An equal volume of 
phenol/chloroform/isoamyl alcohol (ratio of 25:24:1) was added to the digestion reaction, 
briefly vortexed and centrifuged for 8 min at 15,000 rpm. The upper aqueous phase was 
recovered and the DNA was precipitated by adding 2 volumes of absolute ethanol and 0.1 
volume of 3 M sodium acetate (pH 5.5; adjusted with potassium acetate), followed by 
centrifugation at 4°C, 15,000 rpm for 15 min. The DNA precipitate was washed with 70% 
ethanol, centrifuged as above for 10 min and air-dried at room temperature. The DNA was 
dissolved in 30 µl TE, incubated at 65°C for 10 min in order to fully dissolve the DNA and 
stored at −20°C. 
 
DNA ligation 
 
Ligation reactions were prepared with T4 DNA ligase (New England Biolabs GmbH) 
according to standard procedures as described in the manufacturers’ instructions. Depending 
on the size of the fragments to be ligated, the protocol was adjusted to optimize the 
insert:vector ratio for ligation. The ligation mix was incubated at 16°C for 12-24 h. To quantify 
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the specificity of the ligation reaction, respective backbone and insert DNA were subjected to 
separate control ligations. The ligation reactions were used in subsequent heat shock 
transformation of competent bacteria and further analysed. 
 
Klenow fragment fill-in reaction 
 
For blunt-end cloning DNA fragments were treated with DNA Polymerase I (Klenow 
fragment) according to the manufacturers’ instructions (New England Biolabs GmbH). The 
Klenow fragment retains polymerization fidelity and 3’-5’ exonuclease activity, but is devoid 
of 5’-3’ exonuclease activity. Hence, the Klenow fragment forms blunt ends by either filling-in 
5’-overhangs or by removing 3’-overhangs. Linearised DNA was subjected to fill-in reaction 
by Klenow DNA polymerase for 30 min at room temperature.  
 
Dephosphorylation of linearized plasmid DNA 
 
Dephosphorylation of backbone DNA favours the integration of DNA inserts with 
phosphorylated 5’ ends, since re-ligation of the backbone is prevented. Vector DNA was 
dephosphorylated with CIP (calf alkaline phosphatase) (Roche Diagnostics). Pico-mol of 3´or 
5´ ends were calculated according to the average molecular weight of a nucleotide pair (660 
Da), concentration (µg/µl) of DNA to be used and the size of the fragment (bp) to be used. 
One unit of CIP per 1 pmol 3´or 5´terminal phosphorylated DNA fragments was used, and 
the reaction was incubated for 1 h at 37°C. After dephosphorylation of DNA fragments, 
phenol/chloroform/isoamyl alcohol extraction was performed to remove CIP. 
 
Polymerase chain reaction (PCR) 
 
The standard polymerase reaction (PCR) was performed according to manufacturer’s 
instructions (Invitrogen). The individual PCR steps were optimized for each template and 
primer pair combination. For standard (analytical) amplifications, Taq polymerase (Invitrogen) 
was used, whereas the high fidelity polymerase, Platinum Taq DNA Polymerase (Invitrogen) 
was used for cloning purposes according to the manufacturers’ instructions. The DNA to be 
amplified (1-20 ng) was mixed with 1-2.5 units DNA polymerase, 0.5 µM oligonucleotide 
primers (Metabion International AG), 0.2 mM each dNTP (Fermentas GmbH), 1X PCR buffer 
(Invitrogen) and 1.5 mM MgCl2 (Invitrogen). After PCR amplification, the product was 
analyzed for size, quantity, and/or sequence and used in further experimental procedures. 
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Site-directed Txnrd2 mutagenesis 
 
Exchange of single amino acids within Txnrd2 was performed by site-directed PCR 
mutagenesis in a final volume of 50 µl. Primers of 21 nucleotides were designed such that 
the primer sequence contains a mutated codon approximately in the centre of the primer. 
Codons were chosen according to the highest murine codon usage of the respective amino 
acid. Prior to transformation of competent bacteria, PCR products were digested with DpnI. 
DpnI cleaves only methylated DNA, and is thus suitable to remove template DNA prior to 
transformation of the PCR products in bacteria. Mutations were verified by sequencing.  
 
cDNA preparation 
 
Isolated RNA was first reverse-transcribed to cDNA to provide the necessary DNA template 
for Taq polymerase. Single-stranded cDNA was synthesized from 1 µg of isolated mRNA by 
Reverse Transcription System (Promega) according to manufacturers’ instructions (0.5 U/µl 
Avian myeloblastosis virus (AMV) reverse transcriptases, 1 U/µl RNAsin® broad-spectrum 
RNase inhibitor, 50 ng random primer, 0.25 mM each dNTP, 1X reaction buffer and 5 mM 
MgCl2). The incubation time was extended to 60 min to obtain more abundant transcripts. 
The cDNA amplification was performed with random primers at 42°C. After elongation the 
samples were denatured at 95°C for 5 min and than placed on ice for 5 min. The 20 µl 
first-strand cDNA synthesis reaction mix was finally diluted to 100 µl with nuclease-free water 
and subjected to semi-quantitative and quantitative PCR. 
 
Real-time PCR 
 
For expression analysis the LightCycler FastStart DNA MasterPLUS SYBR Green I Kit in 
combination with LightCycler 1.5 System (Roche) was used. Each RT-PCR reaction mix 
contained the respective primer pair, cDNA and the LightCycler Master Mixes (Taq DNA 
polymerase and SYBR Green I dye for detection) according to manufacturers’ instructions 
(Roche). During each PCR cycle, SYBR Green I intercalates specifically into the double 
strand of the amplified PCR products; ongoing amplification is monitored by measuring the 
increase in fluorescence after each cycle. RT-PCR primers were designed with software 
Primer3 (Rozen and Skaletsky, 2000), standardizing optimal TM of approximately 58°C and a 
product size of 200-300 bp. If possible, primer pairs hybridizing on different exons were used 
to minimize unspecific amplification of possible genomic DNA contaminations. Expression 
levels of the target gene were normalized on 18s or aldolase expression levels. To control 
the specificity of the RT-PCR reaction, the synthesized PCR product was correlated to a 
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specific melting point, which was assessed by running a melting curve program after the final 
cycle. 
 
primer mix: oligonucleotide primer stock solution 5 µM for each primer  
 
Cloning of expression and targeting vectors 
 
pCAG-3SIP-based vectors (xCT, EGFP,MCM) 
 
pCAG-3SIP-based vectors contain a strong hybrid promoter, consisting of the chicken β-actin 
promoter and the CMV enhancer, which is highly active in many cell types and organisms 
(Sawicki et al., 1998). 
 
The pCAG-3SIP-based vectors, expressing EGFP or xCT, were a kind gift from Dr. Ana 
Banjac (pCAG-3SIP-EGFP and pCAG-3SIP-mxCT (Banjac, 2005) and Dr. Alexander Seiler 
(pCAG-3SIP-MCM) (Seiler, 2008) (Figure 12). The vector pCAG-3SIP-mxCT contained the 
coding region of murine xCT-light chain, pCAG-3SIP-EGFP contained the red-shifted variant 
of wild-type GFP and pCAG-3SIP-MCM is a vector expressing the Cre recombinase with 
murine estrogen receptor binding domains (Mer) fused at both the N- and C-terminus of Cre. 
This MerCreMer recombinase does not bind to estrogen but retains binding activity to 
tamoxifen (Tam, selective estrogen receptor modulator). In the absence of Tam the 
MerCreMer fusion protein is bound to the hsp90 complex, and thus retained in the 
cytoplasm. Upon Tam administration the hsp90-MerCreMer complex dissociates and the Cre 
translocates from the cytoplasm to the nucleus, where Cre-mediated removal of the loxP-
flanked cassette occurs. 
 
p442L1-based Txnrd2 expression vectors 
 
The vector pGEM-Teasy-mTxnrd2 was a kind gift from Dr. Antonio Miranda-Vizuete (Centro 
Andaluz de Biología del Desarrollo, Espania). The vector contained the partial 5´ sequence 
of murine Txnrd2. 3’-UTR region containing the SECIS element was missing. The remaining 
part was amplified from murine liver cDNA with the primes “Olig_SECI_BglII_for” and 
“Oligo_SECIS_rev”. The resulting 160 bp PCR product including the entire SECIS element 
was purified, cloned into pDrive (Qiagen, Hilden, Germany) to give SECIS-pDrive and 
sequenced. The SECIS element coding sequence was isolated from the SECIS-pDrive with 
PaeI and BglII and inserted into the same restriction enzyme sites of pGEM-T-Easy-Txnrd2 
(4702 bp), yielding pGEM-T-Easy-Txnrd2-SECIS.  
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To generate a cytoplasmic version of Txnrd2 (cyto-Txnrd2) (see also Turanov et al 2005), a 
second PCR was performed with primers “Oligo_TR2_NheI_&_SacI_rev” and 
“Oligo_KpnI_for”. This amplified the 5´ region of Txnrd2 (551 bp), which, however, lacks the 
coding sequence for the MLS. The PCR was designed as such that a SacI site and NheI site 
were generated (NheI was needed for cloning into the NTAPe vector). The purified PCR 
product was digested with SacI and KpnI and ligated into the same sites of 
pGEM-T-Easy-Txnrd2-SECIS, yielding pGEM-T-Easy-cyto-Txnrd2.  
 
For purification of protein complexes, Txnrd2 was additionally tagged with a Tandem Affinity 
Purification enhanced (TAPe) tag, which was a kind gift from Dr. Marius Ueffing and Dr. 
Johannes Gloeckner (Helmholtz Zentrum München). pcDNA3-NTAPe and 
pGEM-T-Easy-cyto-Txnrd2 were digested with NheI and XhoI. The resulting backbone of 
pcDNA3-NTAPe and the corresponding fragment of pGEM-T-Easy-cyto-Txnrd2 
(cyto-Txnrd2) were ligated to obtain pcDNA-NTAPe-cyto-Txnrd2.  
 
To create the TAPe-tagged mitochondrial version of Txnrd2, the start codon of the NTAP had 
to be removed prior to fusing the MLS of Txnrd2 to the 5´end of the TAPe. At first, the MLS 
was amplified by PCR with pGEM-TEasy-mTxnrd2 as template and the primer pair: 
“Oligo_Txnrd2_ATG_MLS_EcoRI” / “Oligo_mTxnrd2_ClaI”. Since a ClaI site was included in 
the resulting 136 bp fragment, encoding the MLS, the product was cut with EcoRI and ClaI. 
In parallel, the start codon of the NTAPe in pcDNA-NTAPe was removed by means of 
site-directed mutagenesis (primer par “Oligo_ClaI_for” / “Oligo_ClaI_rev”), yielding the vector 
pcDNA3-NoMetNTAPe. Subsequently, pcDNA3-NoMetNTAPe was digested with EcoRI and 
ClaI and ligated with MLS to generate pcDNA3-MLS-NoMetNTAPe. pcDNA3-MLS-
NoMetNTAPe and pcDNA-NTAPe-cyto-Txnrd2 were then digested with EcoRI and NheI, and 
the 7156 bp backbone of the pcDNA-NTAPe-cyto-Txnrd2 vector and the 249 bp fragment of 
pcDNA3-MLS-NoMetNTAPe were ligated to obtain pcDNA3-NTAPe-mito-Txnrd2. 
 
The expression vector p442L1 (kind gift from Dr. Tim Schroeder, Helmholtz Zentrum 
München) was used for efficient gene transfer and protein expression in MEFs by viral 
transduction. 
 
Two fragments carrying mitochondrial (1992 bp) or cytosolic (1887 bp) NTAP-tagged 
versions of Txnrd2 were cloned via EcoRI and XhoI into the backbone of p442L1 (7870 bp) 
to generate p442L1-NTAPe-cyto-Txnrd2 and p442L1-NTAPe-mito-Txnrd2. In any of these 
vectors the VENUS nuclear membrane anchor protein (VENUSnucmem) was replaced by 
the puromycin resistance cassette. This cassette was isolated from the plasmid 
 41
  Materials & Methods 
p442L1-NTAPe-Txnrd1 (kind gift from Pankaj Kumar Mandal, PhD thesis, 2009) using the 
restriction enzymes BsrGI and SnaBI. This fragment replaced VENUSnucmem in the 
p442L1-NTAPe-cyto-Txnrd2 and p442L1-NTAPe-mito-Txnrd2 plasmids to gain the 
p442L1-NTAPe-cyto-Txnrd2-puro and p442L1-NTAPe-mito-Txnrd2-puro vectors. 
 
Generation of the xCT knock-in targeting vector (Rosa26 locus)  
 
Murine xCT cDNA was isolated from the pCAG-3SIP-xCT. To this end, the vector was first 
linearised with EcoRI, blunt-ended by Klenow fill-in reaction, and the resulting vector was 
digested with NheI to obtain a 1653 bp long xCT-containing fragment. This fragment was 
ligated into the dephosphorylated backbone of the pBSIIKS-LMP1 (3133 bp) generated with 
PmeI and XbaI. pBSIIKS-mxCT was digested with AscI and the resulting 1913 bp fragment 
was then ligated into the AscI-digested and dephosphorylated pTVRosa26-EBNA1 (Hömig, 
2005). The pTVRosa26-mxCT vector was then used for gene targeting in ES cells.  
 
Generation of the xCT knock-in targeting vector (HPRT locus) 
 
A 1913 bp long fragment containing the murine xCT cDNA was isolated from pBSIIKS-mxCT 
using AscI. The fragment was then ligated into the AscI-digested and dephosphorylated 
backbone pCAG-3SIP-STOP-EBNA1. The resulting vector pCAG-3SIP-STOP-mxCT was 
finally digested with MluI and BstBI to obtain the hCMVieE/chicken β-actin promoter, mxCT 
cDNA, neoR cassette that was then cloned into the backbone of pMB digested with MluI and 
BstBI. The vector pMB-mxCT was used for gene targeting.  
 
Analysis of genomic DNA, RNA and proteins 
 
Isolation of genomic DNA 
 
Tissues and cultured cells were lysed in buffer containing 50 µg/ml proteinase K. After lysis 
at 55°C overnight, DNA was subjected to phenol/chloroform/isoamyl alcohol extraction. 
 
Lysis buffer: 10 mM Tris pH 7.6; 10 mM EDTA; 0.5% SDS; 10 mM NaCl 
Proteinase K buffer: 50 mM Tris-HCl, pH 7.6, 5 mM EDTA pH 8 
 
RNA isolation  
 
For Northern blot analysis and RT-PCR total RNA from cultured cells (up to 1 x 106) or 
tissues (approx. 30 mg) was isolated with RNeasy Mini Kit (Qiagen) according to 
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manufacturers’ instructions. In brief, the samples were lysed and homogenized in the 
appropriate amount of the denaturing guanidine-thiocyanate containing buffer, which 
immediately inactivates RNAses to ensure purification of intact RNA. Ethanol was added to 
provide the proper binding conditions. The sample was then applied onto RNeasy Mini spin 
column, where the total RNA binds to the column and contaminants can be efficiently 
removed. To avoid DNA contaminations, on-column DNase digestion with the RNase-Free 
DNase Set (Qiagen) was performed. Total RNA was then eluted in 30–100 µl RNAse-free 
water. RNA is generally stable at −80°C for up to one year without degradation. 
Final RNA concentrations were determined by measuring the absorbance at 260 nm in a 
spectrophotometer in triplicate (Spectrophotometer DU-64, Beckman Coulter GmbH, Krefeld, 
Germany). 
 
Radioactive labelling of DNA fragment 
 
Radioactively labelled DNA probes were used for Southern and Northern blots. The DNA 
fragments were labelled using Random Primed DNA Labeling Kit (Roche Diagnostics) and 
50 µCi [gamma-32P]-dCTP (3,000 Ci/mmol, 10 mCi/ml, GE Healthcare) according to 
manufacturers’ instructions. The method of “random primed” DNA labelling (Feinberg et al 
1983) is based on the hybridization of a mixture of all possible hexanucleotides to the DNA to 
be labelled. In brief, ~25 ng of linearised DNA template, dATP, dGTP, dTTP (25 µM each), 
hexanucleotide primer mixture, 1X reaction buffer, 50 µCi [gamma-32P]-dCTP and 
2 U Klenow enzyme were mixed in this order with denatured probe and incubated for 1 h at 
37°C. Non-incorporated nucleotides were separated from the labelled probe by using 
Sephadex G-50 columns (GE Healthcare). Labelling efficiency was detected by using a 
bench-top radioisotope counter (Bioscan, Washington D.C., USA). Immediately before 
hybridisation, the probe was heat-denatured at 95°C for 5 min and placed on ice to prevent 
re-annealing of the labelled fragments. 
 
Northern blot 
 
Total RNA was isolated with RNeasy Mini Kit (Qiagen) according to manufacturers’ 
instructions. Briefly, 10 µg of total RNA was dissolved in 1X volume of RNA loading buffer 
and incubated at 65°C for 5 min to minimize RNA secondary structures. RNA was separated 
on a 1% denaturing agarose gel, containing 2.2 M formaldehyde. Gels were run in 20 mM 
MOPS overnight in 1X MOPS buffer at 20 V. Upon separation equal loading of RNA samples 
was assessed by visualisation of the gel using UV (254 nm) trans-illuminator. Afterwards, 
RNA was transferred to an Immobilon-Ny+ membrane by capillary forces using 10X SSC 
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solution. The gel was placed up-side down on a glass plate and Whatman filter papers 
(dipped in reservoirs with 10X SSC solution). On top of the gel, the Immobilon-Ny+ 
membrane (humidified in deionised water), two Whatman filter papers and several layers of 
paper towel were placed. Finally, a glass plate and a weight were put on top of the staple. On 
the next day the RNA was cross-linked to the membrane by UV light (1,200 J/cm2), and 
thereafter pre-hybridised in Church buffer at 62°C for at least 1 h. Hybridisation was 
performed at 62°C overnight in 15-20 ml of fresh Church buffer, containing radioactively 
labelled probe. The membrane was washed twice with 2X SSC, 1% SDS for 15 min at 62°C 
and then twice with 0.1X SSC, 0.5% SDS for 10 min at 62°C. Subsequently, the membrane 
was exposed to an X-ray film (Amersham HyperfilmTMMP) overnight at −80°C. 
 
Formaldehyde agarose gel: 2.2 M formaldehyde, 20 mM MOPS, 1% (w/v) agarose 
MOPS buffer: 0.4 M MOPS (free acid), 100 mM Na-acetate, 10 mM EDTA/NaOH pH 8.0, pH 7.0 
adjusted with 10 N NaOH 
RNA loading buffer: 50% (v/v) formamide, 2.2 M formaldehyde, 1X MOPS buffer, 50 µg/ml ethidium 
bromide, 0.2% (w/v)  
20X SSC: 3 M NaCl, 300 mM Tris-sodium citrate/NaOH pH 7.0 
 
Immunoblotting 
 
For Western blotting, tissue and cell lysates were prepared in LCW lysis buffer containing 
Protease Inhibitor Cocktail (Roche Diagnostics), sonicated (50% duty cycle and 5 ms of 
pulse width) and incubated for 15 min on ice. Prior to sonication tissue was additionally 
minced by using an overhead stirrer (Eurostar RW16, IKA-Labortechnik). Cell debris was 
removed by centrifugation at 15,000 rpm/4°C for 20 min. The protein concentration was 
determined by the DC Protein Assay (Bio-Rad) according to manufacturers’ instructions. 
Equal amounts of protein lysates were mixed with sample loading buffer and heated for 
5 min at 95°C prior to gel electrophoresis. The proteins were separated by 12% SDS-PAGE 
at constant 100 V in a 250/SE 260 Mini-Vertical Gel electrophoresis unit (Bio-Rad). After 
electrophoresis the proteins were transferred to a Hybond-C super nitrocellulose membrane 
(GE Healthcare) in blotting buffer with a Trans-Blot Semi-Dry Blotter (Bio-Rad) at ~800 µA 
constant current per 1 cm2 of membrane for 1 h. The efficiency of protein transfer from the 
gel to the membrane was confirmed by staining the membrane with Ponceau S. The blots 
were blocked with 5% skim milk in TBST for 60 min and hybridized with a primary antibody in 
5% BSA 1X TBS-T at 4°C overnight. On the next day, the blots were incubated with a 
HRP-conjugated secondary antibody for 60 min at room temperature. Afterwards, they were 
washed three times in 1X TBS-T for 15 min and visualized by ECL detection on Hyperfilm. 
Stripping of Hybond-C super membranes was performed with 0.2 M NaOH for 15 min at 
 44
  Materials & Methods 
room temperature. Prior to second hybridisation, the blots were blocked with 5% skim milk in 
1X TBS-T for 60 min. All following steps were performed as described above. 
 
6X sample loading buffer: 375 mM Tris pH 6.8, 9% (w/v) SDS, 9% (v/v) β-mercaptoethanol, 
50% (v/v) Glycerol, 0.03% (w/v) Bromophenol Blue 
10X running buffer: 250 mM Tris, 1% SDS, 2.5 M Glycine 
Blotting buffer: 1X Running Buffer (10X), 20% Methanol 
Ponceau S: 2% (w/v) Ponceau S in 30% TCA 
TBS-T: 25 mM Tris, 125 mM NaCl, 0.1% Tween-20, pH 8.0 
 
The production of antibodies against xCT and murine Txnrd2 
 
The generation of antibodies, specific for human xCT, murine xCT and murine Txnrd2, was 
performed in collaboration with Dr. Elisabeth Kremmer (Helmholtz Zentrum München). 
Antibodies were raised against the different peptide sequences in rats. The peptides 
HHHHGRLPSLGNKEPPGQEKVGLKC and HHHHDKKPRWFRIMSEKITRC (both human 
xCT) and the peptides HHHHGRLPSMGDQEPPGQEKVVLKC and 
HHHHDKKPKWFRRLSDRITRC (both murine xCT) were used to immunize rats. One peptide 
sequence was used to raise monoclonal antibodies for Txnrd2: VKLHISKRSGLEPTVTG. 
The peptides were obtained from Peptide Specialty Laboratories, Heidelberg, Germany and 
were coupled to ovalbumin (OVA) or bovine serum albumin (BSA) at the C-terminus 
(peptide-OVA/KLH). Monoclonal antibodies were produced by hybridoma fusion technology. 
Two hybridoma clones that produced antibodies specific for human xCT and six for Txnrd2 
were identified among numerous supernatants that were tested by immunblotting. 
 
Immunocytochemistry and confocal microscopy 
 
MEFs were plated on cover slips in 6-well cell culture dishes at ~75,000 cells per well and 
cultured in standard DMEM. For fixation, the medium was aspirated from the cell culture 
dish, and the cover slips were rinsed with PBS. The cells were fixed for 15 min in a 2% PFA 
solution. The cover slips were washed with PBS, and the cells were permeabilized three 
times for 5 min with 0.15% Triton X-100 in PBS. Subsequently, unspecific binding was 
blocked by using PBS+ three times for 10 min. The cover slips were incubated overnight with 
the primary antibody at 4°C in a humidified chamber. Thereafter, cover slips were washed for 
5 min with PBS and subsequently with PBS/Triton (0.15%) for 10 min twice and finally for 
10 min in PBS+. Cells were then incubated with a fluorophore-labelled secondary antibody in 
the dark for 45 min. Cover slips were washed twice for 5 min in PBS/Triton (0.15%) and twice 
for 7 min in PBS. Finally, DAPI-solution was added for 90 s, and the cells were subjected to 
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two final washing steps with PBS for 2 min. The glasses were mounted onto microscope 
slides, using mounting medium (Dako, Cytomation). The slides were dried overnight at 4°C, 
protected from light and sealed with nail polish. The pictures were taken by confocal 
microscopy with Leica DM IRBE microscope, Leica TCS SP2 scanner by using Leica 
Confocal software.  
 
2% PFA: 2% (w/v) PFA in PBS 
PBS+: 1% (w/v) BSA, 0.15% (w/v) Glycin in PBS 
DAPI-solution: 1:10,000 in PBS 
 
2.2.4. Flow cytometry 
 
Detection of intracellular ROS 
 
Dichlorofluorescin diacetate (DCFH-DA, Invitrogen) was used as an indicator for monitoring 
intracellular ROS. DCFH-DA is cell permeable and diffuses across cell membranes, 
whereupon it is hydrolysed by intracellular esterases to yield dichlorofluorescin (DCFH), a 
nonfluorescent compound. DCFH can be oxidized by various types of ROS to the fluorescent 
compound DCF. In order to monitor cellular ROS, cells (~5,5 x 104) were plated and 
incubated with 2 μM dichlorofluorescin diacetate (DCFH-DA) in DMEM for 1 h at 37°C, 5% 
CO2 in a water-saturated atmosphere in the dark. After incubation cells were harvested, 
transferred into the round bottom polypropylene tubes, washed in PBS and resuspended in 
~200 µl PBS. Cellular fluorescence intensity was measured in a flow cytometer (BD 
FACSCalibur) using an excitation wavelength of 448 nm and measured at 530 nm emission 
(FL-1). The recorded results were analysed using CellQuestTM software (Becton Dickinson). 
As a cut-off value for obtaining significant values the number of at least 8,000 cells was used. 
 
DCFH-DA solution: 2 mM DCFH-DA in ethanol 
 
Detection of lipid peroxidation 
 
BODIPY581/591 C11 is a lipophilic fluorescent compound that readily intercalates into 
membranes and upon oxidation shifts its fluorescence from red to green. Thus, it can be 
used to efficiently monitor lipid peroxidation. For this purpose, ~5,5 x 104 cells were plated 
and incubated with 2 µM BODIPY in DMEM for 1 h at 37°C in a 5% CO2 water-saturated 
atmosphere in the dark. After incubation, the cells were harvested and treated as described 
above (2.5.1). Cellular fluorescence intensity was measured in a flow cytometer (BD 
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FACSCalibur) in the FL-1 (green) and FL-3 (red) channels. Cell populations of interest were 
gated and analysed using CellQuestTM software (Becton Dickinson). As a cut-off value for 
obtaining significant values the number of at least 8,000 cells was used. 
 
BODIPY581/591 C11 solution: 2 mM BODIPY581/591 C11 in DMSO 
 
Specific detection of hydrogen peroxide in living cells 
 
New boronate-based compounds (kind gift of Dr. Christopher J. Chang, University of 
California, Berkeley, California (Chang et al., 2004a; Dickinson and Chang, 2008; Miller et 
al., 2005) allow the specific detection of H2O2 within the cell, which is produced due to 
environmental stress and/or accumulate due to genetic manipulation of antioxidant enzymes. 
These new fluorophores allow to measure H2O2 levels also in different subcellular 
compartments including mitochondria (mitochondria peroxy yellow 1). For H2O2 
determination by flow cytometry, ~5,5 x 104 cells were plated one day prior to analysis. After 
overnight cultivation, the standard medium was exchanged with DMEM. The cells were 
incubated with 2.5 µM of Peroxi-yellow acetoxy methyl-ester (PYAM), Peroxi-yellow methyl-
ester (PYME) and mitochondrial Peroxi-yellow (mitoPY) for 1 h at 37°C in a 5% CO2 
water-saturated atmosphere protected from the light. After incubation, cells were treated as 
described under 2.5.3. Cellular fluorescence intensity was measured with a flow cytometer 
(BD FACSCalibur) in FL-1 (green) channel with an excitation wavelength of 450 nm. Cells 
were gated and analysed using CellQuestTM software (Becton Dickinson). As a cut-off value 
for obtaining significant values the number of at least 8,000 cells was used. 
 
Boronate-based compounds: 2 mM in DMSO 
 
Determination of cell viability by flow cytometry 
 
Assessment of cellular DNA content 
 
To measure genomic DNA fragmentation and nuclear DNA content, propidium iodide (PI) 
staining of DNA was used. The cells were harvested by trypsinisation, washed with PBS and 
fixed in 2% of formaldehyde for 30 min on ice. After fixation, cells were permeabilised with 
ice cold 100% ethanol for 15 min, pelleted and resuspended in PBS containing RNAase A 
(40 µg/ml). After 30 min incubation at 37°C, cells were harvested and diluted in ~200 µl of 
PBS. The cells prepared in this way are stable for 1 month at 4°C. The fluorogenic dye PI 
intercalates into double-stranded DNA. Cell suspensions were excited with 488 nm and PI 
emission was recorded on channel FL3 at 661 nm.  
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2% formaldehyde: 2% v/w formaldehyde in PBS 
PI solution: 1 mg/ml PI in PBS 
 
Staining of apoptotic cells by Annexin V-FITC/PI 
 
One hallmark of apoptotic cells is the translocation of the membrane glycerophospholipid, 
phosphatidylserine (PS), from the inner to the outer leaflet of the plasma membrane. 
Annexin V is a 35-36 kDa Ca2+-dependent phospholipid-binding protein that has high affinity 
for PS. Annexin V is very sensitive and detects PS exposure occurring early in the onset of 
apoptotic cells. Annexin V–FITC is typically used in conjunction with a dye that stains for 
dead cells, such as propidium iodide (PI), to distinguish early apoptotic cells 
(Annexin V-FITC-positive, PI-negative) from late cell death (Annexin V–FITC-positive, PI-
positive). During the various steps of classical apoptosis, cells are first Annexin V-FITC-
positive/PI-negative and then during late phases Annexin V-FITC-/PI-double positive. In 
non-classical forms of apoptotic cell death, it has been described that 
Annexin V-FITC-positive/PI-negative can never be detected and only 
Annexin V-FITC-/PI-double positive cells are evident. To detect apoptotic cells, 
approximately 1 x 105 cells were harvested and washed with PBS. Collected cells were 
resuspended in ~150 µl binding buffer containing Annexin V-FITC at a concentration of 
1 mg/ml and incubated in the dark at room temperature. After 30 min of incubation, 50 µg/ml 
propidium iodide (PI) in PBS was added and cells were subjected to flow cytometry 
(BD FACSCalibur) with FL-1 (green) and FL-3 (red) channels with an excitation wavelength 
of 488 nm. Cell populations of interest were analysed using CellQuestTM software (Becton 
Dickinson). Data were collected from at least 8,000 cells. 
 
10X Annexin V binding buffer: 0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl; Store at 4 °C. 
 
Microscopy pictures 
 
Pictures of cells were taken with Axiovert Microscopes (Carl Zeiss, Jena GmbH, Germany) 
and processed using Improvision Openlab 3.0.8 software. 
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2.2.5. Biochemical methods 
 
Determination of cellular cystine uptake activity 
 
Cystine uptake activity was determined by measuring the time-dependent increase of 
radioactively labelled L-[14C(U)] cystine inside cells as described (Bannai and Kasuga, 1985). 
Approximately 1 x 106 cells were plated per 6 cm cell culture dish in DMEM, and incubated 
for 24 h. Cells were washed with pre-warmed PBS(+), followed by the addition of 500 µl 
uptake solution and further incubation at 37°C for 90 s. To control for the specific uptake 
activity of system xC−, 2.5 mM glutamate was added to the uptake solution. The uptake 
solution was aspirated, cells were quickly washed with ice-cold PBS and lysed in 500 µl 
0.5 M NaOH overnight. The protein concentration of the samples was determined by the DC 
Protein Assay (Bio Rad). Then, 200 µl cell lysate, 3 ml scintillation cocktail and 100 µl 0.2 M 
Tris-HCl were mixed in a scintillation tube. The amount of L-[14C (U)] cystine was determined 
by a LS 500 TA Scintillation Counter. To correlate cystine concentration and radioactivity, 5 
µl Uptake Solution (50 µM cystine) was mixed with 500 µl 0.5 M NaOH and the “specific 
activity” of L-[14C (U)] cystine was measured. The cellular cystine uptake activity is expressed 
as nmol cystine min−1 mg−1. 
 
Uptake solution: 50 µM cystine, 0.2 µCi/ml [14C(U)] cystine, 10% glucose, 1% CaCl2, 1% MgCl2 in 
PBS. 5 mM cystine stock solution was dissolved in 0.05 M HCL with stirring for several hours at room 
temperature. 
PBS(+): PBS, 10% glucose, 1% CaCl2, 1% MgCl2 
 
GSH determination by HPLC 
 
Estimation of glutathione was done by method described for estimation of homocysteine with 
slight modification (Feussner et al., 1997).The HPLC system consisted of a System Gold 126 
pump, connected to a System Gold 508 autosampler (both Beckman Coulther GmbH, 
Krefeld, Germany) and a RF-10A XL fluorescence spectrophotometer (Shimadzu, Duisburg, 
Germany). The mobile phase consisted of 95% of 30 mM ammonium-formiate, 40 mM 
ammonium-nitrate buffer (adjusted to pH 3.65 with formic acid) and 5% of acetonitrile. The 
column effluent was monitored by fluorescence detection with an excitation wavelength of 
385 nm and an emission of wavelength of 515 nm. 
 
Intracellular GSH levels were measured in Txnrd2 knock-out cells. Cells were plated 24 h 
prior to GSH measurements in 10 cm diameter dishes. Cells were harvested from cell culture 
dishes with the cell scraper, washed in PBS, resuspended in 500 µl Borate Buffer 1 and 
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homogenized by sonication (50% duty cycle, 5 ms of pulse width). For GSH determinations, 
samples (200 µl) were treated on ice with 20 µl 100 µl/l tri-n-butylphosphine in 
dimethylformamide for 30 min in order to reduce thiols and liberate them from proteins. 200 
µl perchloric acid was added to the samples, mixed and incubated for 10 min on ice. Proteins 
were removed by centrifugation at 10,000 x g for 10 min at 0°C. 100 µl of the supernatant, 
250 µl Borate Buffer 2 and 100 µl (SBDF) were mixed and incubated at 60°C for 60 min. To 
terminate the SBDF derivatization step, the solutions were snap-cooled on ice and 
transferred to a pre-cooled autosampler vial. Aliquots of 50 µl were injected into the column. 
Standard samples of GSH (1 to 25 µM) were prepared by serial dilution in Borate Buffer 1. 
 
Borate buffer 1: 0.2 M boric acid, containing 2 mM Na2EDTA, pH 9.5 
Borate buffer 2: 0.2 M boric acid, containing 5 mM Na2EDTA, pH 10.5 
Perchloric acid: 0.5 M perchloric acid, containing 1 mM Na2EDTA 
SBDF: 1.0 g/l 7-fluoro- benzo-2-oxa-1.3-diazole-4- sulphonate in 0.1 M Borate Buffer 1 
 
2.2.6. ES cell technology 
 
E14tg2a ES cell line 
 
The maintenance of ES cell cultures is far more elaborate than that of many other cell lines. 
The major reason for this is to maintain the pluripotent state of ES cells. The E14tg2a ES cell 
line had been previously adapted for the growth on 0.1% gelatine-coated cell culture dishes. 
ES cells were cultured at 37°C in a 5% CO2 water-saturated atmosphere in E14 media 
containing LIF (leukaemia inhibitory factor) to prevent differentiation of ES cells. To minimize 
the risk of differentiation, ES cells were plated as a single cell suspension of approximately 
1.5 x 105 - 4 x 105 cells per cm2. The medium was replaced every day and the cells were 
generally split every other day at ~80% confluency at ratios between 1:4 and 1:10. 
 
ES cell medium: Stempan medium (PAN-Biotech GmbH, Stempan GMEM prepared mix: 
L-Glutamine, 3.7 g/l NaHCO), ESGRO (LIF) 500 U/ml 
 
Gene targeting in E14tg2a ES cells 
 
ES cells were grown to ~80% confluency and harvested by trypsinization. A small aliquot 
was taken to determine the cell number. The rest of the cells were collected by 
centrifugation, resuspended in PBS to a density of 7 x 106 and washed two times in PBS and 
kept on ice. Twenty µg of linearised targeting vector was used for each transfection using an 
electric pulse of 240 V and a capacitance of 500 µF in electroporation cuvettes with 0.4 cm 
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gap width (Bio-Rad). After transfection, cells were allowed to recover at room temperature for 
10 min. The cell suspension was transferred into E14 medium and plated in 10 cm diameter 
cell culture dishes coated with 0.1% gelatine. Selection for antibiotic resistance was initiated 
36 h after electroporation with 200 µg/ml G418-Sulfate. As a control, one plate of non-
transfected ES cells was plated and treated as transfected cells. Cells were kept under 
selection pressure for the next 9-10 days. Neomycin-resistant single cell colonies appeared 
and were visible by eye. Approximately 10 days after electroporation, individual ES cell 
clones were picked with a pipette and transferred to a gelatine-coated 96-well containing ES 
cell medium. The clones were left over night to attach to the dish, and on the next day they 
were washed in PBS and trypsinized to obtain singe cells. These were re-plated in a fresh 
96-well plate and allowed to grow until ~80% confluency was reached. Afterwards, cells were 
split 1:3. Two replica plates were frozen after they reached ~80% confluency for expansion of 
positive clones. One replica plate was further expanded (1:3) for Southern blot analysis in 
order to identify the clones with homologous recombination. 
 
E14 medium: Stempan medium (PAN-Biotech GmbH; Stempan GMEM already prepared mix: 
L-Glutamine, 3.7 g/l NaHCO), ESGRO (LIF) 100 U/ml) 
 
Freezing of ES cells in 96 well plates 
 
ES cells that were used for further electroporation or used in blastocyst injection were frozen 
in E14 medium containing 10% DMSO. ES cell clones that were picked after electroporation 
with the targeting construct and selection were frozen in E14 medium containing 10% DMSO 
directly in the 96 plates. After reaching proper confluency cells were washed with PBS, 
trypsinized in 25 µl trypsin and resuspended. 200 µl of 10% DMSO E14 medium was used to 
inactivate the trypsin and as a freezing medium. The 96-well dishes were wrapped with 
Laboratory Parafilm M (Pechiney Plastic Packaging Company) and paper towels and stored 
at –80°C not longer than 6 weeks. 
 
Isolation of genomic DNA  
 
To screen for homologous recombination of the targeting construct by Southern blot, 
genomic DNA was isolated directly from 96 wells. The amount of DNA obtained with this 
method is sufficient for Southern blot analysis in a 96 well format. After cell lysis overnight, 
DNA was precipitated in 2X volumes of 100% ethanol/150 mM NaCl at constant shaking for 
15 min at room temperature. DNA was collected by centrifugation of the 96 well plates at 
1,000 rpm for 5 min at 4°C. Afterwards, the DNA was washed three times with 70% ethanol. 
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After air-drying, DNA samples were dissolved in 50 µl 1X TE and stored at −20°C until further 
analysis. 
  
Southern blot 
 
Approximately 10 µg of DNA was digested with the corresponding endonuclease at 37°C 
overnight. Since DNA isolated in described way (as described in subsection 2.2.3.) was not 
very pure, spermidine (4 mM final concentration) was added to allow more efficient DNA 
digestion. The next day DNA fragments were separated on a 1% 1X TAE ethidium 
bromide-stained agarose gel in 1X TAE. Before blotting the DNA on the Immobilon-Ny+ 
membrane (Millipore), the gel was incubated in 0.25 N HCl with gentle shaking for 15 min 
and for DNA denaturation for 1 h in denaturation buffer. DNA was transferred to the 
Immobilon-Ny+ membrane by capillary forces overnight. After blotting, the membrane was 
shortly washed in 2X SSC and pre-hybridised for at least 1 h at 62°C in Church buffer 
(hybridisation buffer). Finally radioactively labelled probe was added to the hybridisation 
buffer and hybridised overnight at 62°C in hybridisation buffer. The next day the membrane 
was washed three times for 10 min in washing buffer at 62°C and exposed to an X-ray film 
(Amersham HyperfilmTMMP) overnight at −80°C. 
 
Denaturation buffer: 1.5 M NaCl, 0.5 N NaOH 
20X SSC: 3 M NaCl, 300 mM Trinatriumcitrat, NaOH pH 7.0-optional 
Church buffer (hybridisation buffer): 200 mM NaH2PO4, 400 mM Na2HPO4, 7% (w/v) SDS, 1 mM 
EDTA, pH 7.1-7.2 
Washing buffer: 0.5% SDS, 0.2X SSC  
 
Blastocyst injection of ES cells 
 
Clones with successful homologous recombination were identified by Southern blot (as 
described in section 2.2.3). Positive clones were thawed and individually expanded for 
blastocyst injection. The clone was split 1:2 24 h before blastocyst injection. On the day of 
blastocyst injection the cells were harvested in the usual way, washed in PBS and injected 
into C57BL/6 blastocysts at the Institute of Experimental Genetics (IEG), Helmholtz Zentrum 
München. Embryonic Stem cells reintroduced into host blastocysts can contribute to all adult 
tissues, including germ cells, if the cells used for blasocyst injection were still pluripotent. 
After injection, 15-20 manipulated blastocysts were re-implanted in pseudo-pregnant foster 
mice. Chimeric mice were born and subsequently bred with C57BL/6 for germ line 
transmission.  
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3. Results 
 
3.1. Functional analysis of mitochondrial thioredoxin reductase (Txnrd2) 
 
3.1.1. Phenotype of primary MEFs lacking Txnrd2 
 
To explore the functions of thioredoxin reductase 2 (Txnrd2) in physiology and disease 
development, Txnrd2 knock-out mice have been previously created in our laboratory (Conrad 
et al., 2006) (Figure 6). To establish Txnrd2−/− and Txnrd2+/+ cell lines, mice heterozygous for 
Txnrd2 allele were mated and inspected daily for vaginal mucous plug. Since Txnrd2 
knock-out mice die between E13.5 and E15.5, primary MEFs were isolated from E13.5 
embryos. To verify the knock-out, semi-quantitative RT-PCR with mRNA isolated from the 
cells was performed (Figure 16 A). A primer pair covering the deleted region (Txnrd2E15-18) 
of the Txnrd2 gene was used. 18s rRNA transcripts served as a control. The absence of 
Txnrd2 protein in the MEFs was further confirmed by immunoblotting using an anti-Txnrd2 
antibody (Figure 16 B). As illustrated in Figure 16, full-length Txnrd2 mRNA and Txnrd2 
protein levels were absent in knock-out cells, but clearly detectable in the control cell lines.  
 
 
 
Figure 16. Analysis of Txnrd2 expression in isolated primary MEFs. (A) Semi-quantitative RT-PCR analyses 
of mRNA isolated from primary MEFs was conducted using a primer pair spanning the coding region of exon 15 
to exon 18 (for further details see figure 6). (B) Lack of Txnrd2 expression was also confirmed by Western 
blotting. The 55 kDa band corresponds to the expected molecular weight of Txnrd2 that was detectable in 
Txnrd2+/+ cells, but not in Txnrd2−/− cells. 
 
As previously shown (Conrad et al., 2004), cell proliferation rates of primary Txnrd2−/− MEFs 
were significantly lower than that of wild-type counterparts, although the underlying reasons 
remained widely elusive. To recapitulate the previously observed proliferation defects, equal 
cell numbers were plated and cell proliferation was monitored over a period of six days. As 
shown in Figure 17 A, cell proliferation of knock-out cells was markedly decreased compared 
to wild-type cells.  
  Results 
 
To compare the cell cycle profiles of primary Txnrd2−/− and Txnrd2+/+ fibroblasts, total DNA 
was stained with PI. Flow cytometry analysis revealed no alterations in cell cycle distribution 
between wild-type and knock-out cells (Figure 17 B). Likewise, the size (FSC) and granularity 
(SSC) of the cells was not changed in Txnrd2−/− cells (Figure 17 C and D). 
 
 
 
Figure 17. Determination of cell proliferation, cell cycle distribution, cell size and cell granularity of 
Txnrd2+/+ versus Txnrd2−/− primary MEFs. (A) Primary Txnrd2−/− fibroblasts showed a strongly decreased 
proliferation rate compared to Txnrd2+/+ cells, confirming previous findings . (B) Cell cycle analysis by measuring 
total DNA content by PI did not reveal any differences in the cell cycle distribution of KO and WT cells. (C, D) The 
intensity of the forward and side scatter did not show any alterations in cell size nor in the granularity between 
wild-type and knock-out cells.  
 
3.1.3. Antioxidants rescue loss of Txnrd2  
 
In order to investigate whether the impairment of cell growth of the knock-out cells is due to 
high levels of intracellular ROS, various antioxidants were included in the proliferation 
experiments. N-acetylcysteine (NAC), α-Tocopherol (α-Toc), glutathion (GSH) and sodium-
selenite (NaSe) were used to test this hypothesis. Increasing concentrations of water-soluble 
(NAC, GSH and NaSe) and lipophilic (α-Toc) antioxidants were added to the cell culture 
medium at the same time when the cells were plated. The number of viable cells was 
determined 72 h later by trypan blue exclusion. The growth of Txnrd2−/− cells was clearly 
augmented with increasing concentrations of GSH compared to untreated Txnrd2-/- cells. 
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When compared to Txnrd2+/+ cells, Txnrd2−/− cells showed an equal proliferation rate at 2 mM 
GSH (Figure 18 A). Addition of 500 nM α-Toc (Figure 18B) and 1mM NAC (Figure 18 B) 
increased the proliferation rate of Txnrd2−/− cells so that knock-out cells proliferated similarly 
to wild-type cells (Figure 18 C). 100 nM NaSe fully restored proliferation of Txnrd2−/− as 
compared to Txnrd2+/+ cells, while higher concentrations of NaSe slowed down rather than 
accelerated the proliferation of knock-out cells (Figure 18 D). 
 
 
 
Figure 18. Antioxidant supplementation restored the proliferation defects of Txnrd2−/− cells. (A, B, C) At 
any concentration used, addition of GSH, α-Toc and NAC improved growth of Txnrd2−/− cells. (D) At lower 
concentrations. NaSe supplementation was beneficial, whereas at higher concentrations became toxic. 
 
3.1.4. Intracellular ROS are augmented in cells lacking Txnrd2  
 
Since the thioredoxin 2/thioredoxin reductase 2/peroxiredoxin 3 system has been considered 
to play a major role in controlling mitochondrial ROS levels, it was hypothesised that the 
impairment of this system may lead to increases in cellular ROS concentrations. To address 
this question, MEFs were seeded in the presence or absence of different antioxidants and 
stained 24 h later with different fluorescent dyes to monitor for intracellular ROS 
accumulation. Compared to control cells, Txnrd2−/− cells exhibited a significant increase (one 
order of magnitude) in basal ROS content, as quantified by flow cytometry using DCFH-DA 
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as a non-specific ROS sensor (Figure 19 A). The ROS accumulation in Txnrd2−/− cells could 
be strongly decreased by antioxidant supplements, such as NAC or α-Toc, compared to 
untreated cells, however not to wild-type levels (Figure 19 B). 
 
Since DCFH-DA does not allow discriminating between soluble ROS, such as H2O2, O2.− and 
lipid peroxides (Bilski et al., 2002; Ohashi et al., 2002), BODIPY 581/591 C11 was utilized to 
assess the amount of lipid peroxidation (Drummen et al., 2002; Itoh et al., 2007). BODIPY 
581/591 C11 intercalates into lipid bilayers and shifts its fluorescence from red to green upon 
oxidation. As shown in Figure 19 C (left), Txnrd2 knock-out cells showed clearly increased 
lipid peroxidation when compared with wild-type cells. Culturing Txnrd2−/− cells in the 
presence of NAC for 24 h did not decrease the amount of lipid peroxides in knock-out cells 
(Figure 19 C middle), whereas treatment of Txnrd2−/− cells with α-Toc reduced the amount of 
lipid peroxides almost to wild-type background levels (Figure 19 C, right). 
 
For specific H2O2 measurements, we obtained boronate-based fluorophores, such as peroxi-
yellow acetoxy methyl-ester (PYAM), peroxi-yellow methyl-ester (PYME) and mitochondrial 
peroxi-yellow (mitoPY) from Dr. Christopher Chang (University of California, Berkeley, 
California, USA) (Chang et al., 2004a; Dickinson and Chang, 2008; Miller et al., 2005). These 
reagents are passively loaded into living cells and detection of H2O2 is based on the 
hydrolytyc deprotection of the boronates with H2O2 which produce fluorescent product. When 
PYAM was used as an H2O2 indicator, Txnrd2 knock-out cells displayed significantly higher 
fluorescence compared to wild-type cells (Figure 19 D left). Also, when PYME and mitoPY 
were used, knock-out cells exhibited a higher shift in green fluorescence (Figure 19 D middle 
and right), indicating an increase of basal H2O2 in the cytosol and mitochondria. 
 
3.1.5. Susceptibility of Txnrd2−/− cells towards pro-oxidants and genotoxic 
agents  
 
As Txnrd2−/− cells showed higher levels of ROS, it was hypothesized that Txnrd2−/− cells are 
more susceptible towards genotoxic agents and agents which induce additional oxidative 
stress. Therefore, knock-out and wild-type cells were treated with pro-oxidants and genotoxic 
agents over a wide range of different concentrations, and the cell viability was analysed by 
trypan blue exclusion 72 h after the onset of treatment. 
 
As illustrated in Figure 20, Txnrd2 knock-out cells were only marginally more sensitive to the 
two anticancer drugs doxorubicine and cisplatin (Figures 20 A and B), whereas H2O2 and  
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Figure 19. Txnrd2 ablation in vitro caused high intracellular ROS levels. (A) High levels of ROS were 
detected by flow cytometry in Txnrd2 knock-out MEFs using the non-selective ROS sensor DCFH-DA. Cells were 
analysed 24 hours after seeding. (B) The strong increase of intracellular ROS in knock-out cells could be 
dampened by the antioxidants NAC (500 µM) and α-Toc (500 nM) to some extent, but not to background levels. 
(C) BODIPY 581/591 C11 staining revealed substantial lipid peroxidation in knock-out cells which was insensitive 
to NAC, but which could be prevented by the lipophilic antioxidant α-Toc. Antioxidants were added to the cells at 
the time of plating. (D) Monitoring cellular ROS with the H2O2–specific boronate-based fluorophores PYAM, 
PYME and mitoPY revealed markedly increased H2O2 concentrations in the cytosol (PYAM, PYME) and 
mitochondria (mitoPY). 
 
t-butylhydroperoxide (BOOH) readily induced cell death in Txnrd2 null cells even at very low 
concentrations compared to wild-type cells (Figures 20 C and D). β-phenylethyl 
isothiocyanate (PEITC), which is present in consumable cruciferous vegetables (Yu et al., 
1998), was also used in these experiments, because recent studies suggested that this 
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compound increases ROS and induces apoptosis in cancer cell lines (Trachootham et al., 
2006; Wu et al., 2005; Yu et al., 1998; Zhang et al., 2003). In addition, it was shown that 
PEITC causes rapid oxidation of mitochondrial Prx III (Brown et al., 2008). Similarly to H2O2 
and t-butylhydroperoxide, Txnrd2−/− cells were clearly more vulnerable to increasing PEITC 
concentrations than wild-type cells (Figure 20 E). 
 
The antibiotic antimycin A interrupts the electron flow from semiquinone to ubiquinone in the 
Q-cycle of complex III of the respiratory chain. Antimycin A is thus regarded to trigger the 
formation of large quantities of superoxide anion. When Txnrd2−/− cells were treated with 
antimycin A, they died already at very low concentrations, while wild-type cells were clearly 
more resistant to antimycin A (Figure 20 F). 
 
 
Figure 20. Txnrd2−/− cells are highly sensitive to pro-oxidants, but almost equally resistant to genotoxic 
agents. The same number of the knock-out and wild-type cells was seeded in the presence of different 
pro-oxidants and genotoxic agents, and cell viability was determined 72 h later by trypan blue exclusion. (A, B) 
Txnrd2−/− and Txnrd2+/+ control cells were almost equally resistant to the anticancer drugs doxorubicin and 
cisplatin. (C, D) Txnrd2−/− MEFs rapidly died in response to increasing concentrations of H2O2 and 
t-butylhydroperoxide and to a lesser extent when PEITC was used (E). (F) Antimycin A triggered rapid cell death 
in Txnrd2−/− cells already at very low concentrations. Each value represents the mean±S.D from triplicate assays. 
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From these findings one can conclude that Txnrd2−/− cells show high levels of overall cellular 
ROS, which can be partially blunted by antioxidants, and that Txnrd2−/− cells are highly 
susceptible to pro-oxidants but not to genotoxic agents.  
 
3.1.6. Sensitivity of Txnrd2−/− cells towards inhibition of de novo GSH 
biosynthesis  
 
Reportedly, Txnrd2 knock-out cells are highly susceptible to GSH depletion induced by 
L-buthionine sulfoximine (BSO), a highly specific and irreversible inhibitor of 
γ-glutamyl-cysteinyl-synthetase (γ-GCS) (Conrad et al., 2004). γ-GCS catalyses the first and 
rate-limiting step of GSH synthesis. To test whether Txnrd2−/− cells may show differences in 
basal intracellular GSH concentrations, total (GSH) and oxidised (GSSG) GSH levels were 
determined by HPLC analysis. Interestingly, Txnrd2+/+ cells showed considerably higher level 
of GSH than knock-out cells, while GSSG levels were comparable in both cell types 
(Figure 21 A). As the ratio between the level of glutathion (GSH) and oxidised glutathione 
(GSSG) determines the capability of the cells to buffer an increase in ROS, this finding 
explains the highly increased sensitivity of Txnrd2−/− cells to additional exogenous oxidative 
stress. 
 
Next, the effects of experimental GSH depletion on cell survival and cell death was 
investigated more thoroughly. Preferential killing of the Txnrd2−/− cells was further 
demonstrated by treatment of the cells with increasing BSO concentrations. As illustrated in 
Figure 21 B, Txnrd2−/− cells rapidly died already at very low BSO concentrations. 72 h after 
treatment, 5 µM BSO caused cell death in 59% of the knock-out cells and only in 16% of 
Txnrd2+/+ cells. Overall, Txnrd2+/+ cells were much more resistant to BSO: about 50% of 
Txnrd2+/+ cells were still viable at 20 µM BSO, whereas Txnrd2−/− cells had invariably been 
killed by this BSO concentration (Figure 21 B). 
 
Next, total ROS levels were measured in wild-type and knock-out cells by DCFH-DA in 
response to BSO-induced GSH depletion. Treatment of Txnrd2−/− cells with increasing 
concentrations of BSO caused a strong increase of ROS in these cells (almost 2 orders of 
magnitude) compared to untreated knock-out and wild-type as well as BSO-treated wild-type 
cells (Figure 22 A). Interestingly, ROS levels in Txnrd2+/+ cells treated with 15 µM BSO were 
comparable to that of untreated Txnrd2−/− cells (Figure 22 B). 
  
In order to address whether Txnrd2 knock-out cells die in an apoptotic manner in response to 
BSO-mediated GSH depletion, cells were stained with AnnexinV-FITC/PI and analysed by 
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flow cytometry. During “classical” apoptosis, phosphatidylserine (PS), which normally resides 
at the inner side of the plasma membrane, is externalised, and thus can be used to detect 
 
 
 
Figure 21. Txnrd2−/− cells have strongly diminished levels of reduced glutathione. (A) HPLC analysis of 
glutathion (GSH) and oxidised glutathione (GSSG) in Txnrd2−/− and Txnrd2+/+ cells revealed that knock-out cells 
had strongly decreased levels of reduced GSH (3.8±2.5 nmol/l/g) compared to wild-type cells (17.1±3.4 nmol/l/g). 
(B) Accordingly, Txnrd2−/− cells were highly sensitive to increasing BSO concentrations compared to Txnrd2+/+ 
cells. Cell numbers were evaluated by trypan blue exclusion 72 h after BSO treatment. 
 
early apoptotic cells by Annexin-V, a specific PS-binding protein. Annexin-V in combination 
with propidium iodide (PI) can be used to monitor for early and late apoptotic cells and/or 
necrotic cells. Early apoptotic cells are positive for Annexin-V, but negative for PI. Late 
apoptotic cells and necrotic cells are double positive for Annexin V and PI. Figure 22 C 
shows that when Txnrd2−/− cells were treated with 5 µM BSO for 72 h, they had an increased 
number of Annexin-V-positive cells, reaching almost one third of the complete cell population 
(R1=30%), in comparison to Txnrd2+/+ cells in which 12% of the cells were Annexin-V 
positive (R1=12%). There was also a considerable increase in Annexin-V/PI-double positive 
cells among BSO-treated Txnrd2−/− cells, which was about one third of the whole cell 
population (R2=29%) as compared to BSO-treated Txnrd2+/+ cells (R2=4%). Accordingly, 
84% of the Txnrd2+/+ cells and only 41% of the Txnrd2−/− cells were viable at 72 h post-
treatment. 
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Figure 22. BSO-treatment exacerbates ROS production and cell death in Txnrd2 knock-out cells. (A, B) 
ROS formation was strongly induced by BSO in Txnrd2−/− cells (A) and to a lesser extent in wild-type cells (B). (C) 
Cell death was measured by Annexin-V/PI staining. Txnrd2−/− and Txnrd2+/+ cells were cultured in the presence of 
5 µM BSO for 72 hours. Annexin V and PI staining revealed an increasing number of Annexin V-positive and 
PI-positive Txnrd2−/− compared to control cells. 
 
3.1.7. Expression of mitochondrial peroxiredoxins is increased in Txnrd2−/− 
cells  
 
The mitochondrial thioredoxin system has been postulated to be the major system to provide 
reducing equivalents to mitochondrial peroxiredoxins (Prx III and V), which are critically 
involved in the detoxification of H2O2 and other peroxides generated as a side product of 
mitochondrial respiration. 
 
Since Txnrd2 knock-out cells were shown to have strongly elevated ROS levels (see section 
3.1.4.), it was interesting to see whether Txnrd2-deficiency may impinge on the expression 
and regulation (oxidation) of the different peroxiredoxins.  
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First, mRNA levels of the different peroxiredoxins (Prx I-VI) were analysed by semi-
quantitative RT-PCR analysis in Txnrd2+/+ and Txnrd2−/− cells either treated with BSO or left 
untreated. Semi-quantitative RT-PCR PCR showed that the basal transcript levels of Prx III 
and Prx V were strongly increased in Txnrd2−/− cells as compared to Txnrd2+/+ cells, whereas 
Prx I, Prx II, Prx IV and Prx VI mRNA levels did not differ between wild-type and knock-out 
cells (Figure 23 A). Only when the cells were treated with 15 µM BSO for 12 h, Prx III and 
Prx V expression could be induced in Txnrd2+/+ cells to levels comparable to that in untreated 
Txnrd2−/− cells. Exposure of Txnrd2−/− cells to 15 µM BSO for 12 h did not further enhance 
Prx III and Prx V expression. Next, the protein levels of PrxIII were examined in cells treated 
with increasing H2O2 concentrations. Prx III was strongly up-regulated in knock-out cells by 
treatment with 10 µM H2O2 for 15 min, while a concentration of 750 µM H2O2 was required to 
achieve the same response in wild-type cells (Figure 23 B). 
 
Next, the cells were exposed to t-butyl-hydroperoxide (BOOH) for different time periods to 
explore whether loss of Txnrd2 causes increased oxidation of peroxiredoxins in the cells after 
exogenous oxidative stress. To this end, an antibody was used which recognizes the sulfinic 
(Cys-SO2H) and sulfonic (Cys-SO3H) forms of the active site cysteines of peroxiredoxins . 
Without BOOH treatment, overoxidation of the different peroxiredoxins was neither 
detectable in Txnrd2+/+ nor in Txnrd2−/− cells. However, when cells were treated with BOOH, 
Prx I/Prx II and Prx III appeared to be oxidised to a larger extent in knock-out as compared to 
wild-type cells (Figure 23 C). Due to the same molecular size of Prx I and Prx II, one cannot 
discriminate both peroxiredoxins by one dimensional SDS-PAGE and immunoblotting 
(Figure 23 C). 
 
3.1.8. Time-dependent increase of Prx III levels in response to H2O2 
 
To further explore the kinetics of Prx III up-regulation at the transcription and protein level in 
more detail, Txnrd2+/+ and Txnrd2−/− cells were treated with a given concentration of H2O2 
(250 µM) over a time period of 120 min and the expression analysed by semiquantitative 
RT-PCR and Western blotting. Prx III transcript levels were induced in Txnrd2+/+ cells 5 min 
after H2O2 treatment and remained almost constant up to 60 min after which the transcript 
levels decreased. In Txnrd2−/− cells, due to the higher basal PrxIII expression in untreated 
cells (see Fig. 23 A), Prx III mRNA levels increased only slightly, after 5 min of treatment and 
remained constant during the remaining time period (Figure 24 A). Prx III protein levels were 
high and stayed almost constant in Txnrd2+/+ cells, regardless of H2O2 treatment, whereas 
Prx III protein levels were clearly induced in knock-out cells 5 min after H2O2 exposure 
(Figure 24 B). While in control cells the level of Prx III mRNA and Prx III protein appeared to 
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decrease 60 min after treatment, in knock-out cells both mRNA and protein levels were 
increased irrespective of H2O2 treatment (see Figure 23 A and 24 B). 
 
 
 
Figure 23. Mitochondrial Prx III and Prx V are strongly up-regulated in Txnrd2 knock-out cells. (A) Semi-
quantitative RT-PCR analysis showed that Prx III and Prx V are strongly up-regulated in Txnrd2-/- cells in a 
manner similar to wild-type cells treated with 15 µM BSO for 12 hours. Treatment of Txnrd2-/- cells with BSO did 
not further induce Prx III and Prx V expression. 18s rRNA served as control. (B) Treatment of Txnrd2+/+ and 
Txnrd2−/− fibroblasts with increasing H2O2 concentrations (0.01, 0.05, 0.1, 0.25, 0.5, 0.75 and 1 mM) for 15 min 
strongly induced Prx III protein levels in Txnrd2−/− fibroblasts at very low concentrations. (C) Txnrd2+/+ and 
Txnrd2−/− cells were treated with 500 µM t-butyl-hydroperoxide for 10 and 60 min. Immunoblot analysis with a 
sulfinylation/sulfonylation-specific antibody (Prx-SO3) revealed overoxidation of Prx I/Prx II and Prx III, which 
appeared to be stronger in Txnrd2-/- than in Txnrd2+/+ wild-type cells. 
 
Reduction of the sulfinic acid in the active site cysteine of peroxiredoxins, formed under 
prolonged exposure to oxidants, was shown to require sulfiredoxin (Srx) (Biteau et al., 2003; 
Bondareva et al., 2007; Jeong et al., 2006; Jonsson et al., 2008; Lim et al., 2008; Rhee et al., 
2007; Roussel et al., 2008). It was thus hypothesised that the level of Srx might be elevated 
in the knock-out cells at high H2O2 concentration. Indeed, when the cells were treated for 
different time intervals with H2O2, Srx transcript levels were higher in Txnrd2−/− than in control 
cells, while the Srx mRNA levels in the Txnrd2+/+ control cells were not affected 
(Figure 24 A). 
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Figure 24. Different kinetics in the regulation of Prx III in Txnrd2 wild-type and knock-out cells in response 
to H2O2. (A) Txnrd2−/− and Txnrd2+/+ fibroblasts were treated with 250 µM H2O2 for the indicated time intervals. 
Semi-quantitative RT-PCR showed that the Prx III mRNA levels were only slightly induced in Txnrd2−/− cells 5 min 
after treatment and remained constant throughout the 120 min of treatment, presumably due to the higher basal 
expression of PrxIII in these cells. In contrast, Prx III mRNA expression was clearly induced in Txnrd2+/+ cells after 
5 min and down-regulated at 120 min. The level of the Srx mRNA was elevated at any tested time point in 
Txnrd2−/− cells but not in Txnrd2+/+ cells. 18s rRNA served as control. (B) Coinciding with the increased Prx III 
transcript levels, there was also an increase in the Prx III protein levels 5 min after H2O2 treatment, which reached 
a maximum at 30 min. In knock-out cells Prx III expression was high and remained constant. 
 
3.1.9. Ectopic expression of Txnrd2 and Txnrd1 in Txnrd2−/− cells 
 
At least three N-terminal splicing variants with different subcellular localisation of Txnrd2 
have been described (Turanov et al., 2006) (Figure 25 A). To answer the question whether 
the phenotype of Txnrd2 knock-out cells is due to specific inactivation of Txnrd2 and not due 
to possible secondary side-effects, Txnrd2 expression was reconstituted in Txnrd2−/− cells. 
As a control Txnrd2 wild-type cells were included. Two of the three reported isoforms were 
generated: one is the predominant mitochondrial version of Txnrd2 with the N-terminal 
mitochondrial leader sequence (MLS) (Figure 25 A), the second variant lacks the MLS and 
accordingly has been reported to reside in the cytoplasm (Figure 25 A; Txnrd2a). The 
cytoplasmatic Txnrd2b form, which has an N-terminal extension of 12 amino acids in mice 
and humans was not included in this study (Turanov et al., 2006). To reconstitute Txnrd2 
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expression of both forms, a lentivirus-based system was used (Figure 13). Lentiviral 
transduction is highly efficient in primary cells and expression of the gene of interest is very 
stable. The vectors used for transduction of the cells express the puromycin 
N-acetyltransferase gene for stable selection of transduced cells with puromycine. Of note, 
exogenous Txnrd2 expression was much more pronounced than expression of endogenous 
Txnrd2 in wild-type MEFs (Figures 25 B and C). To assure that Sec is incorporated at the 
UGA codon, cells were supplemented with 25 nM NaSe (Nalvarte et al., 2004a). When the 
lysates of cells overexpressing mitoTxnrd2 were probed with an anti-Txnrd2 antibody, two 
bands appeared (Figure 25 B, second panel), whereas overexpression of Txnrd2a (referred 
to as cytoTxnrd2 in the following) revealed only one band. When the lysates were probed 
with the FLAG antibody only one band was obtained for both mitoTxnrd2 and cytoTxnrd2. 
The origin of the second band has remained elusive. 
 
The subcellular localization of the two isoforms was additionally studied by 
immunocytochemistry using a FLAG-specific antibody and confocal microscopy. As 
predicted, mitoTxnrd2 was clearly detected in mitochondria (Figure 25 D), whereas 
cytoTxnrd2 was found in the cytoplasm (Figure 25 E), thus confirming the previous reports by 
Turanov et al. (Turanov et al., 2006). This indicates that the presence of the N-terminal tag 
had no effect on the subcellular localisation of Txnrd2. Next, the proliferation rates of Txnrd2 
knock-out and wild-type cells expressing either empty-virus (mock), or mitoTxnrd2 and 
cytoTxnrd2 were compared. Compared to mock-transduced Txnrd2−/− cells, knock-out cells 
expressing either mitoTxnrd2 or cytoTxnrd2 had a higher proliferation rate than 
mock-transduced cells (Figure 25 F). Intriguingly, wild-type cells transfected with either 
Txnrd2 variant decreased the growth rate to some minor extent (Figure 25 G). 
 
3.1.10. Stable expression of Txnrd1 in Txnrd2 knock-out cells 
 
Since it was shown previously that Txnrd2 reduces thioredoxin 1 and 2 (Trx1 and Trx2) 
equally well and that there is some kind of in vitro redundancy between Txnrd1 and Txnrd2 
(Conrad et al., 2006; Turanov et al., 2006), it was intriguing to see whether overexpression of 
Txnrd1 had any effect on the formation of ROS and proliferation of Txnrd2−/− cells. To 
express Txnrd1 in the Txnrd2 knock-out cells, the lentiviral expression vector p442L1 was 
used (a kind gift from Pankaj Kumar Mandal) (Figure 26 A). Figure 26 A shows that that 
NTAPe- (N-terminal Tandem Affinity Purification enhanced, TAPe)-tagged Txnrd1 is highly 
expressed in Txnrd2 knock-out cells (for details regarding the TAPe tag see 3.1.12.). 
Confocal microscopy after staining with a FLAG-specific antibody confirmed that NTAPe-
tagged Txnrd1 is expressed in the cytoplasm (Figure 26 C). 
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Figure 25. Stable expression of mitochondrial Txnrd2 and cytoplasmatic Txnrd2 in Txnrd2−/− and Txnrd2+/+ 
cells. (A) Depicted are the three alternative N-terminal variants of Txnrd2 (Turanov et al., 2006). (B) 
Immunoblotting performed with an anti-FLAG or an anti-Txnrd2 antibody revealed high expression of mitoTxnrd2 
and cytoTxnrd2 in Txnrd2−/− and Txnrd2+/+ cells. Endogenous Txnrd2 is detectable after longer exposure in wild-
type but not in knock-out cells. (C-E) The subcellular localization of mitoTxnrd2 and cytoTxnrd2 was further 
analysed by immunocytochemistry and confocal microscopy using an anti-FLAG antibody. Scale bars 
10 µM. (F, G) Add-back of both mitoTxnrd2 and cytoTxnrd2 into Txnrd2−/− cells restored proliferation of Txnrd2-/- 
cells, and slowed down the proliferation of wild-type cells to a minor extent. 
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Figure 26. Stable expression of Txnrd1 in Txnrd2−/− cells. (A) Western blot analysis of two independent 
Txnrd2−/− cell clones stably expressing TAPe-tagged Txnrd1. While the FLAG antibody only detects the tagged 
protein, the Txnrd1-specific antibody also reveals endogenous Txnrd1 levels. (B) The subcellular localization of 
Txnrd1 in Txnrd2−/− MEFs was demonstrated by immunocytochemistry using the FLAG antibody and confocal 
microscopy. Scale bars 10 µM. 
 
3.1.11. Add-back of mitoTxnrd2 rescues Txnrd2−/− cells from cell death induced 
by GSH depletion  
 
To investigate whether the add-back of the different Txnrd2 variants has any impact on 
intracellular ROS levels, Txnrd2−/− cells expressing mitoTxnrd2, cytoTxnrd2 or Txnrd1 were 
stained with DCFH-DA and analysed by flow cytometry. Figure 27 shows that intracellular 
ROS accumulation was effectively dampened in Txnrd2−/− cells expressing mitoTxnrd2, 
cytoTxnrd2 or Txnrd1 as compared to mock-transfected Txnrd2−/− cells. This finding was 
surprising because it had been anticipated that ROS generated by mitochondria would be 
effectively cleared only by the mitochondrial thioredoxin system, but apparently cytoTxnrd2 
and Txnrd1 were also functional. 
 
To investigate whether the different enzyme forms are able to protect Txnrd2−/− cells from 
BSO-induced cell death, Txnrd2−/− cells were treated with different BSO concentrations and 
cell viability was determined 48 h after treatment. As shown in Figure 28, knock-out cells 
stably expressing mitoTxnrd2 were highly resistant to BSO-mediated GSH depletion and 
these cells were even slightly more resistant than mock-transfected Txnrd2+/+ cells. 
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Overexpression of cytoTxnrd2 in Txnrd2−/− cells provided partial rescue of cell viability after 
BSO treatment compared to mock-transduced and Txnrd1-transduced Txnrd2−/− cells. 
 
 
 
Figure 27. Overexpression of Txnrd2 and Txnrd1 reduced ROS levels in Txnrd2−/− cells. Txnrd2-/- cells 
overexpressing the different forms of Txnrd2 and Txnrd1 were plated and stained for ROS with DCFH-DA 24 h 
after BSO treatment. 
 
From this experiment one may conclude that efficient dampening the intracellular ROS levels 
by overexpression of the Txnrd1 and mitochondrial and cytoplasmic Txnrd2 is not 
necessarily coupled to rescue from GSH-depletion-induced cell death.  
 
 
 
Figure 28. Re-expression of mitoTxnrd2 rescues Txnrd2−/− MEFs from BSO-induced cell death. 
Reconstitution of mitochondrial Txnrd2 rescued the cells from BSO-induced cell death, whereas cytoplasmatic 
Txnrd2 could only partially rescue viability and Txnrd1 was ineffective. Cell viability was determined by trypan blue 
exclusion 48 h after BSO treatment.  
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3.1.12. The role of Txnrd2 in normal physiology and disease 
 
3.1.12.1. Identification and functional characterisation of two novel Txnrd2 mutations 
in patients suffering from dilated cardiomyopathy (DCM) 
 
It had been shown previously in our laboratory that mice lacking Txnrd2 die during embryonic 
development due to impaired foetal haematopoiesis and perturbed cardiac development 
(Conrad et al., 2004). In the same study it was also demonstrated that heart-specific 
inactivation of Txnrd2 resulted in a cardiac phenotype reminiscent of human dilated 
cardiomyopathy (DCM) with biventricular dilatation of heart chambers and thinning of 
ventricular walls. Transmission electron microscopy (TEM) analysis of cardiac tissue of heart-
specific Txnrd2 knock-out mice showed swelling of mitochondria and partial destruction of 
mitochondrial cristae (Conrad et al., 2004). 
 
The phenotype of mice with heart-specific deletion of Txnrd2 suggested that Txnrd2 might be 
involved in the pathogenesis of DCM. To address the question whether this is indeed the 
case, a collaborative study was initiated in collaboration with Dr. N. v. Beckerath and 
Dr. D. Sibbling, Klinikum rechts der Isar and Deutsches Herzzentrum, Technische Universität 
München) and Dr. Arne Pfeufer (Institute of Human Genetics, Helmholtz Zentrum München) 
searching for mutations in the Txnrd2 gene of DCM patients. In the course of this study the 
genomic structure of the Txnrd2 gene has been analysed in 227 DCM patients by cycle 
sequencing including the respective forward and reverse primers and BigDye-Terminator 3.1 
(Qiagen, Hilden, Germany) sequencing technology. Two mutations have been identified in 
three patients suffering from DCM. 
 
In this study the Ala codon (GCC) at position 59 was found to be changed to Thr (ACC) and 
the Gly codon (GGG) at position 375 was exchanged to Arg (AGG) (Figure 30). Both 
mutations were not observed in healthy subjects. The presence of these mutations was 
further verified with a additional matrix-assisted laser ionization (MALDI), a technique 
allowing the analysis of proteins by ionization. The ionization is triggered by a laser beam 
and matrix is used to protect the biomolecule from being destroyed by direct laser beam and 
to facilitate vaporization and ionization. The first mutation (Ala59Thr) was found in two out of 
227 DCM patients (2/227=0.88%). The second mutation (Gly375Arg) was found in one out of 
the 227 DCM patients (1/227=0.44%). As identification of amino acid changes in a given 
gene does not imply that the protein is functionally impaired and the molecular aetiology of 
congestive heart failure due to dilated cardiomyopathy (DCM) remains poorly understood, it 
was mandatory to demonstrate that the mutations found in DCM patients impact on the 
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function of Txnrd2. To this end, we used Txnrd2+/+- and Txnrd2−/−-MEFs as a cellular model 
system. As shown in Figure 29, the amino acid sequence of Txnrd2 among mammals is 
highly conserved. Moreover, the positions of the altered amino acid residues are located in 
highly conserved regions of Txnrd2; yet, it was not clear whether the two amino acid 
exchanges may have any impact on Txnrd2 function. To test the functional activity of the 
mutated Txnrd2 forms in cells, the corresponding mutants were generated in the murine 
mitochondrial form of Txnrd2 by site-directed PCR mutagenesis, designated as mitoA59T 
and mitoG375R. 
 
The mitochondrial Txnrd2 variant (mitoTxnrd2) was chosen for mutagenesis because this 
form is the predominant form in cardiac tissue and probably also in most other tissues 
(Kiermayer et al., 2007). Moreover, mitochondrial Txnrd2 was shown to rescue Txnrd2−/− 
cells from BSO-induced cell death (see also Figure 28). Both mutant forms, mitoA59T and 
mitoG375R, were cloned into the lentiviral vector p442L1 and stably expressed in Txnrd2−/− 
and Txnrd2+/+ control cells. The expression levels of mitoTxnrd2 and both mutant forms, 
mitoA59T and mitoG375R, were determined by immunoblotting using an anti-Txnrd2 and a 
FLAG-specific antibody (Figures 30 A and B). While the expression level of mitoA59T was 
similar to the expression level of mitoTxnrd2 (Figure 30 A) in both knock-out and control 
cells, the expression of mitoG375R was strongly reduced in both cell lines (Figure 30 B). The 
expression of mitoG375R in Txnrd2+/+ cells was very low and could not be detected by anti-
FLAG antibody either by Western blotting (not shown) or by immuncytochemistry 
(Figure 30 H). To determine the subcellular localisation of mitoTxnrd2 and both mutant 
forms, immunocytochemical staining using an anti-FLAG antibody and confocal microscopy 
were carried out. Unmutated mitoTxnrd2 was localised to mitochondria in wild-type and 
knock-out cells (Figures 30 C and F). Intriguingly, the number of mitochondria appeared to 
be reduced in Txnrd2-/- as compared to Txnrd2+/+ wt cells. Expression ot the mutants 
revealed that mitoA59T was localised in the cytosol and in particulate structures, which might 
represent structurally abnormal mitochondria in Txnrd2 knock-out cells (Figure 30 D). In 
Txnrd2+/+ control cells, mitoA59T showed a predominant mitochondrial localisation pattern 
(Figure 30 G). Confocal microscopy of the Txnrd2−/− cells transfected with mitoG375R 
revealed that the protein was expressed close to the nucleus, within structures similar to 
aggregated mitochondria (Figure 30 E). Besides the aberrant localisation of both mutant 
forms, the proliferation rates of Txnrd2+/+ cells expressing either of the two mutant forms were 
markedly reduced (Figure 31 A). In Txnrd2-/- cells, expression of both mutant forms did 
neither rescue nor further impair proliferation of Txnrd2 knock-out cells (Fig. 31 B), whereas 
expression of mitoTxnrd2 completely rescued the proliferation defect (as had been also 
previously shown in Fig. 25 F). 
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Figure 29. Amino acid sequence alignment of mammalian Txnrd2s. Identical amino acids shared between 
Txnrd2 of the different organisms are shaded in grey. The N-terminal catalytically active site (CVNVGC) and the 
Sec-containing C-terminal active site (GCUG) involved in electron transport are in indicated in blue. Sequences 
that constitute the FAD-binding domains are marked as red boxes and sequences that constitute the 
NADPH-binding domain as a green box. The positions of the conserved amino acids, that were found to be 
mutated in the DCM patients (A59T and G375R) are indicated by red letters. NCBI accession numbers: Canis 
Familiaris (XM_845088.1), Pan Triglotides (XM_001166615.1), Bos Taurus (NM_174626.2), Rattus Norvegicus 
(NM_022584.1), Mus Musculus (NM_013711.2) and Homo Sapiens (NM_006440.3).  
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Figure 30. Stable expression of the Txnrd2 mutants, Ala59Thr and Gly375Arg, in Txnrd2−/− and Txnrd2+/+ 
cells. (A-B) Expression of both mutant forms of Txnrd2 (mitoAla59Thr and mitoGly375Arg) in wild-type and 
knock-out cells was monitored by Western blot analysis using an anti-Txnrd2 and anti-FLAG antibody. The 
expression level of mitoA59T was similar to the expression level of mitoTxnrd2, the predominant form of Txnrd2 in 
the cells. Expression of the mutant mitoG375R was strongly reduced in Txnrd2 knock-out cells and even more 
reduced in Txnrd2+/+ wt cells when compared with the level of expression of the mitoAla59Thr mutant. (C-H) 
Immunocytochemistry with an anti-FLAG antibody showing an aberrant localisation of the Txnrd2 mutant forms 
(mitoA59T and mitoG375R) expressed either in Txnrd2-/- or Txnrd2+/+ MEFs. Scale bars 10 µm. 
 
Next, it was asked whether the expression of the mutated forms of Txnrd2 is able to rescue 
cells from cell death induced by GSH depletion. In Txnrd2−/− cells transduced with the mutant 
and wt form of mitoTxnrd2, the number of viable cells was determined by trypan blue 
exclusion 48 h after the addition of increasing BSO concentrations. As shown in Figure 33, 
the add-back of mitoTxnrd2 prevented cell death of knock-out cells induced by increasing 
concentrations of BSO (Figure 32 A). By stark contrast, Txnrd2−/− cells expressing either of 
the two mutant forms died very rapidly already at very low BSO concentrations (Figure 32 A). 
Remarkably, these cells died even significantly more rapidly than mock-infected Txnrd2−/− 
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cells. In Txnrd2+/+ MEFs, survival was also substantially impaired when the mitoA59T- and 
mitoG375R-forms were expressed in wild-type cells, (Figure 32 B), indicating that both 
mutant forms act in a dominant-negative fashion.  
 
 
 
Figure 31. Growth properties of Txnrd2−/− and Txnrd2+/+ cells expressing either mitoAla59Thr or the 
mitoGly375Arg mutant forms of Txnrd2. (A) Proliferation was strongly impaired when the two mutant forms of 
Txnrd2 were stably expressed in Txnrd2+/+ cells. (B) The slow proliferation rate of Txnrd2−/− cells was not 
substantially affected by expression of the same mutant forms, whereas expression of the unmutated mitoTxnrd2 
form completely rescued the proliferation defect of Txnrd2 knock-out cells (see also Fig. 25 F).  
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Figure 32. MitoA59T and mitoG375R do not rescue BSO-mediated cell death of Txnrd2−/− cells. Cells were 
treated for 48 h with the indicated BSO concentrations and cell survival was monitored by trypan blue exclusion. 
(A) Stable expression of Ala59Thr and Gly375Arg mutants in Txnrd2−/− cells did not rescue GSH 
depletion-induced cell death. In contrast, cells overexpressing the mutant forms died even more rapidly than 
mock-transduced Txnrd2−/− cells. (B) Cell survival of Txnrd2+/+ cells transduced with either mitoA59T or 
mitoG375R was impaired in response to increasing BSO concentrations, indicating that both mutant forms act in a 
dominant-negative fashion. 
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3.2. The role of system xC− in maintenance of intracellular GSH 
levels and cystine/cysteine redox balance in cultured cells 
 
3.2.1. The protective role of system xC− in Burkitt lymphoma (BL) cells 
 
To address the role of system xC− in cell proliferation and cell death, xCT light chain was 
stably expressed in the Burkitt’s lymphoma (BL) cell line HH514 (Banjac, 2005; Banjac et al., 
2008).  
 
 
 
Figure 33. Stable expression of xCT in the Burkitt’s Lymphoma cell line HH514. (A) Stable expression of 
xCT in the BL cell line HH514 was analysed by immunoblotting using a monoclonal antibody (clone 1B1) specific 
for human xCT. The parental cell line and mock-transfected HH514 cell line served as negative control. The arrow 
points to the xCT protein of approx. 37 kDa. The unspecific band of approx. 40 kDa served as loading control. (B) 
Cells were incubated with increasing concentrations of H2O2 and the number of viable cells was determined 48 h 
after treatment by trypan blue exclusion. (C) Glutathione (2.5mM) supplementation efficiently rescued cell death 
induced by BSO treatment. 
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It was shown that xCT-overexpressing cells were highly resistant to oxidative stress imposed 
by seeding the cells at low cell density or by GSH depletion induced by BSO. In the same 
study, initial evidence was provided that the cystine/cysteine redox cycle may act 
independently of intracellular GSH (Banjac et al., 2008). In the following, antibodies against 
human xCT were generated. This was performed in close collaboration with Dr. Elisabeth 
Kremmer (Helmholtz Zentrum München). Two peptide sequences complementary to the N-
terminal cytoplasmic domain of human xCT were used to raise hybridoma clones that 
generated antibodies specific for human xCT. Out of 34 supernatants, two antibodies that 
recognise human xCT were identified (3A12 and 1B1) (Figure 33 A). The xCT-
overexpressing HH514 cells were used to screen the supernatants for the specific 
antibodies. 
 
Using the same cell lines, it was shown that xCT-overexpressing HH514 cells became highly 
resistant to increasing concentrations of H2O2 as illustrated in Figure 33 B (Banjac et al., 
2008). Addition of 2.5 mM GSH to the cell culture medium rescued the BSO-mediated 
detrimental effects on the proliferation and survival of HH514 cells, ruling out any toxic side 
effects of BSO (coloured boxes in Figure 33 C). 
 
To address whether GSH-depleted cells die in an apoptotic manner, cells were stained with 
Annexin V and propidium iodide (PI) at various time periods after the addition of 30 µM BSO. 
Apoptotic cells, defined by Annexin V-positive, PI-negative staining, could not be detected at 
any time point after BSO treatment, indicating that BSO-treated cells do not undergo a 
classical form of cell death (Figure 34) (Banjac et al., 2008). 
 
3.2.2. The thioredoxin system as the possible driving force for the 
cystine/cysteine redox cycle  
 
GSH is believed to mediate efficient reduction of cystine (Cys)2, that is taken up by system 
xc- into the cells, by forming a mixed disulfide (GS-Cys). A second molecule of GSH is then 
releasing cysteine from the mixed disulfide resulting in the formation of oxidised glutathione 
(GSSG). Oxidised GSH (GSSG) is then recycled by glutathione reductase and NADPH/H+. 
As overexpression of xCT rescues BL cells from cell death also in the presence of the GSH 
synthesis inhibitor BSO (see Fig. 34 C), it is an intriguing question which other redox system 
may compensate for the lack of GSH, i.e. which cellular system besides GSH is capable of 
reducing oxidised cysteine. The need for a second redox system capable of reducing cystne 
was additionally reinforced by the finding that xCT overexpression renders γ-GCS-/- cells, 
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which lack endogenous GSH biosynthesis, independent of exogenous GSH or NAC in the 
medium (Seiler, 2008). 
 
 
 
Figure 34. HH514 cells do not die in an apoptotic manner in response to GSH depletion. HH514, HH514-
mock and HH514-hxCT cell lines were treated with 30 µM BSO and stained with Annexin V/PI for the indicated 
time points (8 h, 12 h, 24 h, 30 h). While no Annexin V-positive/PI-negative cell population could be detected at 
any time point, Annexin V-positive/PI-positive cells were detectable in all cell lines to varying degree in response 
to BSO treatment. This indicates that these cells did not undergo a classical form of apoptosis.  
 
To address the question whether the thioredoxin dependent system is able to reduce cystine 
in the absence of GSH, Txnrd2-deficient cells were stably transfected with the pCAG-3SIP-
based vectors (Figure 35) pCAG-3SIP-EGFP and pCAG-3SIP-mxCT (mxCT = mouse xCT). 
The absence of Txnrd2 in EGFP- or mxCT-transfected Txnrd2−/− cells was confirmed by 
Western blotting (Fig. 35 A). As monitored by fluorescence microscopy and by flow cytometry 
for EGFP, stable selection of pCAG-3SIP-EGFP-transfected cells with puromycine was 
highly efficient (Figure 35 B). To assess xCT expression in these cells, Northern blot 
analysis, qRT-PCR, immunoblotting and cystine uptake measurements were performed 
(Figure 50 C-F). Northern blot analysis revealed strong hybridisation signals for mxCT in 
xCT-transfected Txnrd2+/+ and Txnrd2−/− cells (Figure 35 C), but not in EGFP-transfected 
cells. The hybridisation signal obtained by Northern blot corresponds to the bicistronic xCT-
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IRES-puromycin mRNA sequence of 2.7 kb. The Northern blot results were confirmed by 
quantitative Real Time-PCR in Txnrd2−/− cells, which showed approximately 10-fold higher 
expression levels of xCT in xCT-transfected as compared to EGFP-transfected cells 
(Figure 35 D). By using an xCT-specific antibody (kind gift of Dr. Ann Massie, Brussels, 
Belgium), high expression of murine xCT could be detected (Figure 35 E). Finally, system xC− 
activity was determined in xCT-overexpressing and EGFP-transfected Txnrd2−/− cells by 
measuring the (Cys)2 uptake capacity using radioactively labelled L-[14C(U)] (Cys)2. xCT 
overexpressing cells displayed an about threefold higher cystine uptake capacity than EGFP-
transfected cells (Figure 35  F). 
 
Next, intracellular GSH levels were measured by HPLC in EGFP- and xCT-transfected 
Txnrd2−/− cells (Figures 36 A and B). xCT-overexpressing cells appeared to have a higher 
intracellular content of glutathione (Figure 36 A), but the levels of GSH were not significantly 
different between xCT overexpressing and EGFP expressing control cells, although a 
tendency to higher intracellular GSH levels was detectable (Figure 36 A). Then, it was asked 
whether the enforced expression of xCT in Txnrd2−/− cells provides a growth advantage to 
EGFP expressing control cells, particularly when cells were depleted from intracellular GSH 
by BSO. As illustrated in figure 36 B, xCT-expressing Txnrd2−/− cells became highly resistant 
to BSO-mediated GSH depletion, whereas EGFP-expressing Txnrd2−/− control cells rapidly 
died. This finding perfectly fits with the previous finding, where xCT overexpressing HH514 
cells were shown to be highly resistant to various triggers of oxidative stress including GSH 
depletion (Banjac et al., 2008). In the same study it was also shown that xCT expressing 
HH514 cells secrete vast amounts of reduced cysteine into the medium. Therefore, it was 
investigated whether xCT expressing Txnrd2−/− cells can rescue EGFP expressing Txnrd2−/− 
cells from cell death induced by BSO. In fact, co-culture experiments revealed that EGFP-
transfected cells survived and proliferated at the same rate as xCT-transfected cells in the 
presence of BSO (Figure 36 C). This strongly favors the idea that xCT-expressing cells 
protect EGFP-transfected cells from BSO-induced cell death by secretion of reduced 
cysteine, which is then readily taken up by EGFP-transfected cells, thus bypassing the 
requirement for intracellular GSH for EGFP-transfected cells. On the other hand, these 
findings also imply that Txnrd2 is not responsible for (Cys)2 reduction in the cells. In a parallel 
study by Pankaj Kumar Mandal in our laboratory (PhD thesis submitted to LMU, Munich, July 
2009), evidence has been provided that cytosolic thioredoxin reductase (Txnrd1) is the 
driving force for (Cys)2 reduction in xCT overexpressing cells when GSH is depleted by BSO 
treatment. 
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Figure 35. Stable expression of xCT in Txnrd2-deficient MEFs. (A) Loss of Txnrd2 in Txnrd2−/− cells stably 
expressing murine xCT or EGFP was confirmed by Western blotting. (B) Stable transfection of Txnrd2−/− cells with 
an EGFP expressing plasmid was monitored by fluorescence microscopy and quantified by flow cytometry one 
week after selection with 2 µg/ml puromycine. (C) Northern blot analysis of xCT expression in Txnrd2+/+ and 
Txnrd2−/− cells stably transfected with EGFP or xCT. Equal loading of samples was assessed by visualizing 28s 
and 18s rRNA bands of the corresponding agarose gel. (D) xCT expression in Txnrd2−/− cells was confirmed by 
qRT-PCR. (E) xCT expression was analysed by immunoblotting of cells expressing mouse xCT in Txnrd2−/− 
MEFs. HH514 cells overexpressing human xCT served as positive control. Note, murine and human xCT (37 
kDa) migrate faster than predicted (55 kDa) in SDS-PAGE, which is line with previous reports . An unspecific 
band was used as loading control. (F) Cystine uptake measurements showed a 3-fold increased cystine uptake 
activity of xCT-overexpressing cells as compared to EGFP-transfected cells.  
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Figure 36. xCT overexpression in Txnrd2-/- cells increases the levels of intracellular GSH and rescues 
Txnrd2-/- cells from cell death induced by GSH depletion. (A) Intracellular glutathione levels were measured 
by HPLC, revealing an approx. 3-fold increase in glutathione level in xCT-expressing cells. (B) Overexpression of 
xCT in Txnrd2−/− MEFs protected cells from cell death induced by GSH depletion (10 µM BSO). (C) Co-culture 
experiments were conducted to address whether xCT expressing Txnrd2−/− cells may protect EGFP-transfected 
Txnrd2−/− cells from cell death induced by GSH depletion. Both cell lines were plated at the same cell number in 
the presence of 10 µM BSO, and the number of EGFP-positive cells was evaluated 48 h after plating by flow 
cytometry. xCT overexpressing cells protected EGFP-transfected cells from BSO-induced cell death. xCT 
overexpressing cells reduce cystine and secrete the surplus of reduced cysteine. xCT overexpressing cells thus 
act as feeder cells by providing cysteine and thus recue EGFP-expressing cells from cell death. 
 
3.3. Generation of conditional xCT-knock-in mice 
 
3.3.1 Gene targeting in ES cells  
 
To study the contribution of system xC− to cellular redox balance, its role in antioxidant 
defense, and its function in the immune system and brain development, transgenic knock-in 
mice (designated as R26mxCTflSTOP) that allow spatio-temporal expression of xCT light chain 
were generated. To this end, the Rosa26 locus was chosen for two reasons: (i) the Rosa26 
promoter is ubiquitously active, and (ii) the Rosa26 locus had been frequently and 
successfully used to express numerous genes in mice in a conditional fashion (Farley et al., 
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2000; Hameyer et al., 2007; Homig-Holzel et al., 2008; Ivanova et al., 2005; Jager et al., 
2004; Soriano, 1999; Srinivas et al., 2001). To be able to target the xCT expression cassette 
into the Rosa26 locus of the E14tgTG2 ES cell line (Figure 37 A), a targeting vector for 
homologous recombination in ES cells was generated. Namely, the murine xCT cDNA was 
inserted behind a loxP-flanked cassette consisting of the FRT-flanked neomycin 
phosphotransferase gene followed by a transcriptional STOP (Figure 37 A). The entire 
cassette was additionally flanked by two arms for homologous recombination in ES cells. 
After successful recombination of this cassette into the Rosa26 locus and Cre-mediated 
removal of the neomycin phosphotransferase-STOP element, xCT expression is driven by 
the endogenous Rosa26 promoter. 
 
After electroporation of E14tgTG2a ES cells with the targeting construct 
Rosa26-neoR-STOP-xCT, approximately 300 G418-resistant clones were picked and 
individually expanded. Genomic DNA was isolated and digested with EcoRI. ES cell clones 
carrying the targeted Rosa26-neoR-STOP-xCT allele were identified by Southern blotting 
(Figure 37 B).  
 
 
 
Figure 37. xCT knock-in strategy into the Rosa26 locus of murine ES cells. (A) In the upper line, the wild-
type Rosa26 gene locus is shown. Below, the strategy for the xCT knock-in into the Rosa26 locus is depicted. 
Cre-mediated removal of the neo (neomycin phosphotransferase)-STOP cassette induces gene expression of the 
xCT transgene. Depending on the promoter used for Cre expression, expression of xCT is achieved in a tissue-
specific manner (loxP sites are depicted by yellow triangles and FRT sites by violet triangles). (B) Homologous 
recombination in ES cell clones was confirmed by Southern blotting. The cassette inserted into the unique XbaI 
site in Rosa26 locus introduced an additional EcoRI site. EcoRI-digested ES cell DNA was separated in by gel 
ecelctrophoresis, the fragments transferred onto a nitrocellulose filter and and visualized by hybridization with an 
external probe (Ex.probe), depicted in (A).  
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Eleven clones out of 300 were obtained which successfully harboured the 
Rosa26-neoR-STOP-xCT allele. Thus, homologous recombination occurred at approximately 
3% frequency. Two of these cell lines (E14tg2a-tvRosa26-xCT2 and E14tg2a-tvRosa26-
xCT4) were then used for blastocyst injection (see subsection 2.2.6). 
 
3.3.2. Analysis of the functionality of the neoR-STOP-xCT cassette  
 
To test for the functionality of xCT expression, ES cell clones with successful homologous 
recombination of the neoR-STOP-xCT allele were stably transfected with the 
pCAG-3SIP-based plasmids MerCreMer-IRES-Puro and EGFP-IRES-Puro as control, 
allowing stable selection of transfected clones with puromycin. The presence of Cre in 
MerCreMer-IRES-Puro-transfected cells was confirmed by PCR of genomic ES cell DNA 
(Figure 38 A). 
 
Expression of EGFP in control-transfected cells was determined by flow cytometry (Figure 38 
B). MerCreMer-IRES-Puro-transfected ES cells were treated with 4-OH-tamoxifen (Tam) for 
48 h and cystine uptake was measured using 14C-labelled cystine. Cells, in which the floxed 
neo-STOP cassette had been removed by Cre, displayed an approximately 3-fold increase in 
cystine uptake activity compared to non-treated or EGFP-transfected cell lines. Although 
expression of xCT appears to be rather low, this finding is in line with previous studies, which 
showed that the Rosa26 promoter is a rather weak to moderatively active promoter. 
 
3.3.3. Generation of R26mxCTflSTOP/CreERT2 mice 
 
Seven chimeric mice were obtained from the E14tg2a-tvRosa26-xCT4 cell line and three 
additional chimeric mice from the E14tg2a-tvRosa26-xCT2 cell line (Table 1) (Figure 39 A). 
 
Table 1. Percentage of black and chinchilla coat colour of chimeras obtained by injecting two independent 
E14tg2a cell clones into C57BL/6 blastocysts. 
 
E14tg2a-TVROSA26-xCT-4 black [%] chinchilla [%] 
1 10 90 
2 0 100 
3 40 60 
4 5 95 
5 10 90 
6 5 85 
7 0 100 
E14tg2a-TVROSA26-xCT-2 black [%] chinchilla [%] 
1 0 100 
2 0 100 
3 80 20
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Figure 38. Cystine uptake is significantly increased in xCT-expressing ES cells. (A) Transfection of the ES 
cell clones with MerCreMer (MCM)-IRES-Puro vector was confirmed by PCR. The primer pair CreE/CreD 
specifically detects the Cre-recombinase gene (400 bp). (B) Flow cytometry analysis of ES cells after stable 
transfection and 5 days of puromycin selection with the MerCreMer-pCAG and EGFP-pCAG expression vectors. 
(C) L-[14C(U)]cystine uptake was measured in xCT knock-in ES cell lines, transfected with either EGFP (mock) or 
with the Tam-inducible MerCreMer (two independent clones A9 and C9). 2.5 mM glutamate (Glu) was used to 
specifically inhibit system xc- activity. 
 
All chimeras were backcrossed to C57BL/6 mice for germline transmission. Finally all mice 
with agouti coat colour transmitted the targeted neoR-STOP-xCT allele to progeny mice 
(R26mxCTflSTOP) at a frequency of 24% (Figures 39 B and C). 
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3.3.4. Breeding of xCT-transgenic mice with the Tam-inducible CreERT2-Deleter 
mouse 
 
To activate the xCT transgene in every tissue, the R26mxCTflSTOP mice were crossed to Cre-
transgenic mice expressing CreERT2 (Hameyer et al., 2007). These mice express the Cre- 
estrogen receptor fusion protein (CreERT2) under the control of the Rosa26 promoter in all 
tissues except brain (Hameyer et al., 2007). 
 
 
 
Figure 39. Germline transmission of the targeted xCT knock-in allele. (A) Ten chimeras were generated by 
injecting two different 129/Ola-derived E14tg2a-tvRosa26-xCT cell lines into C57BL/6 blastocysts (see also 
Table 1). (B) The position of the primer pair used for the identification of targeted Rosa26 allele is depicted. (C) 
Confirmation of germline transmission of the targeted Rosa26 allele was performed by PCR of tail biopsies using 
the primer pair that gives a 400 bp fragment, which is specific for the knock-in allele. The targeting vector 
tvRosa26-mxCT was used as a positive control. 
 
This fusion protein is retained in the cytoplasm by binding to the heat shock protein 90 via 
the estrogen receptor. Only upon Tam administration, CreERT2 is liberated from this 
complex and translocates to the nucleus, where Cre-mediated deletion of the loxP-flanked 
STOP cassette occurs. R26mxCTflSTOP/CreERT2 mice were obtained at the Mendelian ratio from 
breeding of Rosa26-CreERT2 deleter-mice with R26mxCTflSTOP mice. R26mxCTflSTOP/CreERT2 
mice were fully viable, grossly normal and fertile. 
 
3.3.4. Phenotypic analysis of R26mxCTflSTOP/CreERT2 mice 
 
3.3.4.1. Analysis of adult haematopoiesis of R26mxCTflSTOP/CreERT2 mice  
 
To activate xCT expression, R26mxCTflSTOP/CreERT2 mice were fed a Tam-containing diet as 
described previously (Kiermayer et al., 2007). Tam administration induced xCT expression, 
as shown for brain, spleen and kidney (Figure 40 A). Thus, apparently there is some 
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contradiction with regard to expression of Cre in brain tissue (see (Hameyer et al., 2007)). 
Already three to four weeks after Tam feeding, R26mxCTflSTOP/CreERT2 transgenic mice started 
to loose weight (Figures 40 B and C) and were suffering as judged by their bristle coat and 
by an abnormal posture. Five to six weeks after Tam administration the xCT transgenic mice 
had to be euthanatized (Figure 40 C).  
 
 
 
Figure 40. Inducible xCT expression appears to be toxic to mice. (A) Protein lysates were prepared from 
snap-frozen tissues from the xCT/CreERT2 double transgenic (tg[xCT]) mice at different time periods after Tam 
induction (0, 1, 3 and 5 weeks), the proteins separated by PAGE, blotted onto nitrocellulose and xCT visualized 
with a xCT-specific antibody (B and C) Double transgenic mice lost body weight two to three weeks after Tam 
feeding. Three to four weeks after Tam feeding, three of six tg[xCT] mice had to be euthanized. Single transgenic 
mice (control) survived Tam treatment. Body weights were measured from a cohort of 9 mice (n=3 control animals 
and n=6 transgenic animals).  
 
Hemogram analysis revealed that the transgenic animals suffered from severe anaemia. This 
was evidenced by a decrease in the number of red blood cells (RBC), lowered haemoglobin 
and a decline in hematocrit value (Figures 41 A-C). The mean cell volume (MCV) was 
decreased, indicating the appearance of microcytic RBCs in the circulation and iron 
deficiency (Figure 41 C).  
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Figure 41. xCT expressing mice suffer from severe anemia as judged by hemogram analysis. (A) Shown 
are the average number of red blood cells (RBC), (B) the average level of haemoglobin, (C) hematocrit, and (D) 
mean cell volume (MCV). In each graph, the mean values are depicted ± SD calculated from n = 6 double 
transgenic animals (filled boxes) and n = 3 for control animals (empty boxes).  
 
In contrast to the severe anaemic phenotype of xCT transgenic mice, the platelet counts in 
transgenic animals were slightly higher than in control animals (Figure 42 A). There were no 
apparent differences in white blood cell (WBC) counts (Figure 42 B) and differential 
leukocyte counts (lymphocytes, monocytes, granulocytes and eosinophiles) when transgenic 
and control animals were compared (Figures 42 C-F). The anaemic phenotype of transgenic 
animals prompted us to investigate the development of haematopoietic cells in the bone 
marrow of transgenic animals in more detail. 
 
3.3.4.2. xCT transgenic mice have a higher percentage of haematopoietic stem cells 
and uncommitted progenitor cells 
 
Haematopoietic stem cells (HSCs) in the adult bone marrow are characterized by a unique 
combination of surface markers. The most primitive HSCs population is characterized by 
high levels of c-kit (c-kit+) and Sca-1 (Sca-1+) and the absence or very low expression of 
lineage markers (CD3, CD19, Gr-1, B220, Mac-1, Ter119, and CD41) (Lin−) (Osawa et al., 
1996). This c-kit+, Sca+, Lin− cell population is termed KSL cells representing multipotent 
progenitor cells.  
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Figure 42. The number of platelets and white blood cells (WBC) was not grossly changed in xCT 
transgenic mice. (A) The average number of platelets appeared to be slightly higher for double transgenic 
animals, while the overall number of WBC (B) and differential leukocyte counts (lymphocytes, monocytes, 
granulocytes and eosinophiles) remained unchanged (C-F). Mean values ± SD are shown that were calculated 
from n = 6 double transgenic animals (filled boxes) and n = 3 for control animals (empty boxes). 
 
Low levels of ROS and a hypoxic microenvironment has been implicated in self-renewal of 
HSCs and cancer stem cells and the maintenance of stemness (Diehn et al., 2009b; Ito et 
al., 2004; Ito et al., 2006). Since redox regulation is emerging as a regulator of stem cell 
differentiation (Ogasawara and Zhang, 2008), the effect of xCT overexpression on the pool of 
HSCs was investigated by analyzing the KSL population by flow cytometry.  
 
The Lin− cells and c-kit+, Sca-1+ positive cells were first gated (Figure 43 A). They 
represented 0.06% of the initial population in R26mxCTCreERT2 mice in the absence of 
Tamoxifen, whereas for xCT expressing, Tamoxifen-treated mice the values reached 0.34% 
of the starting population. In terms of the KSL population this is a considerable difference. 
Hence, the transgenic mice have more cells in the KSL compartment, which indicated that 
there is a preferential accumulation of undifferentiated non-committed progenitor cells in the 
bone marrow of transgenic mice as compared to control mice. 
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Figure 43. Analysis of the KSL population in the bone marrow of xCT transgenic and control mice. (A) 
Bone marrow cells were isolated from 20 weeks old mice maintained for four weeks on a Tam-containing diet. 
Bone marrow cells were stained with c-kit and Sca-1 antibodies to identify haematopoietic progenitor cells. The 
KSL cell population is characterised by undetectable levels of the lineage markers (Lin−), expressed on mature 
haematopoietic cells, and by high levels of c-kit (c-kit+) and Sca-1 (Sca-1+). All progenitors were quantified and 
the numbers presented as percentage of total bone marrow cells. The xCT-expressing mice were found to have 
more cells in the KSL compartment, i.e. they have a higher percentage of non-committed progenitors.  
 
3.3.4.4. xCT expression leads to defective erythropoiesis  
 
Since constitutive xCT expression was associated with a severe anemia in xCT transgenic 
mice, we were interested in a development of erythroid lineages of this mice. A scheme of 
erythroid differentiating progenitors is provided in figure 44 A, which are identified on the 
basis of the expression of the cell surface markers CD71 (CD71+, transferring receptor) and 
Ter119 (Ter119+ glycophorin A-associated protein). A slightly higher percentage of Lin− 
(CD3, CD19, Gr-1, B220 and Mac-1), CD71-negative and Ter119-negative cells representing 
CMPs was found in xCT expressing mice (Figure 44 B). All erythroid precursors like pro-, 
basophilic-, polychromatic- and orthochromatic-erythroblasts were considerably decreased in 
the bone marrow of R26mxCTflSTOP/CreERT2 mice. This clearly indicates that the anaemia 
observed in xCT expressing mice is caused by impaired development of erythrocytes. Since 
the bone marrow analysis of adult R26mxCTCreERT2 mice after four weeks of Tam feeding did 
not show dysplastic changes, it would be interesting to examine the cell cycle profile of the 
bone marrow cells in transgenic mice by flow cytometry. So far, flow cytometry analyses 
provided initial evidence that xCT expression affects bone marrow cell differentiation and 
impairs erythropoiesis.  
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Figure 44. Analysis of the erythroid progenitors in the bone marrow of xCT expressing and control mice. 
(A) A scheme of erythroid progenitor cells, identified on the basis of the expression of CD71 and Ter119 cell 
surface markers. (B) Bone marrow cells were isolated from 20 weeks old mice maintained for four weeks on a 
Tam-containing diet. Bone marrow cells were stained with anti-CD71 (transferrin receptor) and anti-Ter119 
(glycophorin A-associated protein) to identify erythroid progenitor cells. Erythroid maturation was determined in 
control and transgenic bone marrow. All progenitors were quantified and are expressed as percentage of total 
bone marrow cells. The CD71 and Ter119 profiles of bone marrow cells showed abnormal erythroid maturation in 
xCT expressing mice.  
 
3.3.4.5. Constitutive expression of xCT leads to atrophy of spleen and testes and 
thymic aplasia 
 
Already during autopsy of xCT expressing mice it was apparent that the size of some organs 
of the transgenic mice was strongly diminished and that some organs of these mice were 
paler compared to control littermates. As illustrated in Figure 41, the spleen and testis of 
transgenic mice were markedly reduced in size and the weight was reduced by 
approximately 3-fold compared to control mice (Figures 45 A and B). The relative size of the 
other organs like liver, heart and kidney did not show major size differences (Figures 45 C-
E). Furthermore, the thymus was completely absent from xCT transgenic mice. 
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Figure 45. Spleen and testis of xCT expressing mice are strongly reduced in size. (A-E) Age-matched 
animals of the indicated genotypes (tg[xCT]-transgen/cre; control-transgen/wt) were sacrificed between 20 and 30 
weeks of age after feeding with Tam. (A-B) The size of spleen (A) and testis (B) was strongly diminished, whereas 
liver, heart and kidney did not show major differences (C-E). The mean organ weight is presented as percentage 
of the body weight (n=3 transgenic and n=3 control animals). 
 
Examination of histological sections of the testis stained with H&E disclosed the complete 
absence of spermatozoids (Figure 46 B, black arrowheads). In contrast, control mice had 
fully mature and healthy spermatozoids (Figure 46 A, violet arrowheads). Micrographs 
exhibited degenerative structures (Figure 46 A). TUNEL staining in histological sections 
revealed an increase in the number of apoptotic cells in the testis of transgenic animals 
(Figure 46 C and D). 
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Figure 46. Increased apoptosis in testis of transgenic animal. Staining of formalin-fixed, paraffin-embedded 
(FFPE) cross sections of testis from control (transgen/wt); and transgenic mice (tg[xCT]-transgen/cre) are shown. 
Displayed are 10X H&E (haematoxylin and eosin) and TUNEL micrographs. (A-B) H&E micrographs show overall 
testis structure that depict degeneration of testis of xCT transgenic animal. Violet arrowheads are showing mature 
sperm and black arrowheads are indicating absence of the sperm in the testis of the transgenic animals. TUNEL 
staining of the testis cross sections revealed increased number of the apoptotic cells. 
 
Furthermore, histopathological examinations of hematoxylin and eosin (H&E) stained 
sections of the spleen revealed that the spleen of xCT-expressing mice had prominent white 
pulp (Figure 47 B, black arrowheads). Spleen of the tg[xCT] mice also contained increased 
numbers of apoptotic cells in the red pulp, as judged by TUNEL staining (Figures 47 C-
F).This result suggest that perturbed cystine/cysteine imbalance and/or altered GSH 
metabolism triggers apoptosis in this tissue. Observed decrement of the spleen (Figure 45 A) 
could result from an increased rate red pulp apoptosis (Figures 47 C-F). A destruction of red 
blood cells, being a normal spleen function, could be in transgenic animals changed due to a 
lack of red blood cells in the circulation, as already shown in this study. 
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Figure 47. Increased apoptosis in spleen of transgenic animal. Staining of formalin-fixed, paraffin-embedded 
(FFPE) cross sections of spleen from control (transgen/wt); and transgenic mice (tg[xCT]-transgen/cre) are 
shown. Displayed are 10X H&E (haematoxylin and eosin) and TUNEL micrographs. (A-B) H&E micrographs show 
overall splenic architecture. Black arrowheads are indicating white pulp. (C-D) TUNEL micrographs of the spleen 
of transgenic animal revealed increased apoptosis in the red pulp (E-D) which is more prominent on the 
micrographs with 5X magnification. 
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4. Discussion  
 
4.1. Absence of Txnrd2 causes high ROS accumulation, increased 
sensitivity towards pro-oxidants and impaired cell growth 
 
Impairment or ablation of enzymes, which are critically involved in the control of cellular ROS 
concentrations, might cause or aggravate the development of diseases, such as myocardial 
infarction, stroke, neurodegeneration and tumor development (Anversa et al., 1998; Crack et 
al., 2001; Diehn et al., 2009b; Francis, 2001; Griendling and FitzGerald, 2003a; Griendling 
and FitzGerald, 2003b; Ide et al., 2000; Laurent et al., 2005; Lebovitz et al., 1996; Maulik et 
al., 1998; Nguyen et al., 2006; Pennington et al., 2007; Seiler et al., 2008; Selenius et al., 
2008; Talbot et al., 2008; Yang et al., 1996; Yoo et al., 2007). While some recent biochemical 
and computational studies have revealed the mechanism of Txnrd2 catalysis, understanding 
the physiological role of Txnrd2 in cells and tissues is still at its infancy. Txnrd2 is 
predominantly localised in mitochondria, which are the cells’ major site of energy production, 
but which are also involved in the regulation of key cellular processes, such as cell growth, 
and cell death (Cregan et al., 2004; Gustafsson and Gottlieb, 2008; Karunagaran et al., 
2007; Mazumder et al., 2007; Saelens et al., 2004). Although we have provided initial 
evidence that Txnrd2 is important for the maintenance of mitochondrial function, presumably 
due to scavenging of mitochondrial ROS (Conrad et al., 2004), the underlying cellular and 
biochemical mechanisms have only been partially addressed.  
 
Our cellular system with targeted disruption for Txnrd2 is thus a highly suitable tool for the 
thorough investigation of Txnrd2-dependent cellular processes. To specifically interfere with 
Txnrd2 function, Kim and colleagues established on the other hand a cellular system in 
which a dominant-negative form of Txnrd2 (TXNR2DN) is overexpressed in a tetracycline-
regulatable manner (Tet-off-system) (Kim et al., 2003b). The construct was designed such 
that it lacks the SECIS element. Thereby the UGA codon is read as a translational stop 
codon and thus yields a truncated mutant lacking the two C-terminal residues Sec and Gly. 
The dominant negative effect of this mutant was confirmed by measuring decreased Txnrd 
activity. Moreover, cells expressing TXNRD2DN were shown to produce more hydrogen 
peroxide than non-induced cells when stimulated with EGF (Kim et al., 2003b). In a follow-up 
study, Chang et al., 2005 overexpressed an alternative splicing variant of TXNRD2 under 
Tet-off control, which had 3 independent point deletions in the coding region and an insertion 
of 1228 bp in the 3’-UTR, between the stop codon and the SECIS element (Chang et al., 
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2005). Again, TXNRD activity in whole cell lysates was decreased which resulted in 
alterations of cellular ROS levels and increased apoptosis.  
 
A genetic model is certainly preferable to ablate Txnrd2 function because overexpression of 
dominant negative mutants of Txnrd2 may cause side effects as artificial gain of function. For 
instance, it has been shown that a C-terminally truncated form of Txnrd1 acquires NADPH 
oxidase activity as gain-of function and causes increased oxidative stress and apoptosis 
(Anestal et al., 2008). Moreover, it was also shown recently that the N-terminal catalytic site 
alone may harbour specific functions independently of the C-terminal catalytic site (Lothrop 
et al., 2009). Pharmacological studies that would specifically target Txnrd2 might be 
interesting, but certainly hardly feasible, since Txnrd1 and Txnrd2 are highly homologous and 
the basic catalytic mechanisms are virtually identical. In general, inhibiting either Txnrd1 or 
Txnrd2 specifically will be a major challenge, but certainly worthwhile as Txnrd1 and Txnrd2 
are involved in different cellular functions. For instance, overexpression of Txnrd1 (and Txn1) 
has been frequently linked to tumor growth, and thus targeting Txnrd1 alone might be an 
interesting strategy for cancer treatment (Brigelius-Flohe, 2008; Nguyen et al., 2006; 
Pennington et al., 2007; Selenius et al., 2008; Talbot et al., 2008; Yoo et al., 2007). 
 
As described earlier (Conrad et al., 2004), primary Txnrd2−/− MEFs showed reduced 
proliferation and/or increased apoptosis compared to wild-type counterparts. Since Txnrd2 
has been implicated in the protection of cells from toxic amounts of mitochondrial ROS, 
Txnrd2−/− cells were treated with different antioxidants, such as NAC, GSH and α-Toc, to 
substantiate this notion: NAC, a frequently used antioxidant providing cells with cysteine for 
GSH biosynthesis, is reported to protect cells against various triggers of oxidative stress (van 
Zandwijk, 1995); GSH is a cofactor of GSH-dependent enzymes, including GSH 
peroxidases; α-Toc disrupts the lipid peroxidation chain by one electron reduction of alkyl 
radicals or peroxyl radicals (Ikeda et al., 2003; Seiler et al., 2008; Tagami et al., 1998). By 
using these different antioxidants it was possible to complement the lack of Txnrd2: knock-
out cells were thus able to proliferate in a manner similar to Txnrd2 wild-type cells. 
 
Damdimopoulos and colleagues have previously shown that overexpression of human 
mitochondrial Trx (Trx2) in HEK-293 cells confers resistance towards etoposide and 
increases the mitochondrial membrane potential (Damdimopoulos et al., 2004). Furthermore, 
mice specifically lacking Trx2 die during midgestation due to massive apoptosis (Nonn et al., 
2003b). Since under physiological conditions Txnrd2 is the main enzyme for maintaining Trx2 
in its reduced state, it was hypothesized that loss of Txnrd2 causes an increase in 
intracellular (mitochondrial) ROS. The flow cytometry analyses of Txnrd2−/− MEFs, stained 
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with redox-sensitive dyes CM-H2DCF-DA, BODIPY 581/591 C11 and boronate- based 
fluorophores (PYAM, PYME and mitoPY) revealed strongly elevated ROS levels, such as 
lipid peroxides and H2O2, in mitochondria and in the cytosol of knock-out cells. This rise in 
ROS could be even exacerbated when GSH was depleted from the cells. On the contrary, 
the amount of total ROS, as monitored by the non-specific ROS sensor CM-H2DCF-DA, 
could be dampened by using the antioxidants NAC and α-Toc. Lipid peroxidation, as 
determined by BODIPY 581/591 C11, could also be detected in the knock-out cells, which 
was insensitive to NAC but sensitive to α-Toc. These results confirmed that NAC has no 
scavenging activity towards lipid peroxides, while α-Toc efficiently scavenges lipid peroxides 
which might be the initial source of ROS. More specifically boronate-based fluorophores 
which are highly specific for H2O2, unmasked higher amounts of H2O2 in the cytoplasm as 
well as in mitochondria of Txnrd2−/− cells when compared to wild-type cells. Of course, more 
studies are required to answer whether lipid peroxidation is the cause or secondary to the 
generation of other oxygen radical species. Nonetheless, the use of the redox-sensitive dyes 
corroborates the generation of significant amounts of ROS in cells lacking Txnrd2 which 
supports the hypothesis that an increase in ROS is the primary culprit in the impairment of 
cellular growth. Since the Txnrd2 knock-out was designed as such that all Txnrd2 isoforms 
are simultaneously inactivated, it was an obvious question whether the increase in cellular 
ROS can be blunted by overexpression of either mitochondrial or cytoplasmic variants of 
Txnrd2. The complex mammalian selenoprotein translational machinery has previously been 
considered to be the main hurdle when overexpressing selenoproteins in mammalian cells. 
Yet, in this study it was possible to stably express two wild-type and the two mutant forms of 
Txnrd2 in Txnrd2 knock-out (and wild-type) cells. To achieve this, a lentiviral system was 
used for expression of TAPe-tagged Txnrd2 in MEFs. For the mitochondrial and 
cytoplasmatic isoforms, the TAPe-tags were placed after the N-terminal mitochondrial leader 
sequence (MLS) or directly at the N-terminus, respectively. Since the C-terminus harbouring 
the catalytic site -Gly-Cys-Sec-Gly- is highly flexible and important for thioredoxin reductase 
function (Gasdaska et al., 1999b; Gladyshev et al., 1996; Lee et al., 1999; Miranda-Vizuete 
et al., 1999; Sandalova et al., 2001; Tamura and Stadtman, 1996; Watabe et al., 1999; 
Zhong and Holmgren, 2000), the N-terminus was used for fusion with TAPe-tag. When the 
cell lysates of mitoTxnrd2 overexpressing cells were immunoblotted with an anti-Txnrd2 
antibody, two bands appeared. This was not the case when the lysates were blotted against 
anti-FLAG, suggesting that upon transport into mitochondria the MLS of mitoTxnrd2 was 
processed as such that either the MLS alone or the MLS along with the TAPe-tag were 
removed (Chang et al., 2005); apparently, both forms were produced at an equal ratio. On 
the other hand, for the cytoplasmatic form there was only one single band detectable with 
both antibodies, which was equal in size with the larger mitochondrial form due to the tag. To 
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further confirm their subcellular localisation, immunocytochemical staining with the anti-FLAG 
antibody and confocal microscopy were performed. The mitochondrial form of Txnrd2 was in 
fact localised in mitochondria and the cytoplasmatic form was evenly distributed throughout 
the cytosol.  
 
It is highly likely that the mitochondrial isoform plays an important role in the scavenging of 
mitochondrial ROS generated as a side product of oxidative phosphorylation. On the other 
hand, the role of cytoplasmatic form, e.g. in ROS removal, is not known. The add-back of the 
cytoplasmatic variant of Txnrd2 was also shown to decrease the level of ROS in Txnrd2 
knock-out cells, which was unexpected. However, as the uncharged H2O2 can freely diffuse 
across membranes it may be concluded that the major form of ROS released by 
mitochondria might be H2O2. Needless to say, many questions regarding the nature and the 
spatiotemporal generation of ROS remain to be addressed in the future. Recently, a novel 
method was developed that allows to monitor the dynamic changes of redox-based 
processes in living cells by using appropriate redox biosensors (Gutscher et al., 2008). This 
biosensor is a fusion protein between human glutaredoxin-1 (Grx1) and the sensor protein 
roGFP2. Stable expression of the Grx1-roGFP2 fusion protein allows dynamic live imaging of 
the cellular redox potential, which is mainly based on the pool of intracellular reduced 
glutathione (glutathione is present up to 10 mM in cells). Since the biosensor can be targeted 
to different subcellular compartments one may also study the redox potential in the different 
compartements. It thus facilitates the real-time determination of redox changes in response 
to growth factor stimulation, cell density, mitochondrial depolarization, respiratory burst 
activity and immune receptor stimulation. Hence, this technique offers new opportunities to 
analyze in more detail the intracellular generation and distribution of ROS in Txnrd2 knock-
out cells. 
 
Reportedly, MEFs overexpressing Txnrd were shown to have slightly retarded growth 
(Patenaude et al., 2004; Powis et al., 1997a; Powis et al., 1997b; Spyrou et al., 1997). The 
overexpression of Trx2 and Txnrd2 efficiently lowered the level of ROS and consequently 
reduced p42/p44 MAPK phosphorylation, which was proposed to be the mechanism that 
slows down cell proliferation (Zhou et al., 2008). It thus appears that the redox status in cells 
controlled by the thioredoxin/thioredoxin reductase system affects growth and differentiation 
and is involved in fine tuning of molecular signalling pathways.  
 
To address whether Txnrd2−/− MEFs are also more sensitive to exogenous stress, cells were 
treated with compounds, such as doxorubicin, cisplatin, peroxides, antimycin A and PEITC, 
all known to induce the generation of free radicals. It is well established that doxorubicin 
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intercalates into DNA, but also induces ROS (Bachur et al., 1977; Gutierrez et al., 1983) by 
using electrons from mitochondrial complex I (Davies et al., 1983). Cisplatin, another 
anticancer drug, was included in these studies. cis-Diammineplatinum(II) dichloride causes 
the formation of cisplatin-platinum complexes in cells, which bind and lead to cross-linking of 
DNA, ultimately triggering cell death and the generation of ROS (Martins et al., 2008). Txnrd2 
knock-out cells were only moderately more sensitive to the treatment of the anticancer drugs 
in terms of cell death; however in the presence of peroxides, antimycin A and PEITC treated 
Txnrd2 knock-out cells readily died. Thus, the higher ROS content of Txnrd2 null cells was 
apparently exacerbated by these compounds, eventually triggering the rapid onset of cell 
death due to the severe impairment of Txnrd2 null cells to cope with the additional ROS.  
 
The initial observation that Txnrd2−/− cells are highly sensitive to GSH depletion induced by 
BSO (Conrad et al., 2004), prompted us to study the GSH levels in Txnrd2 knock-out cells. 
The determination of GSH levels in the knock-out and control cells showed that wild-type 
cells had three times higher GSH levels than Txnrd2−/−. This confirmed that Txnrd2 knock-out 
cells apparently compensate for the lack of Txnrd2 by consuming higher levels of GSH thus 
leaving the cells highly sensitive towards the GSH-depleting compound BSO. These results 
demonstrated that cells lacking only one of the key enzymes of the thioredoxin system, when 
devoid of glutathione, the second important intracellular antioxidant system, undergo cell 
death due to the additive adverse effects. Thus, the two pathways act in a collaborative 
manner to protect cells against oxidative stress. Recently, Lu and colleagues showed that 
inhibition of thioredoxin reductase by arsenic trioxide (ATO) in human breast MCF-7 cancer 
cells sensitizes them to apoptosis, particularly when used in combination with agents that 
reduce the intracellular GSH concentrations, such as BSO (Lu et al., 2007). The authors 
discussed several mechanisms, which may lead to this phenotype. The combination of ATO 
and BSO may result in the disruption of the electron supply for DNA synthesis and 
simultaneously induce augmented oxidative stress which cooperates in the induction of cell 
death. These effects are considered to be the reason for H2O2 accumulation in cells upon 
ATO treatment (Jing et al., 1999). Trx provide electrons to peroxiredoxins for scavenging 
H2O2 and alkyl peroxides (Kang et al., 2004). GSH also participates in removing 
hydroperoxides by acting as a cofactor for glutathione peroxidases  (Conrad, 2009). Both 
thioredoxins and glutaredoxins/GSH provide electrons to ribonucleotide reductase (RNR), 
which is essential for DNA synthesis (Holmgren, 1985; Holmgren, 1989; Lammers and 
Follmann, 1984; Reichard, 1988; Thelander and Reichard, 1979). Moreover, DNA repair 
activity through Ref1, p53, and RNR is also controlled by Trx, and inactivation of the Trx 
system presumably impedes DNA repair process (Seemann and Hainaut, 2005; Tanaka et 
al., 2000). Trx is also cofactor of methionine sulfoxide reductases, and thus is involved in the 
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repair of oxidised proteins (Hoshi and Heinemann, 2001). Yet, the use of ATO does not 
discriminate between the two thioredoxin reductases and thus does not allow to specifically 
target either mitochondrial or cytoplasmatic thioredoxin reductase. Also bearing in mind the 
in vitro observation of Turanov and colleagues (Turanov et al., 2006) that Trx1 can be 
equally well reduced by Txnrd2 as Trx2, the role of Txnrd2 on some of the processes that 
take place in cytoplasm should not be underestimated, particularly considering the presence 
of two Txnrd2 isoforms localised in cytoplasm. 
 
4.2. Compensatory up-regulation of mitochondrial peroxiredoxins III 
and V in response to Txnrd2 disruption  
 
Mammalian cells express two peroxiredoxins that are mainly localised in mitochondria: Prx III 
and Prx V. Prx III is exclusively expressed in mitochondria, Prx V is also localised to 
peroxisomes (Seo et al., 2000) and the nucleus (Kinnula et al., 2002). The mitochondrial 
thioredoxin system was already shown to provide electrons for peroxiredoxin III in ex vivo 
studies. It was shown that SP-22 (= Prx III) along with Trx2, partially purified mitochondrial 
thioredoxin reductase from bovine adrenocortical mitochondria, and NADPH had the ability to 
protect oxyhemoglobin against ascorbate-induced damage (Watabe et al., 1995; Watabe et 
al., 1997; Zhang et al., 2007). Furthermore, NADPH was consumed in equimolar amounts by 
Txnrd2, Trx2, and Prx III to reduce hydrogen peroxide and t-butylhydroperoxide (Watabe et 
al., 1997). Only the combination of all these factors conferred the hemoglobin-protecting and 
peroxide reducing activities. Evidence for these in vitro findings at the cellular level could be 
provided by this work. Here, it could be shown that basal Prx III and Prx V protein levels were 
increased in Txnrd2−/− cells and that the expression of Prx III and Prx V could be further 
stimulated by various triggers of oxidative stress. The analysis of the oxidation state of the 
catalytically active site cysteines with an antibody specifically detecting the sulfenic and 
sulfinic forms of Prx I and Prx II (Woo et al., 2003a; Woo et al., 2003b) provided initial 
insights that the overoxidised forms of Prx I and PrxII/PrxIII were present at higher levels in 
knock-out than in wild-type cells in response to increasing H2O2 concentrations. However, it 
still remains to be clarified whether this is in fact due to overoxidation or due to augmented 
transcription and/or translation of the respective genes and proteins. The rapid H2O2-induced 
up-regulation, in particular of Prx III and Prx V, suggests that this is regulated at the 
translational and posttranslational rather than at the transcriptional level. It is temptative to 
speculate that there are systems in cells which sense and swiftly respond to increasing 
concentrations of ROS by enhancing the translation efficiency of antioxidant enzymes 
through binding to yet-unrecognized regulatory elements on their mRNAs. 
 98
  Discussion 
The fact that the mRNA and protein levels of other Prxs were not changed suggests that the 
impairment of Txnrd2 function mainly affects mitochondrial peroxiredoxins. This implies that 
Txnrd2, Trx2 and Prx III and Prx V are indeed functionally connected in vivo. Similarly, in 
yeast the lack of the Trx enzyme induced increased expression of thioredoxin-dependent 
peroxidases, encoded by TSA1 (thiol-specific antioxidant protein encoding the major 
cytosolic form 2-Cys Prx), AHP1, YDR453C, YBL064C and YIL010W (Carmel-Harel et al., 
2001). Hence, it seems that the role of the thioredoxin dependent system is phylogenetically 
conserved:  its proper function is vital for protection from oxidative stress, and also for 
ensuring tightly controlled levels of ROS so that H2O2 can be used as signalling molecules 
(Veal et al., 2007). 
 
It has been postulated that peroxiredoxins evolved in eukaryotes to remove even low levels 
of H2O2 as they have the potential to modulate cell signalling pathways. When H2O2 levels 
exceed a certain threshold, peroxiredoxins are oxidized and inactivated (Woo et al., 2003a). 
Previously, it was believed that the sulfinic forms of the active site cysteines of 
peroxiredoxins are irreversibly oxidised. Toledano’s laboratory then identified a yeast 
enzyme, sulfiredoxin (Srx), which in the presence of ATP or GTP is capable to of reducing 
the sulfinic form of peroxiredoxins thus preventing them from further and irreversible 
oxidation to sulfonic acid (Biteau et al., 2003). Srx was considered to be solely localised in 
the cytoplasm, however, recent data revealed that under stress conditions Srx translocates 
from the cytosol into mitochondria and regenerates hyperoxidized Prx III (Noh et al., 2009). 
Here it could be shown that disruption of Txnrd2 increased Srx transcript levels in Txnrd2−/− 
cells, most likely to prevent Prx III and Prx V from overoxidation and inactivation. This cellular 
knock-out model could be further used to shed more light on the role of mitochondrial ROS 
on the regulation of sulfiredoxin at the transcriptional and translational level as well as of its 
subcellular trafficking (Figure 50). 
 
4.3. Txnrd1 and Txnrd2 do not show functional redundancy in vivo 
 
Gene targeting of Txnrd1 and Txnrd2 in mice showed that both enzymes play distinct and 
essential roles in embryonic development and organ functions and that they can not 
substitute each other (Conrad et al., 2004; Jakupoglu et al., 2005). Txnrd1 knock-out mice 
die during early development and knock-out embryos display severe overall developmental 
and growth retardation - only the embryonic heart was spared from the Txnrd1 knock-out and 
developped normally. The dispensable role for Txnrd1 in cardiac tissue was underlined by 
heart-specific disruption of Txnrd1, which did not affect viability of mice or caused any 
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apparent phenotype (Jakupoglu et al., 2005). Numerous studies showed that Txnrd1 is 
involved in cell growth and differentiation and both, protein level and thioredoxin reductase 
activity have been shown to be elevated in several tumors and tumor cell lines (Arner and 
Holmgren, 2006; Biaglow and Miller, 2005; Fujino et al., 2006; Moos et al., 2003; Pennington 
et al., 2007; Rundlof and Arner, 2004; Yoo et al., 2007). 
 
 
 
Figure 48. Model for the intertwined thioredoxin-dependent ROS-regulating system in mitochondria. The 
presumed Prx catalytic cycles in mitochondria and inferred compensation for Txnrd2 disruption (adopted and 
modified from (Bondareva et al., 2007)). Characteristic for eukaryotic 2-Cys Prxs is the slow formation of an 
intermolecular disulfide bridge. Even at moderate H2O2 concentrations, the sulfenic acid intermediate can react 
with a second H2O2 molecule to form a sulfinic acid before it reacts with the resolving cysteine to form a disulfide. 
Sulfinic acid cannot be reduced by Trx. The left cycle is Txnrd2 dependent and functions to reduce H2O2 at low 
concentrations. The right cycle is Txnrd2-independent and mainly active at high H2O2 concentrations. Disruption 
of Txnrd2 is expected to ablate the cycle responsible for removal of low H2O2 concentrations. In Txnrd2−/− cells 
mitochondrial peroxiredoxins (Prx III and Prx V) are strongly upregulated especially when the cells are exposed to 
additional oxidative stress. To compensate for the lack of Txnrd2, cells induce the expression of Prx III, Prx V and 
Srx which allows them to control increased ROS to some extent.  
 
On the contrary, Txnrd2 knock-out mouse die at the foetal stage between E13.5 and E15.5 
due to improper heart development and perturbed haematopoiesis (Conrad et al., 2004). In a 
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study by Turanov and colleagues (Turanov et al., 2006) a certain overlap between Trx1 and 
Trx2 was postulated. By a proteomic approach it was found that Trx1 is the major target of 
Txnrd2 in the cytosolic fraction of rat and mouse hepatocytes. Given that Txnrd2 may also 
play an important role in the cytoplasma, it was important to study whether Txnrd1 or Txnrd2 
specifically targeted to the cytoplasm, is capable to rescue loss of Txnrd2. To this end, 
Txnrd1 (a kind gift from, Mandal Kumar Pankaj, PhD thesis 2009) and Txnrd2 lacking a 
mitochondrial leader sequence (MLS) were stably expressed in Txnrd2 knock-out cells. 
These experiments showed that Txnrd1 overexpression could only partially prevent cell 
death of Txnrd2−/− cells treated with increasing BSO concentrations. Partial protection of 
Txnrd2−/− cells by Txnrd1 overexpression appeared to be comparable to the effect of 
overexpression of cytosolic Txnrd2: only re-expression of Txnrd2 harbouring a MLS fully 
rescued the Txnrd2 knock-out cells confirming that the observed phenotypes were solely 
caused by Txnrd2 inactivation and were not due to other side effects. This also implies that 
subcellular localisation of Txnrd2 is of major importance for proper cell function. To address 
the question whether both enzymes harbour distinct and non-redundant functions apart from 
the different tissue-specific expression patterns, one should insert mitochondria-targeted 
Txnrd1 into the Txnrd2 locus and cytoplasmic Txnrd2 into the Txnrd1 locus in mice and ask 
whether the mice are viable and develop normally. The present findings obtained by tissue-
specific disruption of either gene indicated that both enzymes exert non-redundant functions. 
Yet, it cannot be excluded that the differences observed are due to the different tissue- and 
time-specific expression pattern of Txnrd1 and Txnrd2 (Conrad et al., 2004; Jakupoglu et al., 
2005; Soerensen et al., 2008). 
 
4.4. Txnrd2 is dispensable for maintaining the Cys/(Cys)2 cycle  
 
In normal cell culture conditions, the major part of intracellular Cys derives from the (Cys)2, 
the oxidized and predominant form of Cys in the extracellular space. (Cys)2 is transported 
into the cells via the cystine/glutamate amino acid antiporter, system xC−, and then reduced 
to Cys. Cysteine is used for protein and GSH synthesis, however quite a substantial fraction 
may be released back into the medium via neutral amino acid transport systems. Thus, 
system xC− is regarded to be the central constituent of the Cys/(Cys)2 cycle, which is 
essential for the maintenance of cellular GSH levels (Bannai, 1986) and the sustaining of the 
Cys/(Cys)2 redox balance (Bannai et al., 1989). In our laboratory it was shown recently that 
enforced expression of xCT, the substrate-specific subunit of system xC−, in Burkitt’s 
lymphoma cell drives the Cys/(Cys)2 cycle, characterized by uptake of (Cys)2, intracellular 
reduction to Cys, secretion of Cys and re-oxidation to (Cys)2 (Banjac et al., 2008), and 
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renders the cells resistant to inhibition of GSH synthesis by BSO. In a subsequent study it 
was also shown by our laboratory that genetic GSH-deficiency could be bypassed by stable 
expression of xCT in γ-GCS knock-out cells, further corroborating the Cys/(Cys)2 cycle as an 
independent redox circuit (Mandal et al., submitted). Anderson et al. showed that HT-29 cells 
have the capacity to regulate the extracellular Cys/(Cys)2 redox state by mechanisms that 
are independent of cellular GSH (Anderson et al., 2007). Earlier Jones et al. showed that the 
steady-state redox potential of the cysteine/cystine couple provides a redox node that is 
independent and distinct of the two redox couples, reduced and oxidized thioredoxin at one 
hand and reduced and oxidized glutathione at the other hand (Jones et al., 2004).  
 
Therefore, the question arose what is the intracellular driving force behind the Cys/(Cys)2 
redox cycle. Under normal conditions, it is conceivable that GSH is the prime candidate. By 
forming mixed disulfides with (Cys)2 it first yields Cys and GS-S-Cys, the latter releases Cys 
with a second molecule GSH to form GSSG. At the expense of NADPH, GSSG is then 
recycled by glutathione reductase to yield 2 molecules of GSH. But what occurs in cells 
which lack endogenous GSH biosynthesis like in γ-GCS null cells or cells depleted of GSH 
by BSO? In fact, initial in vitro observations by Holmgren implicated bovine thioredoxin 
reductase in (Cys)2 reduction in a manner independent of thioredoxin (Holmgren, 1977). 
Therefore, xCT was stably expressed in Txnrd2−/− cells. xCT overexpressing cells were 
challenged with BSO to address the role of thioredoxin reductases in intracellular (Cys)2 
reduction. As shown previously, Txnrd2−/− cells rapidly died in response to GSH depletion, 
which could be prevented by NAC (Conrad et al., 2004). Overexpression of xCT in Txnrd2−/− 
cells efficiently rescued the cells from BSO-mediated cell death and even prevented cell 
death of eGFP-expressing Txnrd2−/− control cells when these were co-cultured with 
xCT-overexpressing Txnrd2−/− cells. This finding fits very well with our previous observations 
that enforced expression of xCT rescues BL cells from cell death induced by BSO-mediated 
GSH depletion (Banjac et al., 2008). The results obtained with Txnrd2−/− and γ-GCS−/− cells 
(Pankaj Kumar Mandal, PhD thesis submitted) provided conclusive evidence that the 
(Cys)2/Cys redox cycle is functional and intact even in the absence of GSH and/or Txnrd2. In 
a parallel study by Pankaj Kumar Mandal strong evidence could be provided that it is Txnrd1 
which is the driving force behind the Cys/(Cys)2 redox cycle: xCT-transfected Txnrd1−/− cells 
were unable to exploit the beneficial and protective effects of this cycle, but they rapidly died 
in response to BSO-mediated GSH depletion (Pankaj Kumar Mandal, PhD thesis submitted). 
Thus, by using three genetically defined cellular systems, we could show that Txnrd1 is 
essential for the utilization and recycling of small thiol-containing compounds and is the main 
driving force for the (Cys)2/Cys redox cycle (Pankaj Kumar Mandal, PhD thesis submitted). 
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4.5. Txnrd2 protects myocardial tissue from oxidative damage and 
is implicated in the pathogenesis of Dilatative Cardiomyopathy 
 
Cardiac tissue has a particularly high demand for energy in form of ATP, which is mainly 
produced by oxidative phosphorylation. Hence, cardiomyocytes are packed with mitochon-
dria, and up to 40% of the cellular mass is made up of mitochondria. Reduction of O2 to H2O 
is a highly dangerous process as it requires the transfer of four electrons and the 
intermediates of the electron transfer reaction are not stable. Single electron reduction of O2 
leads to the generation of substantial amounts (up to 4% of total oxygen) of superoxide anion 
(O2. -) as a toxic by-product (Forman et al., 1982; Shigenaga et al., 1994). Oxidative stress 
has been associated with many cardiovascular diseases, including infarction 
(ischemia/reperfusion injury) and heart failure (Francis, 2001; Griendling and FitzGerald, 
2003a; Ide et al., 2000). Ischemia causes alterations in cellular defense mechanisms against 
oxygen free radicals, mainly a reduction in the activity of SOD and GSH, yielding oxidized 
glutathione (GSSG) (Ferrari et al., 2004). Then, the condition is exacerbated following 
reperfusion due to increased ROS production, although the molecular mechanisms are still 
widely unclear. Myocardial infarction after ischemia/reperfusion is a consequence of 
profound cell death (either necrosis or apoptosis), and excessive ROS production has been 
considered to be the major trigger of cell death (Anversa et al., 1998; Maulik et al., 1998). 
Hence, cardiac tissue needs effective antioxidant and antiapoptotic systems like the 
thioredoxin (Trx) and the glutaredoxin (Grx) systems to maintain cellular redox balance. The 
mitochondrial thioredoxin system has been shown to be crucial for cardiac tissue 
(Bodenstein et al., 1993; Conrad et al., 2004), and in general, its expression pattern and 
distribution correlates well with the metabolic activity of the tissue (Spyrou et al., 1997). As 
mentioned earlier, mice that ubiquitously lack Txnrd2 die at E13.5, and perturbed heart 
development was identified as one of the underlying reasons for embryonic death. This was 
further corroborated by heart-specific disruption Txnrd2, which causes post-natal death due 
to biventricular dilatation of the heart and mitochondrial aberrations of cardiomyocytes 
(Conrad et al., 2004). 
 
Additional suggestive evidence for a possible involvement of Txnrd2 in the pathogenesis of 
cardiac disease stems from patients who suffered from Keshan disease, an endemic 
cardiomyopathy resulting from severe nutritional deficiency of the trace element selenium 
(Xu et al., 1997) in combination with a coxsackie B virus infection (Beck et al., 2003a; Beck 
et al., 2003b). In a collaborative study with Dr. N. von Beckerath (Deutsches Herzzentrum 
München) and Dr. A. Pfeufer (Institute of Human Genetics, Helmholtz Zentrum München) 
sequencing of all TXNRD2 exons of DNA samples from Dilatative Cardiomyopathy (DCM) 
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patients (n = 227) along with controls (n = 683) identified two novel mutations in three 
heterozygous carriers of 227 patients (3/227=1.3%). Both 175G>A (Ala59Thr) and 1124G>A 
(Gly375Arg) were not observed in the general population (Sibbing D, Perisic T 2009, in 
preparation). The recently published crystal structure of Txnrd2 (Biterova et al., 2005) 
allowed to precisely locate the two identified mutations of Txnrd2, which are positioned in 
highly conserved regions within the FAD binding domain of Txnrd2. It is noteworthy, that both 
mutations that had been engeneered into the murine Txnrd2 protein, failed to rescue 
Txnrd2−/− cells form BSO-mediated cell death when stably expressed in Txnrd2−/− cells. 
When expressed in wild-type cells, cell death of these cells was accelerated compared to 
mock-transfected cells. Moreover, Txnrd2+/+ cells expressing the mutated forms proliferated 
very slowly, unlike Txnrd2−/− fibroblasts transfected with these mutants. In conclusion, these 
data strongly suggest that both mutants behave like dominant-negative forms. In this context, 
it should be stressed that the patients carrying these mutations were heterozygous. Hence, 
Txnrd2+/+ or Txnrd2−/− cells expressing mutated Txnrd2 represent an appropriate model to 
describe the in vivo condition found in the DCM patients with mutated Txnrd2. From these 
investigations one may conclude that a small percentage of DCM cases might be caused by 
these novel Txnrd2 mutations. After the identification of four mutations in the SelN gene that 
cause muscle disorders in humans (SEPN1-related myopathy) (Allamand et al., 2006; Maiti 
et al., 2009; Moghadaszadeh et al., 2001; Tajsharghi et al., 2005), Txnrd2 is the second 
selenoenzyme in which mutations were found that predispose to a distinct human disease.  
 
4.6. Inducible overexpression of xCT in mice is not protective, but 
causes spleen, thymus and testis atrophy and defective 
erythropoiesis 
 
A large part of this thesis has been devoted to better understand possible redundancies 
between different redox systems, i.e. of the thioredoxin and the glutathione system. It was 
shown above that cells deficient for Txnrd2 are more sensitive to agents causing oxidative 
stress than wildtype cells and that Txnrd2 knock-out cells are particularly susceptible to 
depletion of glutathione by BSO. As uptake of cystine is the limiting step for glutathione 
synthesis in many cellular systems, the cystine/glutamate exchange transporter xC−, had 
initially been regarded as an important part of the glutathione system. Yet, overexpression 
studies of xCT in wildtype cells (Banjac et al., 2008), in γ-GCS-/- cells (Mandal et al., 
submitted) and Txnrd2−/− cells (this thesis) performed in our laboratory had revealed that the 
cystine/cysteine cycle driven by system xC−, represents a redox system that can operate also 
independently of glutathione in vitro. Hence, system xC−, plays a dual role: it may increase 
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the level of glutathione in cells in which GSH synthesis is intact and cystine uptake is limiting, 
and alternatively, it may sustain the redox balance on its own when glutathione is depleted 
and/or glutathione synthesis is inhibited.  
 
So far, little is known about the biological role of system xC−, in vivo. Previously, Sato and 
colleagues showed that loss of function of xCT by targeted disruption of the gene in mice did 
not cause any overt phenotype in terms of viability, fertility and gross morphological changes 
(Sato et al., 2005). xCT knock-out mice only showed an imbalance in plasma Cys levels. 
Oppositely, it was our aim to generate a gain of function system for xCT. Since xCT has 
been mainly associated with the protection of cells and tissues from oxidative stress, it was 
hypothesized that gain of function of xCT would render transgenic mice more resistant to 
oxidative damage. If ageing is indeed associated with increased oxidative stress and tissue 
damage, overexpression of xCT might even prolong the life of transgenic mice. This 
assumption had been corroborated by the finding of showed that xCT is central for 
glutathione metabolism in rat brain and its overexpression is neuroprotective by enhancing 
glutathione export from non-neuronal cells (Shih and Murphy, 2001). But also adverse effects 
of ectopic xCT expression might have to be envisioned: Massie et al. reported the 
involvement of the xCT in aberrant glutamate neurotransmission in the striatum of a rat 
Parkinsonian brain (Massie et al., 2008), and Savaskan et al. found that pharmacological 
inhibition of xCT or silencing by small interfering RNAs in human malignant brain tumours 
inhibited neurodegeneration and alleviated brain edema most likely by decreasing glutamate-
induced excitotoxicity (Savaskan et al., 2008). A transgenic mouse with inducible xCT 
expression was thus regarded as a valuable tool to investigate the role of xCT in various 
models of neurodegeneration including stroke and Parkinson’s disease. 
 
Beside this, we sought to study the role of ROS, of an hypoxic microenvironment and of the 
intracellular redox balance for stem cell maintenance and differentiation (Diehn et al., 2009a; 
Diehn et al., 2009b; Ito et al., 2006). Evidence has been accumulated over the last years 
showing that stem cell maintenance requires an hypoxic, ROS-free environment, i.e. the 
osteoblastic niche, whereas hematopoietic differentiation is associated with leaving the 
niche, a normoxic environment and increased ROS levels (Diehn et al., 2009a; Diehn et al., 
2009b; Ito et al., 2006). Moreover, since system xC−, is the major amino acid transporter 
induced in response to LPS and cytokine treatment in macrophages (Sato et al., 1991; Sato 
et al., 1987; Watanabe and Bannai, 1987), it was hypothesized that xCT transgenic mice 
might be more resistant towards bacterial infection and LPS-mediated toxicity, and hence 
could serve as a valuable mouse model to study the involvement of ROS in inflammation.  
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To express xCT in a spatio-temporal manner, the Rosa26 locus was chosen, as the Rosa26 
promoter is ubiquitously active and this locus has been frequently used for ectopic gene 
expression in mice (Farley et al., 2000; Hameyer et al., 2007; Homig-Holzel et al., 2008; 
Ivanova et al., 2005; Jager et al., 2004; Soriano, 1999; Srinivas et al., 2001). After successful 
generation of conditional xCT knock-in mice, these mice were crossed to tamoxifen-inducible 
CreERT2-deleter mice. To our surprise, induction of xCT expression upon tamoxifen feeding 
resulted in severe symptoms like gradual weight loss, abnormal posture, and suffering of the 
mice so that the tamoxifen-feeded transgenic mice eventually had to be euthanized after 5 
weeks. Careful examination of these mice revealed that many organs were pale suggestive 
of anemia. Moreover, there was an atrophy of spleen and testes and the thymus was 
completely lacking. Histological analysis of the spleen revealed a clear reduction in the red 
pulp. The decrease in splenic size probably resulted from the increase in the number of 
apoptotic cells, the reasons for which are not understood yet. According to the hemogram 
analysis xCT transgenic mice were severely anaemic. This phenotype prompted us to further 
investigate the haematopoietic system in more detail. Analysis of bone marrow cells by flow 
cytometry revealed that transgenic mice expressing xCT had a 6-fold increase in 
undifferentiated non-committed progenitor cells (KSL population) in the bone marrow as 
identified on the basis of the high expression of c-kit and Sca-1 and the absence of lineage 
markers on the cell surface (Lin−) . Unfortunately, the available data did not allow to draw the 
conclusion whether there is an absolute increase in the number of KSL cells or a relative 
increase that might be caused merely by the decrease of differentiated cells. Further 
investigation of erythrocyte differentiation showed that all committed erythrocytic precursors 
like pro-erythroblasts, as well as basophilic-, polychromatic- and orthochromatic-
erythroblasts were decreased in transgenic mice, whereas the percentage of megakaryocytic 
and erythroblastic precursor cells was relatively increased. The impaired differentiation of 
cells of the erythrocytic lineage may explain the anaemic phenotype of the xCT transgenic 
animals. Our preliminary investigation thus showed that transgenic animals have 
dysfunctional erythropoiesis that possibly resembles a refractory anemia/myelodysplastic 
syndrome. Whether increased destruction of mature RBCs in the spleen may also contribute 
to the anaemic phenotype, remains open at present. This will be answered by kinetic studies 
determining the half life of mature erythrocytes in vivo. But it is noteworthy that the 
phenotype is clearly different from a haemolytic anemia that is characterized by increased 
spleen weight due to increased degradation of erythrocytes and compensatory 
overproduction of red blood cell precursors.   
 
The phenotype described here is compatible with published reports that a low level of ROS 
and hypoxic microenvironment promotes self-renewal of HSCs (Diehn et al., 2009a; Diehn et 
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al., 2009b; Ito et al., 2004; Osawa et al., 1996). Thus, by promoting the cystine uptake and 
boosting the intracellular cysteine level, xCT overexpression may reduce the overall ROS 
burden to a minimal level. By generating a highly reducing intracellular environment xCT 
overexpression may shift the balance between self renewal and differentiation towards self 
renewal and may thus inhibit differentiation of uncommitted progenitors into mature red blood 
cells. This may be corroborated experimentally by showing that not only the relative number 
but also the absolute number of KSL cells (harbouring the stem cells) has increased in xCT 
transgenic mice. To address the question whether the phenotype observed is due to a cell-
autonomous effect of xCT overexpression in hematopoietic cells or due to a cell non-
autonomous action of xCT in stroma cells supporting hematopoiesis, bone marrow cells of 
xCT-transgenic mice have to be transplanted into wildtype mice and vice versa, wildtype 
bone marrow cells into xCT transgenic mice.  
 
Although the phenotype observed in hematopoietic cells is exciting and promising, a note of 
caution is also required regarding the interpretation of data obtained from xCT transgenic 
mice. In vivo, xCT overexpression may not only lead to an increase in the intracellular supply 
of cysteine (and thus in an increase in reduced intracellular glutathione), it may also lead – 
due to the export of glutamate coupled to the import of cystine - to a decrease in the 
intracellular glutamate and an increase in the extracellular glutamate concentration both of 
which might be harmful to the cell. Thus, intracellular depletion of glutamate may impact on 
the physiology of hematopoietic cells or alternatively, xCT overexpression may cause 
glutamate-mediated toxicity in a manner similar to that in neurons. Recent studies have 
shown that glutamate not only acts as a neurotransmitter, it also has been reported to have 
immunomodulatory function. This is supported by the finding that glutamate receptors are 
expressed on T-cells and glutamate transporters in antigen presenting cells like dendritic 
cells and macrophages (Pacheco et al., 2007). A final caveat is necessary also regarding the 
intracellular supply of NADPH. The continuous import of oxidized cystine and export of 
reduced cysteine represents a steadily ongoing loss of reducing equivalents. Regardless 
whether glutathione or thioredoxin reductase 1 are used for reduction of cystine, the reducing 
equilvalents finally stem from the degradation of glucose in the pentose phosphate cycle and 
glucose-6-phosphate dehydrogenase (G6PDH) that is generating NADPH as the universal 
supplier of electrons for various biosynthetic pathways. Regarding the phenotype of xCT 
overexpression in vivo, it may be necessary to show that the supply of NADPH is ensured 
also in vivo and that the cells are not exhausted due to the continuous loss of reducing 
equivalents. Yet, even though the in vivo phenotype of xCT overexpression is difficult to 
interpret for the reasons mentioned above, the importance of xCT expression for culturing 
cells in vitro is well established: in vitro, the supply of glutamate is guaranteed by the uptake 
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of glutamine from the medium and the intracellular deamination of glutamine to glutamate. 
Likewise, the generation of reducing equivalents through glucose and G6PDH is not limiting 
in culture conditions in vitro. We are thus left with the curious situation that the relevance of 
the phenotype observed by xCT overexpression in vivo has to be verified in vitro culture 
systems, in which all confounding parameters may be controlled and the impact of xCT 
overexpression on metabolic parameters can be dissected experimentally. It will be 
particularly important to study differentiation of hemaptoietic cells in colony assays in 
methylcellulose in vitro to which tamoxifen can be added at different time points, by following 
the fate of single cells (Eilken et al., 2009; Rieger et al., 2009).  
 
Besides the role of xCT overexpression for renewal and differentiation of hematopoetic cells, 
it will be particularly interesting to study the impact of xCT overexpression in the brain. It is 
impossible to predict which of two opposing phenotypes may prevail: protection of neuronal 
cells from oxidative stress by increasing the intracellular glutathione concentration, or 
increased neurotoxicity due to an increase in the extracellular glutamate levels. Hameyer et 
al. have reported that the CreERT2 deleter mouse has no detectable CreERT2 activity in the 
brain (Hameyer et al., 2007). Yet, our own preliminary data showed increased xCT levels in 
whole brain lysates of xCT transgenic mice after 5 weeks of Tamoxifen feeding. To ensure 
extensive broad xCT expression in the brain, R26mxCTflSTOP mice will be crossed to Nestin-
Cre mice, which express Cre in neuronal (and also some non-neuronal) cells. These mice 
will prove most suitable to dissect putative protective or detrimental effects of increased 
cystine uptake: either neuroprotection to due increased GSH synthesis or neurotoxicity due 
to increased glutamate levels. Of note, ongoing studies in our laboratory in collaboration with 
Dr. H. Beck (LMU München) and Dr. N. Plesnila (RCSI Dublin, Ireland) provided initial 
evidence that xCT knock-out mice have reduced infarct size upon transient 
ischemia/reperfusion (Beck et al, submitted) due to reduced levels of extracellular glutamate 
and hence reduced glutamate-mediated neurotoxicity. In addition to studying the role of xCT 
loss of function in xCT knock-out animals, the xCT transgenic mice will provide 
complementary data in a xCT gain of function model. 
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5. Summary 
 
The thioredoxin system, along with the glutathione (GSH)-dependent system, is critically 
involved in the maintenance of the intracellular redox balance. The thioredoxin dependent 
system consists of thioredoxin reductases, thioredoxins and thioredoxin-dependent 
peroxidases. The mitochondrial thioredoxin reductase (Txnrd2) is an important component of 
the mitochondrial antioxidant system. Using Txnrd2 null cells we show that Txnrd2−/− cells 
produced more ROS, and were highly susceptible to different prooxiditans and GSH 
depletion. Administration of various antioxidants, such as NAC, GSH and α-Toc, reverted the 
phenotyp of the Txnrd2−/− cells. The up-regulation of the mitochondrial peroxiredoxins Prx III 
and Prx V and sulfiredoxin transcripts in Txnrd2−/− cells could be a compensatory mechanism 
for loss of Txnrd2. However, under oxidative stress, Txnrd2−/− cells showed higher amount of 
overoxidation of Prx I and PrxII/PrxIII indicating that in absence of Txnrd2 ROS scavenging 
efficiency of Trx2-Prx system is greatly compromised.  
 
Oxidative stress has been implicated in cardiovascular diseases, including infarction and 
heart failure. Disruption of Txnrd2 leads to perturbed heart development and embryonic 
lethality in mice. Heart-specific Txnrd2 disruption causes post-natal death due to biventricular 
dilatation of the heart and mitochondrial aberrations of cardiomyocytes. Additional evidence 
for a possible involvement of Txnrd2 in the pathogenesis of cardiac diseases came form the 
study of the patients suffering from dialated cardiomyopathy (DCM). By DNA sequence 
analysis of these samples, we found two novel mutations (Ala59Thr and Gly375Arg) in 
TXNRD2. Stable expression of murine Txnrd2 harboring these two mutations in Txnrd2−/− 
cells showed a dominant negative effect and were unable to rescue the cells from GSH 
depletion. Our data strongly suggest that the mutations found in a small percentage of DCM 
cases might be due to loss of Txnrd2 functions.  
 
The cellular redox balance is maintained by thioredoxin- and GSH-dependent system along 
with Cys/(Cys)2-cycle which is a distinct redox node of major importance. Previous study in 
the lab showed that the essential requirement of GSH can be bypassed by the Cys/(Cys)2-
cycle. To gain further insights into the role of the thioredoxin system being a driving force for 
the Cys/(Cys)2-cycle, xCT was overexpressed in Txnrd2−/− fibroblasts. xCT overexpression 
rescued the Txnrd2−/− cells form GSH depletion. This suggests that the (Cys)2/Cys redox 
cycle is functional and intact even in the absence of GSH and/or mitochondrial thioredoxin 
reductase. In a parallel study, we found that cytosolic thioredoxin reductase (Txnrd1) is the 
driving force behind the Cys/(Cys)2 redox cycle. 
 
  Summary 
xCT epression provided growth advantages in culture conditions. In order to recapitulate our 
findings in vivo, we generated xCT knock-in mice, in which xCT expression can be induced in 
a spatio-temporal manner by tamoxifen. To our great surprise, overexpression of xCT in mice 
resulted in adverse effects like atrophy of spleen, thymus and testis, defective erythropoiesis 
and ultimately death after 5 weeks of induction. Detailed analysis of the bone marrow 
revealed that although there is an increase in the hematopoietic stem cell population, xCT 
overexpression leads to impaired erythropoiesis. The observed paradox with xCT 
overexpression could be due to glutamate-mediated toxicity or impaired redox balance.  
  
 
 110
  References 
 111
6. References 
 
Allamand, V., Richard, P., Lescure, A., Ledeuil, C., Desjardin, D., Petit, N., Gartioux, C., 
Ferreiro, A., Krol, A., Pellegrini, N., et al. (2006). A single homozygous point mutation in a 
3'untranslated region motif of selenoprotein N mRNA causes SEPN1-related myopathy. 
EMBO Rep 7, 450-454. 
Anderson, C. L., Iyer, S. S., Ziegler, T. R., and Jones, D. P. (2007). Control of extracellular 
cysteine/cystine redox state by HT-29 cells is independent of cellular glutathione. Am J 
Physiol Regul Integr Comp Physiol 293, R1069-1075. 
Andersson, M., Holmgren, A., and Spyrou, G. (1996). NK-lysin, a disulfide-containing effector 
peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. 
Implication for a protective mechanism against NK-lysin cytotoxicity. J Biol Chem 271, 
10116-10120. 
Anestal, K., Prast-Nielsen, S., Cenas, N., and Arner, E. S. (2008). Cell Death by SecTRAPs: 
Thioredoxin Reductase as a Prooxidant Killer of Cells. PLoS ONE 3, e1846. 
Anversa, P., Cheng, W., Liu, Y., Leri, A., Redaelli, G., and Kajstura, J. (1998). Apoptosis and 
myocardial infarction. Basic Res Cardiol 93 Suppl 3, 8-12. 
Araki, M., Nanri, H., Ejima, K., Murasato, Y., Fujiwara, T., Nakashima, Y., and Ikeda, M. 
(1999). Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular 
system. J Biol Chem 274, 2271-2278. 
Arner, E. S., and Holmgren, A. (2000). Physiological functions of thioredoxin and thioredoxin 
reductase. Eur J Biochem 267, 6102-6109. 
Arner, E. S., and Holmgren, A. (2006). The thioredoxin system in cancer. Semin Cancer Biol 
16, 420-426. 
Arner, E. S., Nordberg, J., and Holmgren, A. (1996). Efficient reduction of lipoamide and 
lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Commun 225, 
268-274. 
Atkins, J. F., and Gesteland, R. F. (2000). The twenty-first amino acid. Nature 407, 463, 465. 
Bachur, N. R., Gordon, S. L., and Gee, M. V. (1977). Anthracycline antibiotic augmentation of 
microsomal electron transport and free radical formation. Mol Pharmacol 13, 901-910. 
Baker, A., Payne, C. M., Briehl, M. M., and Powis, G. (1997). Thioredoxin, a gene found 
overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57, 
5162-5167. 
Banjac, A. (2005) Cystine-Import and regulation of apoptosis n B-Lymphocytes. Dissertation, 
LMU, Munich. 
Banjac, A., Perisic, T., Sato, H., Seiler, A., Bannai, S., Weiss, N., Kolle, P., Tschoep, K., 
Issels, R. D., Daniel, P. T., et al. (2008). The cystine/cysteine cycle: a redox cycle 
regulating susceptibility versus resistance to cell death. Oncogene 27, 1618-1628. 
Banmeyer, I., Marchand, C., Clippe, A., and Knoops, B. (2005). Human mitochondrial 
peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen 
peroxide. FEBS Lett 579, 2327-2333. 
Bannai, S. (1984). Induction of cystine and glutamate transport activity in human fibroblasts 
by diethyl maleate and other electrophilic agents. J Biol Chem 259, 2435-2440. 
Bannai, S. (1986). Exchange of cystine and glutamate across plasma membrane of human 
fibroblasts. J Biol Chem 261, 2256-2263. 
  References 
Bannai, S., and Ishii, T. (1982). Transport of cystine and cysteine and cell growth in cultured 
human diploid fibroblasts: effect of glutamate and homocysteate. J Cell Physiol 112, 265-
272. 
Bannai, S., and Kasuga, H. (1985). Anti-inflammatory drug inhibition of transport of cystine 
and glutamate in cultured human fibroblasts. Biochem Pharmacol 34, 1852-1854. 
Bannai, S., Sato, H., Ishii, T., and Sugita, Y. (1989). Induction of cystine transport activity in 
human fibroblasts by oxygen. J Biol Chem 264, 18480-18484. 
Bannai, S., Sato, H., Ishii, T., and Taketani, S. (1991). Enhancement of glutathione levels in 
mouse peritoneal macrophages by sodium arsenite, cadmium chloride and 
glucose/glucose oxidase. Biochim Biophys Acta 1092, 175-179. 
Bauer, H., Massey, V., Arscott, L. D., Schirmer, R. H., Ballou, D. P., and Williams, C. H., Jr. 
(2003). The mechanism of high Mr thioredoxin reductase from Drosophila melanogaster. 
J Biol Chem 278, 33020-33028. 
Beck, M. A., and Levander, O. A. (1998). Dietary oxidative stress and the potentiation of viral 
infection. Annu Rev Nutr 18, 93-116. 
Beck, M. A., Levander, O. A., and Handy, J. (2003a). Selenium deficiency and viral infection. 
J Nutr 133, 1463S-1467S. 
Beck, M. A., Williams-Toone, D., and Levander, O. A. (2003b). Coxsackievirus B3-resistant 
mice become susceptible in Se/vitamin E deficiency. Free Radic Biol Med 34, 1263-1270. 
Biaglow, J. E., and Miller, R. A. (2005). The thioredoxin reductase/thioredoxin system: novel 
redox targets for cancer therapy. Cancer Biol Ther 4, 6-13. 
Bilski, P., Belanger, A. G., and Chignell, C. F. (2002). Photosensitized oxidation of 2',7'-
dichlorofluorescin: singlet oxygen does not contribute to the formation of fluorescent 
oxidation product 2',7'-dichlorofluorescein. Free Radic Biol Med 33, 938-946. 
Birringer, M., Pilawa, S., and Flohe, L. (2002). Trends in selenium biochemistry. Nat Prod 
Rep 19, 693-718. 
Biteau, B., Labarre, J., and Toledano, M. B. (2003). ATP-dependent reduction of cysteine-
sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425, 980-984. 
Biterova, E. I., Turanov, A. A., Gladyshev, V. N., and Barycki, J. J. (2005). Crystal structures 
of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of 
the reaction mechanism. Proc Natl Acad Sci U S A 102, 15018-15023. 
Bjornstedt, M., Hamberg, M., Kumar, S., Xue, J., and Holmgren, A. (1995). Human 
thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine 
strongly stimulates the reaction via catalytically generated selenols. J Biol Chem 270, 
11761-11764. 
Bodenstein, N. P., McIntosh, W. A., Vlantis, A. C., and Urquhart, A. C. (1993). Clinical signs 
of orbital ischemia in rhino-orbitocerebral mucormycosis. Laryngoscope 103, 1357-1361. 
Bondareva, A. A., Capecchi, M. R., Iverson, S. V., Li, Y., Lopez, N. I., Lucas, O., Merrill, G. 
F., Prigge, J. R., Siders, A. M., Wakamiya, M., et al. (2007). Effects of thioredoxin 
reductase-1 deletion on embryogenesis and transcriptome. Free Radic Biol Med 43, 911-
923. 
Bosl, M. R., Takaku, K., Oshima, M., Nishimura, S., and Taketo, M. M. (1997). Early 
embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA 
gene (Trsp). Proc Natl Acad Sci U S A 94, 5531-5534. 
Boveris, A. (1984). Determination of the production of superoxide radicals and hydrogen 
peroxide in mitochondria. Methods Enzymol 105, 429-435. 
 112
  References 
Brandt, W., and Wessjohann, L. A. (2005). The functional role of selenocysteine (Sec) in the 
catalysis mechanism of large thioredoxin reductases: proposition of a swapping catalytic 
triad including a Sec-His-Glu state. Chembiochem 6, 386-394. 
Bridges, C. C., Hu, H., Miyauchi, S., Siddaramappa, U. N., Ganapathy, M. E., Ignatowicz, L., 
Maddox, D. M., Smith, S. B., and Ganapathy, V. (2004). Induction of cystine-glutamate 
transporter xc- by human immunodeficiency virus type 1 transactivator protein tat in 
retinal pigment epithelium. Invest Ophthalmol Vis Sci 45, 2906-2914. 
Brigelius-Flohe, R. (2008). Selenium compounds and selenoproteins in cancer. Chem 
Biodivers 5, 389-395. 
Brigelius-Flohe, R., and Banning, A. (2006). Part of the series: from dietary antioxidants to 
regulators in cellular signaling and gene regulation. Sulforaphane and selenium, partners 
in adaptive response and prevention of cancer. Free Radic Res 40, 775-787. 
Brown, K. K., Eriksson, S. E., Arner, E. S., and Hampton, M. B. (2008). Mitochondrial 
peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol 
Med 45, 494-502. 
Burdo, J., Dargusch, R., and Schubert, D. (2006). Distribution of the cystine/glutamate 
antiporter system xc- in the brain, kidney, and duodenum. J Histochem Cytochem 54, 
549-557. 
Carmel-Harel, O., Stearman, R., Gasch, A. P., Botstein, D., Brown, P. O., and Storz, G. 
(2001). Role of thioredoxin reductase in the Yap1p-dependent response to oxidative 
stress in Saccharomyces cerevisiae. Mol Microbiol 39, 595-605. 
Chae, H. Z., Chung, S. J., and Rhee, S. G. (1994). Thioredoxin-dependent peroxide 
reductase from yeast. J Biol Chem 269, 27670-27678. 
Chang, E. Y., Son, S. K., Ko, H. S., Baek, S. H., Kim, J. H., and Kim, J. R. (2005). Induction 
of apoptosis by the overexpression of an alternative splicing variant of mitochondrial 
thioredoxin reductase. Free Radic Biol Med 39, 1666-1675. 
Chang, M. C., Pralle, A., Isacoff, E. Y., and Chang, C. J. (2004a). A selective, cell-permeable 
optical probe for hydrogen peroxide in living cells. J Am Chem Soc 126, 15392-15393. 
Chang, T. S., Cho, C. S., Park, S., Yu, S., Kang, S. W., and Rhee, S. G. (2004b). 
Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by 
mitochondria. J Biol Chem 279, 41975-41984. 
Chang, T. S., Jeong, W., Woo, H. A., Lee, S. M., Park, S., and Rhee, S. G. (2004c). 
Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized 
peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J 
Biol Chem 279, 50994-51001. 
Chavatte, L., Brown, B. A., and Driscoll, D. M. (2005). Ribosomal protein L30 is a component 
of the UGA-selenocysteine recoding machinery in eukaryotes. Nat Struct Mol Biol 12, 
408-416. 
Chen, Y. W., Bycroft, M., and Wong, K. B. (2003). Crystal structure of ribosomal protein L30e 
from the extreme thermophile Thermococcus celer: thermal stability and RNA binding. 
Biochemistry 42, 2857-2865. 
Choi, H. J., Kang, S. W., Yang, C. H., Rhee, S. G., and Ryu, S. E. (1998). Crystal structure of 
a novel human peroxidase enzyme at 2.0 A resolution. Nat Struct Biol 5, 400-406. 
Choi, M. H., Sajed, D., Poole, L., Hirata, K., Herdman, S., Torian, B. E., and Reed, S. L. 
(2005). An unusual surface peroxiredoxin protects invasive Entamoeba histolytica from 
oxidant attack. Mol Biochem Parasitol 143, 80-89. 
 113
  References 
Chung, W. J., Lyons, S. A., Nelson, G. M., Hamza, H., Gladson, C. L., Gillespie, G. Y., and 
Sontheimer, H. (2005). Inhibition of cystine uptake disrupts the growth of primary brain 
tumors. J Neurosci 25, 7101-7110. 
Conrad, M. (2009). Transgenic mouse models for the vital selenoenzymes cytosolic 
thioredoxin reductase, mitochondrial thioredoxin reductase and glutathione peroxidase 4. 
Biochim Biophys Acta. 
Conrad, M., Brielmeier, M., and Bornkamm, G. W. (2006). Mitochondrial and Cytosolic 
Thioredoxin Reductase Knockout Mice. Selenium : Its Molecular Biology and Role in 
Human Health: Springer, New York.). 
Conrad, M., Jakupoglu, C., Moreno, S. G., Lippl, S., Banjac, A., Schneider, M., Beck, H., 
Hatzopoulos, A. K., Just, U., Sinowatz, F., et al. (2004). Essential role for mitochondrial 
thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell 
Biol 24, 9414-9423. 
Copeland, P. R., and Driscoll, D. M. (1999). Purification, redox sensitivity, and RNA binding 
properties of SECIS-binding protein 2, a protein involved in selenoprotein biosynthesis. J 
Biol Chem 274, 25447-25454. 
Copeland, P. R., Fletcher, J. E., Carlson, B. A., Hatfield, D. L., and Driscoll, D. M. (2000). A 
novel RNA binding protein, SBP2, is required for the translation of mammalian 
selenoprotein mRNAs. Embo J 19, 306-314. 
Copeland, P. R., Stepanik, V. A., and Driscoll, D. M. (2001). Insight into mammalian 
selenocysteine insertion: domain structure and ribosome binding properties of Sec 
insertion sequence binding protein 2. Mol Cell Biol 21, 1491-1498. 
Crack, P. J., Taylor, J. M., Flentjar, N. J., de Haan, J., Hertzog, P., Iannello, R. C., and Kola, 
I. (2001). Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-
1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. J Neurochem 
78, 1389-1399. 
Cregan, S. P., Dawson, V. L., and Slack, R. S. (2004). Role of AIF in caspase-dependent 
and caspase-independent cell death. Oncogene 23, 2785-2796. 
D'Autreaux, B., and Toledano, M. B. (2007). ROS as signalling molecules: mechanisms that 
generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8, 813-824. 
Da Silva-Azevedo, L., Jahne, S., Hoffmann, C., Stalder, D., Heller, M., Pries, A. R., 
Zakrzewicz, A., and Baum, O. (2009). Up-regulation of the peroxiredoxin-6 related 
metabolism of reactive oxygen species in skeletal muscle of mice lacking neuronal nitric 
oxide synthase. J Physiol 587, 655-668. 
Damdimopoulos, A. E., Miranda-Vizuete, A., Treuter, E., Gustafsson, J. A., and Spyrou, G. 
(2004). An alternative splicing variant of the selenoprotein thioredoxin reductase is a 
modulator of estrogen signaling. J Biol Chem 279, 38721-38729. 
Davies, K. J., Doroshow, J. H., and Hochstein, P. (1983). Mitochondrial NADH 
dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative 
inactivity of 5-iminodaunorubicin. FEBS Lett 153, 227-230. 
de Jesus, L. A., Hoffmann, P. R., Michaud, T., Forry, E. P., Small-Howard, A., Stillwell, R. J., 
Morozova, N., Harney, J. W., and Berry, M. J. (2006). Nuclear assembly of UGA 
decoding complexes on selenoprotein mRNAs: a mechanism for eluding nonsense-
mediated decay? Mol Cell Biol 26, 1795-1805. 
DeYulia, G. J., Jr., Carcamo, J. M., Borquez-Ojeda, O., Shelton, C. C., and Golde, D. W. 
(2005). Hydrogen peroxide generated extracellularly by receptor-ligand interaction 
facilitates cell signaling. Proc Natl Acad Sci U S A 102, 5044-5049. 
Dickinson, B. C., and Chang, C. J. (2008). A targetable fluorescent probe for imaging 
hydrogen peroxide in the mitochondria of living cells. J Am Chem Soc 130, 9638-9639. 
 114
  References 
Diehn, M., Cho, R. W., and Clarke, M. F. (2009a). Therapeutic implications of the cancer 
stem cell hypothesis. Semin Radiat Oncol 19, 78-86. 
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., 
Ailles, L. E., Wong, M., et al. (2009b). Association of reactive oxygen species levels and 
radioresistance in cancer stem cells. Nature 458, 780-783. 
Ding, F., and Grabowski, P. J. (1999). Identification of a protein component of a mammalian 
tRNA(Sec) complex implicated in the decoding of UGA as selenocysteine. Rna 5, 1561-
1569. 
Driscoll, D. M., and Copeland, P. R. (2003). Mechanism and regulation of selenoprotein 
synthesis. Annu Rev Nutr 23, 17-40. 
Drummen, G. P., van Liebergen, L. C., Op den Kamp, J. A., and Post, J. A. (2002). C11-
BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: 
(micro)spectroscopic characterization and validation of methodology. Free Radic Biol 
Med 33, 473-490. 
Egler, R. A., Fernandes, E., Rothermund, K., Sereika, S., de Souza-Pinto, N., Jaruga, P., 
Dizdaroglu, M., and Prochownik, E. V. (2005). Regulation of reactive oxygen species, 
DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 24, 8038-8050. 
Eilken, H. M., Nishikawa, S., and Schroeder, T. (2009). Continuous single-cell imaging of 
blood generation from haemogenic endothelium. Nature 457, 896-900. 
Fagegaltier, D., Hubert, N., Yamada, K., Mizutani, T., Carbon, P., and Krol, A. (2000). 
Characterization of mSelB, a novel mammalian elongation factor for selenoprotein 
translation. Embo J 19, 4796-4805. 
Farley, F. W., Soriano, P., Steffen, L. S., and Dymecki, S. M. (2000). Widespread 
recombinase expression using FLPeR (flipper) mice. Genesis 28, 106-110. 
Ferrari, R., Guardigli, G., Mele, D., Percoco, G. F., Ceconi, C., and Curello, S. (2004). 
Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 10, 
1699-1711. 
Feussner, A., Rolinski, B., Weiss, N., Deufel, T., Wolfram, G., and Roscher, A. A. (1997). 
Determination of total homocysteine in human plasma by isocratic high-performance 
liquid chromatography. Eur J Clin Chem Clin Biochem 35, 687-691. 
Finkel, T. (1998). Oxygen radicals and signaling. Curr Opin Cell Biol 10, 248-253. 
Fisher, A. B., Dodia, C., Manevich, Y., Chen, J. W., and Feinstein, S. I. (1999). Phospholipid 
hydroperoxides are substrates for non-selenium glutathione peroxidase. J Biol Chem 
274, 21326-21334. 
Fletcher, J. E., Copeland, P. R., Driscoll, D. M., and Krol, A. (2001). The selenocysteine 
incorporation machinery: interactions between the SECIS RNA and the SECIS-binding 
protein SBP2. Rna 7, 1442-1453. 
Fomenko, D. E., and Gladyshev, V. N. (2003). Identity and functions of CxxC-derived motifs. 
Biochemistry 42, 11214-11225. 
Forman, H. J., Williams, J. J., Nelson, J., Daniele, R. P., and Fisher, A. B. (1982). Hyperoxia 
inhibits stimulated superoxide release by rat alveolar macrophages. J Appl Physiol 53, 
685-689. 
Francis, G. S. (2001). Pathophysiology of chronic heart failure. Am J Med 110 Suppl 7A, 
37S-46S. 
Freemerman, A. J., Gallegos, A., and Powis, G. (1999). Nuclear factor kappaB 
transactivation is increased but is not involved in the proliferative effects of thioredoxin 
overexpression in MCF-7 breast cancer cells. Cancer Res 59, 4090-4094. 
 115
  References 
Fujino, G., Noguchi, T., Takeda, K., and Ichijo, H. (2006). Thioredoxin and protein kinases in 
redox signaling. Semin Cancer Biol 16, 427-435. 
Gasdaska, J. R., Berggren, M., and Powis, G. (1995a). Cell growth stimulation by the redox 
protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 6, 1643-
1650. 
Gasdaska, J. R., Harney, J. W., Gasdaska, P. Y., Powis, G., and Berry, M. J. (1999a). 
Regulation of human thioredoxin reductase expression and activity by 3'-untranslated 
region selenocysteine insertion sequence and mRNA instability elements. J Biol Chem 
274, 25379-25385. 
Gasdaska, P. Y., Berggren, M. M., Berry, M. J., and Powis, G. (1999b). Cloning, sequencing 
and functional expression of a novel human thioredoxin reductase. FEBS Lett 442, 105-
111. 
Gasdaska, P. Y., Gasdaska, J. R., Cochran, S., and Powis, G. (1995b). Cloning and 
sequencing of a human thioredoxin reductase. FEBS Lett 373, 5-9. 
Gasdaska, P. Y., Oblong, J. E., Cotgreave, I. A., and Powis, G. (1994). The predicted amino 
acid sequence of human thioredoxin is identical to that of the autocrine growth factor 
human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human 
tumors. Biochim Biophys Acta 1218, 292-296. 
Gasol, E., Jimenez-Vidal, M., Chillaron, J., Zorzano, A., and Palacin, M. (2004). Membrane 
topology of system xc- light subunit reveals a re-entrant loop with substrate-restricted 
accessibility. J Biol Chem 279, 31228-31236. 
Geisberger, R., Kiermayer, C., Homig, C., Conrad, M., Schmidt, J., Zimber-Strobl, U., and 
Brielmeier, M. (2007). B- and T-cell-specific inactivation of thioredoxin reductase 2 does 
not impair lymphocyte development and maintenance. Biol Chem 388, 1083-1090. 
Geiszt, M., and Leto, T. L. (2004). The Nox family of NAD(P)H oxidases: host defense and 
beyond. J Biol Chem 279, 51715-51718. 
Gelpi, C., Sontheimer, E. J., and Rodriguez-Sanchez, J. L. (1992). Autoantibodies against a 
serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc 
Natl Acad Sci U S A 89, 9739-9743. 
Gilberger, T. W., Walter, R. D., and Muller, S. (1997). Identification and characterization of 
the functional amino acids at the active site of the large thioredoxin reductase from 
Plasmodium falciparum. J Biol Chem 272, 29584-29589. 
Gladyshev, V. N., Jeang, K. T., and Stadtman, T. C. (1996). Selenocysteine, identified as the 
penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to 
TGA in the human placental gene. Proc Natl Acad Sci U S A 93, 6146-6151. 
Griendling, K. K., and FitzGerald, G. A. (2003a). Oxidative stress and cardiovascular injury: 
Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912-1916. 
Griendling, K. K., and FitzGerald, G. A. (2003b). Oxidative stress and cardiovascular injury: 
Part II: animal and human studies. Circulation 108, 2034-2040. 
Gromer, S., and Gross, J. H. (2002). Methylseleninate is a substrate rather than an inhibitor 
of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium. J 
Biol Chem 277, 9701-9706. 
Gromer, S., Urig, S., and Becker, K. (2004). The thioredoxin system--from science to clinic. 
Med Res Rev 24, 40-89. 
Gromer, S., Wissing, J., Behne, D., Ashman, K., Schirmer, R. H., Flohe, L., and Becker, K. 
(1998). A hypothesis on the catalytic mechanism of the selenoenzyme thioredoxin 
reductase. Biochem J 332 ( Pt 2), 591-592. 
 116
  References 
Gustafsson, A. B., and Gottlieb, R. A. (2008). Recycle or die: the role of autophagy in 
cardioprotection. J Mol Cell Cardiol 44, 654-661. 
Gutierrez, P. L., Gee, M. V., and Bachur, N. R. (1983). Kinetics of anthracycline antibiotic 
free radical formation and reductive glycosidase activity. Arch Biochem Biophys 223, 68-
75. 
Gutscher, M., Pauleau, A. L., Marty, L., Brach, T., Wabnitz, G. H., Samstag, Y., Meyer, A. J., 
and Dick, T. P. (2008). Real-time imaging of the intracellular glutathione redox potential. 
Nat Methods 5, 553-559. 
Hameyer, D., Loonstra, A., Eshkind, L., Schmitt, S., Antunes, C., Groen, A., Bindels, E., 
Jonkers, J., Krimpenfort, P., Meuwissen, R., et al. (2007). Toxicity of ligand-dependent 
Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic 
recombination in peripheral tissues. Physiol Genomics 31, 32-41. 
Haridas, V., Ni, J., Meager, A., Su, J., Yu, G. L., Zhai, Y., Kyaw, H., Akama, K. T., Hu, J., Van 
Eldik, L. J., and Aggarwal, B. B. (1998). TRANK, a novel cytokine that activates NF-
kappa B and c-Jun N-terminal kinase. J Immunol 161, 1-6. 
Hattori, H., Imai, H., Furuhama, K., Sato, O., and Nakagawa, Y. (2005a). Induction of 
phospholipid hydroperoxide glutathione peroxidase in human polymorphonuclear 
neutrophils and HL60 cells stimulated with TNF-alpha. Biochem Biophys Res Commun 
337, 464-473. 
Hattori, N., Machida, Y., and Noda, K. (2005b). [Pathogenesis of Parkinson's disease: a 
common pathway between alpha-synuclein and parkin and the mechanism of Lewy 
bodies formation]. Rinsho Shinkeigaku 45, 905-907. 
Hill, K. E., Zhou, J., Austin, L. M., Motley, A. K., Ham, A. J., Olson, G. E., Atkins, J. F., 
Gesteland, R. F., and Burk, R. F. (2007). The selenium-rich C-terminal domain of mouse 
selenoprotein P is necessary for the supply of selenium to brain and testis but not for the 
maintenance of whole body selenium. J Biol Chem 282, 10972-10980. 
Hirosawa-Takamori, M., Chung, H. R., and Jackle, H. (2004). Conserved selenoprotein 
synthesis is not critical for oxidative stress defence and the lifespan of Drosophila. EMBO 
Rep 5, 317-322. 
Hirosawa-Takamori, M., Jackle, H., and Vorbruggen, G. (2000). The class 2 
selenophosphate synthetase gene of Drosophila contains a functional mammalian-type 
SECIS. EMBO Rep 1, 441-446. 
Hirotsu, S., Abe, Y., Okada, K., Nagahara, N., Hori, H., Nishino, T., and Hakoshima, T. 
(1999). Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 
kDa/proliferation-associated gene product. Proc Natl Acad Sci U S A 96, 12333-12338. 
Holmgren, A. (1977). Bovine thioredoxin system. Purification of thioredoxin reductase from 
calf liver and thymus and studies of its function in disulfide reduction. J Biol Chem 252, 
4600-4606. 
Holmgren, A. (1985). Thioredoxin. Annu Rev Biochem 54, 237-271. 
Holmgren, A. (1989). Thioredoxin and glutaredoxin systems. J Biol Chem 264, 13963-13966. 
Homig-Holzel, C., Hojer, C., Rastelli, J., Casola, S., Strobl, L. J., Muller, W., Quintanilla-
Martinez, L., Gewies, A., Ruland, J., Rajewsky, K., and Zimber-Strobl, U. (2008). 
Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB 
pathway and promotes lymphomagenesis. J Exp Med 205, 1317-1329. 
Hömig, C. (2005) Einfluss der Epstein-Barr-Virus Proteine LMP1 und EBNA2 auf die B-
Zellentwicklung in vivo, LMU, Munich. 
Hoshi, T., and Heinemann, S. (2001). Regulation of cell function by methionine oxidation and 
reduction. J Physiol 531, 1-11. 
 117
  References 
Ide, T., Tsutsui, H., Kinugawa, S., Suematsu, N., Hayashidani, S., Ichikawa, K., Utsumi, H., 
Machida, Y., Egashira, K., and Takeshita, A. (2000). Direct evidence for increased 
hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 86, 152-
157. 
Ikeda, K., Kumagai, Y., Nagano, Y., Matsuzawa, N., and Kojo, S. (2003). Change in the 
concentration of vitamins C and E in rat tissues by paraquat administration. Biosci 
Biotechnol Biochem 67, 1130-1131. 
Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama, K., 
Hosokawa, K., Sakurada, K., Nakagata, N., et al. (2004). Regulation of oxidative stress 
by ATM is required for self-renewal of haematopoietic stem cells. Nature 431, 997-1002. 
Ito, K., Hirao, A., Arai, F., Takubo, K., Matsuoka, S., Miyamoto, K., Ohmura, M., Naka, K., 
Hosokawa, K., Ikeda, Y., and Suda, T. (2006). Reactive oxygen species act through p38 
MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12, 446-451. 
Itoh, N., Cao, J., Chen, Z. H., Yoshida, Y., and Niki, E. (2007). Advantages and limitation of 
BODIPY as a probe for the evaluation of lipid peroxidation and its inhibition by 
antioxidants in plasma. Bioorg Med Chem Lett 17, 2059-2063. 
Ivanova, A., Signore, M., Caro, N., Greene, N. D., Copp, A. J., and Martinez-Barbera, J. P. 
(2005). In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment 
A. Genesis 43, 129-135. 
Jager, R., Maurer, J., Jacob, A., and Schorle, H. (2004). Cell type-specific conditional 
regulation of the c-myc proto-oncogene by combining Cre/loxP recombination and 
tamoxifen-mediated activation. Genesis 38, 145-150. 
Jakupoglu, C., Przemeck, G. K., Schneider, M., Moreno, S. G., Mayr, N., Hatzopoulos, A. K., 
de Angelis, M. H., Wurst, W., Bornkamm, G. W., Brielmeier, M., and Conrad, M. (2005). 
Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for 
cardiac development. Mol Cell Biol 25, 1980-1988. 
Jeong, W., Park, S. J., Chang, T. S., Lee, D. Y., and Rhee, S. G. (2006). Molecular 
mechanism of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by 
mammalian sulfiredoxin. J Biol Chem 281, 14400-14407. 
Jin, D. Y., Chae, H. Z., Rhee, S. G., and Jeang, K. T. (1997). Regulatory role for a novel 
human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem 272, 30952-30961. 
Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G., and Waxman, S. (1999). Arsenic 
trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen 
peroxide-dependent pathway. Blood 94, 2102-2111. 
Jones, D. P., Go, Y. M., Anderson, C. L., Ziegler, T. R., Kinkade, J. M., Jr., and Kirlin, W. G. 
(2004). Cysteine/cystine couple is a newly recognized node in the circuitry for biologic 
redox signaling and control. Faseb J 18, 1246-1248. 
Jonsson, T. J., Tsang, A. W., Lowther, W. T., and Furdui, C. M. (2008). Identification of intact 
protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin 
by human sulfiredoxin. J Biol Chem 283, 22890-22894. 
Kang, S. W., Baines, I. C., and Rhee, S. G. (1998a). Characterization of a mammalian 
peroxiredoxin that contains one conserved cysteine. J Biol Chem 273, 6303-6311. 
Kang, S. W., Chae, H. Z., Seo, M. S., Kim, K., Baines, I. C., and Rhee, S. G. (1998b). 
Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response 
to growth factors and tumor necrosis factor-alpha. J Biol Chem 273, 6297-6302. 
Kang, S. W., Chang, T. S., Lee, T. H., Kim, E. S., Yu, D. Y., and Rhee, S. G. (2004). 
Cytosolic peroxiredoxin attenuates the activation of Jnk and p38 but potentiates that of 
Erk in Hela cells stimulated with tumor necrosis factor-alpha. J Biol Chem 279, 2535-
2543. 
 118
  References 
Karunagaran, D., Joseph, J., and Kumar, T. R. (2007). Cell growth regulation. Adv Exp Med 
Biol 595, 245-268. 
Keightley, J. A., Anitori, R., Burton, M. D., Quan, F., Buist, N. R., and Kennaway, N. G. 
(2000). Mitochondrial encephalomyopathy and complex III deficiency associated with a 
stop-codon mutation in the cytochrome b gene. Am J Hum Genet 67, 1400-1410. 
Kiermayer, C., Michalke, B., Schmidt, J., and Brielmeier, M. (2007). Effect of selenium on 
thioredoxin reductase activity in Txnrd1 or Txnrd2 hemizygous mice. Biol Chem 388, 
1091-1097. 
Kim, H. J., Chae, H. Z., Kim, Y. J., Kim, Y. H., Hwangs, T. S., Park, E. M., and Park, Y. M. 
(2003a). Preferential elevation of Prx I and Trx expression in lung cancer cells following 
hypoxia and in human lung cancer tissues. Cell Biol Toxicol 19, 285-298. 
Kim, M. R., Chang, H. S., Kim, B. H., Kim, S., Baek, S. H., Kim, J. H., Lee, S. R., and Kim, J. 
R. (2003b). Involvements of mitochondrial thioredoxin reductase (TrxR2) in cell 
proliferation. Biochem Biophys Res Commun 304, 119-124. 
Kim, S. Y., Kim, T. J., and Lee, K. Y. (2008). A novel function of peroxiredoxin 1 (Prx-1) in 
apoptosis signal-regulating kinase 1 (ASK1)-mediated signaling pathway. FEBS Lett 582, 
1913-1918. 
Kinnula, V. L., Lehtonen, S., Kaarteenaho-Wiik, R., Lakari, E., Paakko, P., Kang, S. W., 
Rhee, S. G., and Soini, Y. (2002). Cell specific expression of peroxiredoxins in human 
lung and pulmonary sarcoidosis. Thorax 57, 157-164. 
Kinzy, S. A., Caban, K., and Copeland, P. R. (2005). Characterization of the SECIS binding 
protein 2 complex required for the co-translational insertion of selenocysteine in 
mammals. Nucleic Acids Res 33, 5172-5180. 
Krol, A. (2002). Evolutionarily different RNA motifs and RNA-protein complexes to achieve 
selenoprotein synthesis. Biochimie 84, 765-774. 
Kumar, S., Bjornstedt, M., and Holmgren, A. (1992). Selenite is a substrate for calf thymus 
thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of 
NADPH in the presence of oxygen. Eur J Biochem 207, 435-439. 
Kwon, J., Lee, S. R., Yang, K. S., Ahn, Y., Kim, Y. J., Stadtman, E. R., and Rhee, S. G. 
(2004). Reversible oxidation and inactivation of the tumor suppressor PTEN in cells 
stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101, 16419-16424. 
Lammers, M., and Follmann, H. (1984). Deoxyribonucleotide biosynthesis in yeast 
(Saccharomyces cerevisiae). A ribonucleotide reductase system of sufficient activity for 
DNA synthesis. Eur J Biochem 140, 281-287. 
Laurent, A., Nicco, C., Chereau, C., Goulvestre, C., Alexandre, J., Alves, A., Levy, E., 
Goldwasser, F., Panis, Y., Soubrane, O., et al. (2005). Controlling tumor growth by 
modulating endogenous production of reactive oxygen species. Cancer Res 65, 948-956. 
Laurent, T. C., Moore, E. C., and Reichard, P. (1964). Enzymatic Synthesis of 
Deoxyribonucleotides. Iv. Isolation and Characterization of Thioredoxin, the Hydrogen 
Donor from Escherichia Coli B. J Biol Chem 239, 3436-3444. 
Lebovitz, R. M., Zhang, H., Vogel, H., Cartwright, J., Jr., Dionne, L., Lu, N., Huang, S., and 
Matzuk, M. M. (1996). Neurodegeneration, myocardial injury, and perinatal death in 
mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93, 9782-
9787. 
Lee, S. R., Kim, J. R., Kwon, K. S., Yoon, H. W., Levine, R. L., Ginsburg, A., and Rhee, S. G. 
(1999). Molecular cloning and characterization of a mitochondrial selenocysteine-
containing thioredoxin reductase from rat liver. J Biol Chem 274, 4722-4734. 
 119
  References 
Lerman-Sagie, T., Rustin, P., Lev, D., Yanoov, M., Leshinsky-Silver, E., Sagie, A., Ben-Gal, 
T., and Munnich, A. (2001). Dramatic improvement in mitochondrial cardiomyopathy 
following treatment with idebenone. J Inherit Metab Dis 24, 28-34. 
Lescure, A., Gautheret, D., Carbon, P., and Krol, A. (1999). Novel selenoproteins identified in 
silico and in vivo by using a conserved RNA structural motif. J Biol Chem 274, 38147-
38154. 
Li, L., Shoji, W., Takano, H., Nishimura, N., Aoki, Y., Takahashi, R., Goto, S., Kaifu, T., 
Takai, T., and Obinata, M. (2007). Increased susceptibility of MER5 (peroxiredoxin III) 
knockout mice to LPS-induced oxidative stress. Biochem Biophys Res Commun 355, 
715-721. 
Lim, J. C., Choi, H. I., Park, Y. S., Nam, H. W., Woo, H. A., Kwon, K. S., Kim, Y. S., Rhee, S. 
G., Kim, K., and Chae, H. Z. (2008). Irreversible oxidation of the active-site cysteine of 
peroxiredoxin to cysteine sulfonic acid for enhanced molecular chaperone activity. J Biol 
Chem 283, 28873-28880. 
Lothrop, A. P., Ruggles, E. L., and Hondal, R. J. (2009). No selenium required: reactions 
catalyzed by mammalian thioredoxin reductase that are independent of a selenocysteine 
residue. Biochemistry 48, 6213-6223. 
Low, S. C., and Berry, M. J. (1996). Knowing when not to stop: selenocysteine incorporation 
in eukaryotes. Trends Biochem Sci 21, 203-208. 
Lu, J., Chew, E. H., and Holmgren, A. (2007). Targeting thioredoxin reductase is a basis for 
cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104, 12288-12293. 
Maiti, B., Arbogast, S., Allamand, V., Moyle, M. W., Anderson, C. B., Richard, P., Guicheney, 
P., Ferreiro, A., Flanigan, K. M., and Howard, M. T. (2009). A mutation in the SEPN1 
selenocysteine redefinition element (SRE) reduces selenocysteine incorporation and 
leads to SEPN1-related myopathy. Hum Mutat 30, 411-416. 
Martins, N. M., Santos, N. A., Curti, C., Bianchi, M. L., and Santos, A. C. (2008). Cisplatin 
induces mitochondrial oxidative stress with resultant energetic metabolism impairment, 
membrane rigidification and apoptosis in rat liver. J Appl Toxicol 28, 337-344. 
Massie, A., Schallier, A., Mertens, B., Vermoesen, K., Bannai, S., Sato, H., Smolders, I., and 
Michotte, Y. (2008). Time-dependent changes in striatal xCT protein expression in hemi-
Parkinson rats. Neuroreport 19, 1589-1592. 
Matsui, M., Oshima, M., Oshima, H., Takaku, K., Maruyama, T., Yodoi, J., and Taketo, M. M. 
(1996). Early embryonic lethality caused by targeted disruption of the mouse thioredoxin 
gene. Dev Biol 178, 179-185. 
Matsushima, S., Ide, T., Yamato, M., Matsusaka, H., Hattori, F., Ikeuchi, M., Kubota, T., 
Sunagawa, K., Hasegawa, Y., Kurihara, T., et al. (2006). Overexpression of mitochondrial 
peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction 
in mice. Circulation 113, 1779-1786. 
Maulik, N., Yoshida, T., Engelman, R. M., Deaton, D., Flack, J. E., 3rd, Rousou, J. A., and 
Das, D. K. (1998). Ischemic preconditioning attenuates apoptotic cell death associated 
with ischemia/reperfusion. Mol Cell Biochem 186, 139-145. 
May, J. M., Cobb, C. E., Mendiratta, S., Hill, K. E., and Burk, R. F. (1998). Reduction of the 
ascorbyl free radical to ascorbate by thioredoxin reductase. J Biol Chem 273, 23039-
23045. 
Mazumder, S., Plesca, D., and Almasan, A. (2007). A jekyll and hyde role of cyclin E in the 
genotoxic stress response: switching from cell cycle control to apoptosis regulation. Cell 
Cycle 6, 1437-1442. 
 120
  References 
Miller, E. W., Albers, A. E., Pralle, A., Isacoff, E. Y., and Chang, C. J. (2005). Boronate-
based fluorescent probes for imaging cellular hydrogen peroxide. J Am Chem Soc 127, 
16652-16659. 
Miranda-Vizuete, A., Damdimopoulos, A. E., Pedrajas, J. R., Gustafsson, J. A., and Spyrou, 
G. (1999). Human mitochondrial thioredoxin reductase cDNA cloning, expression and 
genomic organization. Eur J Biochem 261, 405-412. 
Miranda-Vizuete, A., and Spyrou, G. (2002). Genomic organization and identification of a 
novel alternative splicing variant of mouse mitochondrial thioredoxin reductase (TrxR2) 
gene. Mol Cells 13, 488-492. 
Mizusawa, H., Ishii, T., and Bannai, S. (2000). Peroxiredoxin I (macrophage 23 kDa stress 
protein) is highly and widely expressed in the rat nervous system. Neurosci Lett 283, 57-
60. 
Moghadaszadeh, B., Petit, N., Jaillard, C., Brockington, M., Roy, S. Q., Merlini, L., Romero, 
N., Estournet, B., Desguerre, I., Chaigne, D., et al. (2001). Mutations in SEPN1 cause 
congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. 
Nat Genet 29, 17-18. 
Moos, P. J., Edes, K., Cassidy, P., Massuda, E., and Fitzpatrick, F. A. (2003). Electrophilic 
prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and 
hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol 
Chem 278, 745-750. 
Nalvarte, I., Damdimopoulos, A. E., Nystom, C., Nordman, T., Miranda-Vizuete, A., Olsson, 
J. M., Eriksson, L., Bjornstedt, M., Arner, E. S., and Spyrou, G. (2004a). Overexpression 
of enzymatically active human cytosolic and mitochondrial thioredoxin reductase in HEK-
293 cells. Effect on cell growth and differentiation. J Biol Chem 279, 54510-54517. 
Nalvarte, I., Damdimopoulos, A. E., and Spyrou, G. (2004b). Human mitochondrial 
thioredoxin reductase reduces cytochrome c and confers resistance to complex III 
inhibition. Free Radic Biol Med 36, 1270-1278. 
Nguyen, P., Awwad, R. T., Smart, D. D., Spitz, D. R., and Gius, D. (2006). Thioredoxin 
reductase as a novel molecular target for cancer therapy. Cancer Lett 236, 164-174. 
Noh, D. Y., Ahn, S. J., Lee, R. A., Kim, S. W., Park, I. A., and Chae, H. Z. (2001). 
Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21, 2085-2090. 
Noh, Y. H., Baek, J. Y., Jeong, W., Rhee, S. G., and Chang, T. S. (2009). Sulfiredoxin 
Translocation into Mitochondria Plays a Crucial Role in Reducing Hyperoxidized 
Peroxiredoxin III. J Biol Chem 284, 8470-8477. 
Nonn, L., Berggren, M., and Powis, G. (2003a). Increased expression of mitochondrial 
peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and 
drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1, 682-689. 
Nonn, L., Williams, R. R., Erickson, R. P., and Powis, G. (2003b). The absence of 
mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early 
embryonic lethality in homozygous mice. Mol Cell Biol 23, 916-922. 
Nordberg, J., and Arner, E. S. (2001). Reactive oxygen species, antioxidants, and the 
mammalian thioredoxin system. Free Radic Biol Med 31, 1287-1312. 
Oberley, T. D., Verwiebe, E., Zhong, W., Kang, S. W., and Rhee, S. G. (2001). Localization 
of the thioredoxin system in normal rat kidney. Free Radic Biol Med 30, 412-424. 
Ogasawara, M. A., and Zhang, H. (2008). Redox Regulation and its Emerging Roles in Stem 
Cells and Stem-Like Cancer Cells. Antioxid Redox Signal. 
 
 121
  References 
Ohashi, T., Mizutani, A., Murakami, A., Kojo, S., Ishii, T., and Taketani, S. (2002). Rapid 
oxidation of dichlorodihydrofluorescin with heme and hemoproteins: formation of the 
fluorescein is independent of the generation of reactive oxygen species. FEBS Lett 511, 
21-27. 
Okado-Matsumoto, A., Matsumoto, A., Fujii, J., and Taniguchi, N. (2000). Peroxiredoxin IV is 
a secretable protein with heparin-binding properties under reduced conditions. J Biochem 
127, 493-501. 
Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tamba, M., Wang, H., Sohda, S., Hamada, 
H., Yoshikawa, H., Kondo, T., and Bannai, S. (2003). Role of cystine transport in 
intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. 
Br J Cancer 88, 951-956. 
Osawa, M., Hanada, K., Hamada, H., and Nakauchi, H. (1996). Long-term 
lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem 
cell. Science 273, 242-245. 
Pacheco, R., Gallart, T., Lluis, C., and Franco, R. (2007). Role of glutamate on T-cell 
mediated immunity. J Neuroimmunol 185, 9-19. 
Papp, L. V., Lu, J., Striebel, F., Kennedy, D., Holmgren, A., and Khanna, K. K. (2006). The 
redox state of SECIS binding protein 2 controls its localization and selenocysteine 
incorporation function. Mol Cell Biol 26, 4895-4910. 
Park, H. S., Lee, S. H., Park, D., Lee, J. S., Ryu, S. H., Lee, W. J., Rhee, S. G., and Bae, Y. 
S. (2004a). Sequential activation of phosphatidylinositol 3-kinase, beta Pix, Rac1, and 
Nox1 in growth factor-induced production of H2O2. Mol Cell Biol 24, 4384-4394. 
Park, J. Y., Seong, J. K., and Paik, Y. K. (2004b). Proteomic analysis of diet-induced 
hypercholesterolemic mice. Proteomics 4, 514-523. 
Patenaude, A., Ven Murthy, M. R., and Mirault, M. E. (2004). Mitochondrial thioredoxin 
system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J 
Biol Chem 279, 27302-27314. 
Pedrajas, J. R., Miranda-Vizuete, A., Javanmardy, N., Gustafsson, J. A., and Spyrou, G. 
(2000). Mitochondria of Saccharomyces cerevisiae contain one-conserved cysteine type 
peroxiredoxin with thioredoxin peroxidase activity. J Biol Chem 275, 16296-16301. 
Pennington, J. D., Jacobs, K. M., Sun, L., Bar-Sela, G., Mishra, M., and Gius, D. (2007). 
Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer 
therapy. Curr Pharm Des 13, 3368-3377. 
Persson-Moschos, M. E., Stavenow, L., Akesson, B., and Lindgarde, F. (2000). 
Selenoprotein P in plasma in relation to cancer morbidity in middle-aged Swedish men. 
Nutr Cancer 36, 19-26. 
Powis, G., Gasdaska, J. R., and Baker, A. (1997a). Redox signaling and the control of cell 
growth and death. Adv Pharmacol 38, 329-359. 
Powis, G., Gasdaska, J. R., Gasdaska, P. Y., Berggren, M., Kirkpatrick, D. L., Engman, L., 
Cotgreave, I. A., Angulo, M., and Baker, A. (1997b). Selenium and the thioredoxin redox 
system: effects on cell growth and death. Oncol Res 9, 303-312. 
Qiao, H. X., Hao, C. J., Li, Y., He, X., Chen, R. S., Cui, J., Xu, Z. H., and Li, W. (2008). JNK 
activation mediates the apoptosis of xCT-deficient cells. Biochem Biophys Res Commun 
370, 584-588. 
Rabilloud, T., Heller, M., Gasnier, F., Luche, S., Rey, C., Aebersold, R., Benahmed, M., 
Louisot, P., and Lunardi, J. (2002). Proteomics analysis of cellular response to oxidative 
stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol 
Chem 277, 19396-19401. 
 122
  References 
Reichard, P. (1988). Interactions between deoxyribonucleotide and DNA synthesis. Annu 
Rev Biochem 57, 349-374. 
Rhee, S. G. (1999). Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol 
Med 31, 53-59. 
Rhee, S. G., Bae, Y. S., Lee, S.-R. a., and Kwon, J. (2000). Hydrogen peroxide: a key 
messenger that modulates protein phosphorylation through cysteine oxidation. 
Science'sstke 2000, p. pe1-6. 
Rhee, S. G., Chae, H. Z., and Kim, K. (2005). Peroxiredoxins: a historical overview and 
speculative preview of novel mechanisms and emerging concepts in cell signaling. Free 
Radic Biol Med 38, 1543-1552. 
Rhee, S. G., Jeong, W., Chang, T. S., and Woo, H. A. (2007). Sulfiredoxin, the cysteine 
sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of 
action, and biological significance. Kidney Int Suppl, S3-8. 
Rhee, S. G., Kang, S. W., Chang, T. S., Jeong, W., and Kim, K. (2001). Peroxiredoxin, a 
novel family of peroxidases. IUBMB Life 52, 35-41. 
Rieger, M. A., Hoppe, P. S., Smejkal, B. M., Eitelhuber, A. C., and Schroeder, T. (2009). 
Hematopoietic cytokines can instruct lineage choice. Science 325, 217-218. 
Rohrbach, S., Gruenler, S., Teschner, M., and Holtz, J. (2006). The thioredoxin system in 
aging muscle: key role of mitochondrial thioredoxin reductase in the protective effects of 
caloric restriction? Am J Physiol Regul Integr Comp Physiol 291, R927-935. 
Roussel, X., Bechade, G., Kriznik, A., Van Dorsselaer, A., Sanglier-Cianferani, S., Branlant, 
G., and Rahuel-Clermont, S. (2008). Evidence for the formation of a covalent thiosulfinate 
intermediate with peroxiredoxin in the catalytic mechanism of sulfiredoxin. J Biol Chem 
283, 22371-22382. 
Rozen, S., and Skaletsky, H. (2000). Primer3 on the WWW for general users and for 
biologist programmers. Methods Mol Biol 132, 365-386. 
Rundlof, A. K., and Arner, E. S. (2004). Regulation of the mammalian selenoprotein 
thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. 
Antioxid Redox Signal 6, 41-52. 
Rundlof, A. K., Carlsten, M., Giacobini, M. M., and Arner, E. S. (2000). Prominent expression 
of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and 
thioredoxin reductase mRNA variants differing at the 5' untranslated region. Biochem J 
347 Pt 3, 661-668. 
Rundlof, A. K., Fernandes, A. P., Selenius, M., Babic, M., Shariatgorji, M., Nilsonne, G., Ilag, 
L. L., Dobra, K., and Bjornstedt, M. (2007). Quantification of alternative mRNA species 
and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation 
75, 123-132. 
Saelens, X., Festjens, N., Vande Walle, L., van Gurp, M., van Loo, G., and Vandenabeele, P. 
(2004). Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861-
2874. 
Sandalova, T., Zhong, L., Lindqvist, Y., Holmgren, A., and Schneider, G. (2001). Three-
dimensional structure of a mammalian thioredoxin reductase: implications for mechanism 
and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci U S A 98, 
9533-9538. 
Sasaki, H., Sato, H., Kuriyama-Matsumura, K., Sato, K., Maebara, K., Wang, H., Tamba, M., 
Itoh, K., Yamamoto, M., and Bannai, S. (2002). Electrophile response element-mediated 
induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem 
277, 44765-44771. 
 123
  References 
Sato, H., Ishii, T., Sugita, Y., and Bannai, S. (1991). Induction of cationic amino acid 
transport activity in mouse peritoneal macrophages by lipopolysaccharide. Biochim 
Biophys Acta 1069, 46-52. 
Sato, H., Shiiya, A., Kimata, M., Maebara, K., Tamba, M., Sakakura, Y., Makino, N., 
Sugiyama, F., Yagami, K., Moriguchi, T., et al. (2005). Redox imbalance in 
cystine/glutamate transporter-deficient mice. J Biol Chem 280, 37423-37429. 
Sato, H., Tamba, M., Kuriyama-Matsumura, K., Okuno, S., and Bannai, S. (2000). Molecular 
cloning and expression of human xCT, the light chain of amino acid transport system xc. 
Antioxid Redox Signal 2, 665-671. 
Sato, H., Tamba, M., Okuno, S., Sato, K., Keino-Masu, K., Masu, M., and Bannai, S. (2002). 
Distribution of cystine/glutamate exchange transporter, system x(c)-, in the mouse brain. 
J Neurosci 22, 8028-8033. 
Sato, H., Watanabe, H., Ishii, T., and Bannai, S. (1987). Neutral amino acid transport in 
mouse peritoneal macrophages. J Biol Chem 262, 13015-13019. 
Savaskan, N. E., Heckel, A., Hahnen, E., Engelhorn, T., Doerfler, A., Ganslandt, O., Nimsky, 
C., Buchfelder, M., and Eyupoglu, I. Y. (2008). Small interfering RNA-mediated xCT 
silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14, 
629-632. 
Sawicki, J. A., Morris, R. J., Monks, B., Sakai, K., and Miyazaki, J. (1998). A composite CMV-
IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous 
epithelium. Exp Cell Res 244, 367-369. 
Schneider, M., Forster, H., Boersma, A., Seiler, A., Wehnes, H., Sinowatz, F., Neumuller, C., 
Deutsch, M. J., Walch, A., Hrabe de Angelis, M., et al. (2009). Mitochondrial glutathione 
peroxidase 4 disruption causes male infertility. Faseb J. 
Schroder, E., Littlechild, J. A., Lebedev, A. A., Errington, N., Vagin, A. A., and Isupov, M. N. 
(2000). Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 
1.7 A resolution. Structure 8, 605-615. 
Schweizer, U., Brauer, A. U., Kohrle, J., Nitsch, R., and Savaskan, N. E. (2004). Selenium 
and brain function: a poorly recognized liaison. Brain Res Brain Res Rev 45, 164-178. 
Seemann, S., and Hainaut, P. (2005). Roles of thioredoxin reductase 1 and APE/Ref-1 in the 
control of basal p53 stability and activity. Oncogene 24, 3853-3863. 
Seiler, A. (2008). Dissecting the molecular mechanism of glutathione-dependent regulation of 
cell proliferation and cell death. 
Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., Culmsee, C., Plesnila, N., 
Kremmer, E., Radmark, O., Wurst, W., et al. (2008). Glutathione peroxidase 4 senses 
and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated 
cell death. Cell Metab 8, 237-248. 
Selenius, M., Fernandes, A. P., Brodin, O., Bjornstedt, M., and Rundlof, A. K. (2008). 
Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the 
thioredoxin system. Biochem Pharmacol 75, 2092-2099. 
Seo, M. S., Kang, S. W., Kim, K., Baines, I. C., Lee, T. H., and Rhee, S. G. (2000). 
Identification of a new type of mammalian peroxiredoxin that forms an intramolecular 
disulfide as a reaction intermediate. J Biol Chem 275, 20346-20354. 
Shigenaga, M. K., Hagen, T. M., and Ames, B. N. (1994). Oxidative damage and 
mitochondrial decay in aging. Proc Natl Acad Sci U S A 91, 10771-10778. 
Shih, A. Y., and Murphy, T. H. (2001). xCt cystine transporter expression in HEK293 cells: 
pharmacology and localization. Biochem Biophys Res Commun 282, 1132-1137. 
 124
  References 
Small-Howard, A., Morozova, N., Stoytcheva, Z., Forry, E. P., Mansell, J. B., Harney, J. W., 
Carlson, B. A., Xu, X. M., Hatfield, D. L., and Berry, M. J. (2006). Supramolecular 
complexes mediate selenocysteine incorporation in vivo. Mol Cell Biol 26, 2337-2346. 
Soerensen, J., Jakupoglu, C., Beck, H., Forster, H., Schmidt, J., Schmahl, W., Schweizer, U., 
Conrad, M., and Brielmeier, M. (2008). The role of thioredoxin reductases in brain 
development. PLoS ONE 3, e1813. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat 
Genet 21, 70-71. 
Spyrou, G., Enmark, E., Miranda-Vizuete, A., and Gustafsson, J. (1997). Cloning and 
expression of a novel mammalian thioredoxin. J Biol Chem 272, 2936-2941. 
Srinivas, S., Watanabe, T., Lin, C. S., William, C. M., Tanabe, Y., Jessell, T. M., and 
Costantini, F. (2001). Cre reporter strains produced by targeted insertion of EYFP and 
ECFP into the ROSA26 locus. BMC Dev Biol 1, 4. 
Stadtman, T. C. (1991). Biosynthesis and function of selenocysteine-containing enzymes. J 
Biol Chem 266, 16257-16260. 
Su, D., and Gladyshev, V. N. (2004). Alternative splicing involving the thioredoxin reductase 
module in mammals: a glutaredoxin-containing thioredoxin reductase 1. Biochemistry 43, 
12177-12188. 
Su, D., Novoselov, S. V., Sun, Q. A., Moustafa, M. E., Zhou, Y., Oko, R., Hatfield, D. L., and 
Gladyshev, V. N. (2005). Mammalian selenoprotein thioredoxin-glutathione reductase. 
Roles in disulfide bond formation and sperm maturation. J Biol Chem 280, 26491-26498. 
Sun, Q. A., Kirnarsky, L., Sherman, S., and Gladyshev, V. N. (2001a). Selenoprotein 
oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad 
Sci U S A 98, 3673-3678. 
Sun, Q. A., Su, D., Novoselov, S. V., Carlson, B. A., Hatfield, D. L., and Gladyshev, V. N. 
(2005). Reaction mechanism and regulation of mammalian thioredoxin/glutathione 
reductase. Biochemistry 44, 14528-14537. 
Sun, Q. A., Wu, Y., Zappacosta, F., Jeang, K. T., Lee, B. J., Hatfield, D. L., and Gladyshev, 
V. N. (1999). Redox regulation of cell signaling by selenocysteine in mammalian 
thioredoxin reductases. J Biol Chem 274, 24522-24530. 
Sun, Q. A., Zappacosta, F., Factor, V. M., Wirth, P. J., Hatfield, D. L., and Gladyshev, V. N. 
(2001b). Heterogeneity within animal thioredoxin reductases. Evidence for alternative first 
exon splicing. J Biol Chem 276, 3106-3114. 
Tagami, M., Yamagata, K., Ikeda, K., Nara, Y., Fujino, H., Kubota, A., Numano, F., and 
Yamori, Y. (1998). Vitamin E prevents apoptosis in cortical neurons during hypoxia and 
oxygen reperfusion. Lab Invest 78, 1415-1429. 
Tajsharghi, H., Darin, N., Tulinius, M., and Oldfors, A. (2005). Early onset myopathy with a 
novel mutation in the Selenoprotein N gene (SEPN1). Neuromuscul Disord 15, 299-302. 
Talbot, S., Nelson, R., and Self, W. T. (2008). Arsenic trioxide and auranofin inhibit 
selenoprotein synthesis: implications for chemotherapy for acute promyelocytic 
leukaemia. Br J Pharmacol 154, 940-948. 
Tamura, T., and Stadtman, T. C. (1996). A new selenoprotein from human lung 
adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc 
Natl Acad Sci U S A 93, 1006-1011. 
Tanaka, T., Hosoi, F., Yamaguchi-Iwai, Y., Nakamura, H., Masutani, H., Ueda, S., 
Nishiyama, A., Takeda, S., Wada, H., Spyrou, G., and Yodoi, J. (2002). Thioredoxin-2 
(TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. Embo J 21, 
1695-1703. 
 125
  References 
Tanaka, T., Nakamura, H., Nishiyama, A., Hosoi, F., Masutani, H., Wada, H., and Yodoi, J. 
(2000). Redox regulation by thioredoxin superfamily; protection against oxidative stress 
and aging. Free Radical Research 33, 851-855. 
Thelander, L., and Reichard, P. (1979). Reduction of ribonucleotides. Annu Rev Biochem 48, 
133-158. 
Toohey, J. I. (1975). Sulfhydryl dependence in primary explant hematopoietic cells. Inhibition 
of growth in vitro with vitamin B12 compounds. Proc Natl Acad Sci U S A 72, 73-77. 
Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., 
Achanta, G., Arlinghaus, R. B., Liu, J., and Huang, P. (2006). Selective killing of 
oncogenically transformed cells through a ROS-mediated mechanism by beta-
phenylethyl isothiocyanate. Cancer Cell 10, 241-252. 
Tsutsui, H., Kinugawa, S., and Matsushima, S. (2009). Mitochondrial oxidative stress and 
dysfunction in myocardial remodelling. Cardiovasc Res 81, 449-456. 
Tujebajeva, R. M., Copeland, P. R., Xu, X. M., Carlson, B. A., Harney, J. W., Driscoll, D. M., 
Hatfield, D. L., and Berry, M. J. (2000). Decoding apparatus for eukaryotic selenocysteine 
insertion. EMBO Rep 1, 158-163. 
Turanov, A. A., Su, D., and Gladyshev, V. N. (2006). Characterization of alternative cytosolic 
forms and cellular targets of mouse mitochondrial thioredoxin reductase. J Biol Chem 
281, 22953-22963. 
van Zandwijk, N. (1995). N-acetylcysteine for lung cancer prevention. Chest 107, 1437-1441. 
Veal, E. A., Day, A. M., and Morgan, B. A. (2007). Hydrogen peroxide sensing and signaling. 
Mol Cell 26, 1-14. 
Veal, E. A., Findlay, V. J., Day, A. M., Bozonet, S. M., Evans, J. M., Quinn, J., and Morgan, 
B. A. (2004). A 2-Cys peroxiredoxin regulates peroxide-induced oxidation and activation 
of a stress-activated MAP kinase. Mol Cell 15, 129-139. 
Walczak, R., Carbon, P., and Krol, A. (1998). An essential non-Watson-Crick base pair motif 
in 3'UTR to mediate selenoprotein translation. Rna 4, 74-84. 
Watabe, S., Hasegawa, H., Takimoto, K., Yamamoto, Y., and Takahashi, S. Y. (1995). 
Possible function of SP-22, a substrate of mitochondrial ATP-dependent protease, as a 
radical scavenger. Biochem Biophys Res Commun 213, 1010-1016. 
Watabe, S., Hiroi, T., Yamamoto, Y., Fujioka, Y., Hasegawa, H., Yago, N., and Takahashi, S. 
Y. (1997). SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur J 
Biochem 249, 52-60. 
Watabe, S., Makino, Y., Ogawa, K., Hiroi, T., Yamamoto, Y., and Takahashi, S. Y. (1999). 
Mitochondrial thioredoxin reductase in bovine adrenal cortex its purification, properties, 
nucleotide/amino acid sequences, and identification of selenocysteine. Eur J Biochem 
264, 74-84. 
Watanabe, H., and Bannai, S. (1987). Induction of cystine transport activity in mouse 
peritoneal macrophages. J Exp Med 165, 628-640. 
Williams, C. H., Arscott, L. D., Muller, S., Lennon, B. W., Ludwig, M. L., Wang, P. F., Veine, 
D. M., Becker, K., and Schirmer, R. H. (2000). Thioredoxin reductase two modes of 
catalysis have evolved. Eur J Biochem 267, 6110-6117. 
Woo, H. A., Chae, H. Z., Hwang, S. C., Yang, K. S., Kang, S. W., Kim, K., and Rhee, S. G. 
(2003a). Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid 
formation. Science 300, 653-656. 
Woo, H. A., Jeong, W., Chang, T. S., Park, K. J., Park, S. J., Yang, J. S., and Rhee, S. G. 
(2005). Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys 
peroxiredoxins. J Biol Chem 280, 3125-3128. 
 126
  References 
Woo, H. A., Kang, S. W., Kim, H. K., Yang, K. S., Chae, H. Z., and Rhee, S. G. (2003b). 
Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid. 
Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing 
sequence. J Biol Chem 278, 47361-47364. 
Wood, Z. A., Schroder, E., Robin Harris, J., and Poole, L. B. (2003). Structure, mechanism 
and regulation of peroxiredoxins. Trends Biochem Sci 28, 32-40. 
Wu, S. J., Ng, L. T., and Lin, C. C. (2005). Effects of antioxidants and caspase-3 inhibitor on 
the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human 
PLC/PRF/5 cells. Eur J Pharmacol 518, 96-106. 
Xu, G. L., Wang, S. C., Gu, B. Q., Yang, Y. X., Song, H. B., Xue, W. L., Liang, W. S., and 
Zhang, P. Y. (1997). Further investigation on the role of selenium deficiency in the 
aetiology and pathogenesis of Keshan disease. Biomed Environ Sci 10, 316-326. 
Xu, X. M., Carlson, B. A., Mix, H., Zhang, Y., Saira, K., Glass, R. S., Berry, M. J., Gladyshev, 
V. N., and Hatfield, D. L. (2007). Biosynthesis of selenocysteine on its tRNA in 
eukaryotes. PLoS Biol 5, e4. 
Xu, X. M., Mix, H., Carlson, B. A., Grabowski, P. J., Gladyshev, V. N., Berry, M. J., and 
Hatfield, D. L. (2005). Evidence for direct roles of two additional factors, SECp43 and 
soluble liver antigen, in the selenoprotein synthesis machinery. J Biol Chem 280, 41568-
41575. 
Yamamoto, Y., Nagata, Y., Niki, E., Watanabe, K., and Yoshimura, S. (1993). Plasma 
glutathione peroxidase reduces phosphatidylcholine hydroperoxide. Biochem Biophys 
Res Commun 193, 133-138. 
Yanagawa, T., Iwasa, S., Ishii, T., Tabuchi, K., Yusa, H., Onizawa, K., Omura, K., Harada, 
H., Suzuki, H., and Yoshida, H. (2000). Peroxiredoxin I expression in oral cancer: a 
potential new tumor marker. Cancer Lett 156, 27-35. 
Yang, K. S., Kang, S. W., Woo, H. A., Hwang, S. C., Chae, H. Z., Kim, K., and Rhee, S. G. 
(2002). Inactivation of human peroxiredoxin I during catalysis as the result of the 
oxidation of the catalytic site cysteine to cysteine-sulfinic acid. J Biol Chem 277, 38029-
38036. 
Yang, M., Nazhat, N. B., Jiang, X., Kelsey, S. M., Blake, D. R., Newland, A. C., and Morris, 
C. J. (1996). Adriamycin stimulates proliferation of human lymphoblastic leukaemic cells 
via a mechanism of hydrogen peroxide (H2O2) production. Br J Haematol 95, 339-344. 
Yoo, M. H., Xu, X. M., Carlson, B. A., Patterson, A. D., Gladyshev, V. N., and Hatfield, D. L. 
(2007). Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient 
growth and DNA replication. PLoS ONE 2, e1112. 
Yoshida, T., Maulik, N., Engelman, R. M., Ho, Y. S., Magnenat, J. L., Rousou, J. A., Flack, J. 
E., 3rd, Deaton, D., and Das, D. K. (1997). Glutathione peroxidase knockout mice are 
susceptible to myocardial ischemia reperfusion injury. Circulation 96, II-216-220. 
Yu, R., Mandlekar, S., Harvey, K. J., Ucker, D. S., and Kong, A. N. (1998). Chemopreventive 
isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res 58, 
402-408. 
Zavacki, A. M., Mansell, J. B., Chung, M., Klimovitsky, B., Harney, J. W., and Berry, M. J. 
(2003). Coupled tRNA(Sec)-dependent assembly of the selenocysteine decoding 
apparatus. Mol Cell 11, 773-781. 
Zhang, H., Go, Y. M., and Jones, D. P. (2007). Mitochondrial thioredoxin-2/peroxiredoxin-3 
system functions in parallel with mitochondrial GSH system in protection against 
oxidative stress. Arch Biochem Biophys 465, 119-126. 
 127
  References 
Zhang, P., Liu, B., Kang, S. W., Seo, M. S., Rhee, S. G., and Obeid, L. M. (1997). 
Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from 
that of Bcl-2. J Biol Chem 272, 30615-30618. 
Zhang, Y., Tang, L., and Gonzalez, V. (2003). Selected isothiocyanates rapidly induce 
growth inhibition of cancer cells. Mol Cancer Ther 2, 1045-1052. 
Zhao, W., Fan, G. C., Zhang, Z. G., Bandyopadhyay, A., Zhou, X., and Kranias, E. G. (2009). 
Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and 
apoptosis. Basic Res Cardiol 104, 377-389. 
Zhong, L., Arner, E. S., and Holmgren, A. (2000). Structure and mechanism of mammalian 
thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide 
formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A 
97, 5854-5859. 
Zhong, L., Arner, E. S., Ljung, J., Aslund, F., and Holmgren, A. (1998). Rat and calf 
thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal 
elongation containing a conserved catalytically active penultimate selenocysteine 
residue. J Biol Chem 273, 8581-8591. 
Zhong, L., and Holmgren, A. (2000). Essential role of selenium in the catalytic activities of 
mammalian thioredoxin reductase revealed by characterization of recombinant enzymes 
with selenocysteine mutations. J Biol Chem 275, 18121-18128. 
Zhou, J., Eleni, C., Spyrou, G., and Brune, B. (2008). The mitochondrial thioredoxin system 
regulates nitric oxide-induced HIF-1alpha protein. Free Radic Biol Med 44, 91-98. 
Zhou, Y., Kok, K. H., Chun, A. C., Wong, C. M., Wu, H. W., Lin, M. C., Fung, P. C., Kung, H., 
and Jin, D. Y. (2000). Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits 
p53-induced apoptosis. Biochem Biophys Res Commun 268, 921-927. 
 
 128
  Appendix 
 129
7. Appendix 
 
7.1. Acknowledgements 
 
Standing at a crucial juncture of my academic journey and before I step across the finish line, 
its time to take a pause and to express my gratitude in retrospect to all those people who 
supported me throughout this learning process.  
I would start and would like to thank to my supervisor Dr. Marcus Conrad for his support and 
guidance. I appreciate the freedom given to me while doing my PhD thesis. He was always 
accommodative to the suggestions or criticisms, which stimulated the independent thinking.  
I am indebted to Prof. Georg W. Bornkamm for giving me the opportunity to do my PhD in 
Germany. It was a great experience working under him. His ideas and suggestions were very 
valuable which finally concluded in the form of the present manuscript.  
I express my best regards to my Dr. father Prof. Dr. Dirk Eick, for his supportive attitude 
towards me. Without his help it would have not been possible to submit the thesis in such a 
smooth manner.  
I thank my present and former lab members Ana Banjac, Madhu Sukumar, Pankaj Kumar 
Mandal, Alexander Seiler, Heidi Förster, Alexander Mannes and Katja Möllmann for 
supporting me during day-to-day work, sharing their valuable experiences and making the 
stay in the lab memorable. I wish all of them a great success in life. 
I would like to put emphasis on the help and support provided by Dr. Heike Beck, and of 
course, the members of her group: Juliane Hrdina, Matthias Semisch and Markus 
Worthmann. The unselfish help provided by Manuela Schneider at the bigining of my days in 
Munich deserve a special note of appreciation. They were the integral part of numerous 
sessions of discussion on ongoing projects. 
Also I would like to thank Pirkko Kölle from Medizinische Poliklinik Innenstadt des Klinikum 
der LMU for doing HPLC measurements which added substantial information to the thesis.  
I want to thank Dr. Elisabeth Kremmer for raising monoclonal antibody against mouse 
thioredoxin reductase 2 and human xCT for us.  
I express my sincere thank to the people of Prof. Dr. Dick Eicks lab, specially Thomas 
Harasim, Martin Heidemann, Anastassia Malamoussi, Anita Gruber-Eber for sparing 
reagents and providing support at the hour of need.  
I am very obliged to Dr. Ralf Kühn for coming up with the precise solution at the needed 
moment; without his help some of the data included would have never seen the light of the 
day. 
I am expressing my thankfulness to Dr. Josef Mautner, whom I tried to awoid at the end of 
my thesis. Time and time again I have tried to sneak through the 1st floor where he was 
working. Every time when being caught, I was compelled by unpleasant question: Why I am 
still working and not writing my thesis?  
  Appendix 
I would like to thank people of KMOLB for help and encouragement.  
The effort done by people in the animal facility is really appreciated and I thank all of them. 
Additionally, I would like to thank my friend Adriana Gil-Monux, for her support and sharing 
nice time in Munich. 
At last I want to dedicate this paragraph to acknowledge my family. Mom and Dad, thank you 
for all your mental support which was giving me great strength. And I would highlight the help 
provided by my sister, for always beliving in me, standing behind me, and having the time 
and patience when nobody would. I would like to thank Dominik Flüge, for being the 
flambeau in moments when I was stuck in dark labirinth.  
 
             
Tamara Perisic  
 
 130
  Appendix 
 131
7.2. Curriculum vitae 
 
Name: Tamara PERISIC 
Date and place of Birth: 29th May 1978, Travnik, Bosnia and Herzegovina  
Nationality: Montenegrinian 
Permanent address: Lofererstr 17, 81671 München, Germany 
E-Mail: tamara.perisic@helmholtz-muenchen.de 
 
Educational profile 
 
PhD student at the Institute Of Clinical Molecular Biology And Tumor Genetics, Helmholtz 
Zentrum München (Feb 2005 – May 2009) 
 
University education in molecular biology and physiology, Faculty of biology, Belgrade 
University, Belgrade, Serbia (Oct 1997- July 2004) 
 
List of Publications 
 
Mitochondrial Thioredoxin reductase but not cytosolic Thioredoxin reductase protects against 
myocardial ischemia-reperfusion injury: role of intrinsic apoptosis induction.  
Perisic T*, Horstkotte J*, Schneider M, Lange P, Schroeder M, Hinkel R, Foerster H, Neumüller C, Sinowatz F, 
Molkenti JD, Boekstegers P, Brielmeier M, Conrad M, Kupatt C (In preparation). 
* These author contributed equally to the manuscript 
 
Mutations in the Gene encoding mitochondrial thioredoxin reductase are associated with 
dilated cardiomyopathy.  
Perisic T*, Sibbing D*,  Pfeufer A*, Akyol M, Unwin S, Sinner MF, Jalilzadeh S, Conrad M, Bornkamm GW, 
Gieger C, Glöckner J, Wichmann HE, Hinterseer M, Näbauer M, MD, Kääb S, Meitinger T, Schömig A, Kastrati A, 
von Beckerath N. (submitted)  
* These author contributed equally to the manuscript 
 
System xC- and Thioredoxin Reductase 1 Cooperatively Rescue Glutathione Deficiency 
Perisic T*, Mandal P K* Seiler A*, Banjac-Canak A, Förster H, Kölle P, Weiss N, Lieberman M, Bannai S, Sato H, 
Kuhlencordt P, Bornkamm G.W, and Conrad M (submitted) 
* These author contributed equally to the manuscript  
 
The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell 
death. 
Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, Kölle P, Tschoep K, Issels RD, Daniel PT, Conrad M, 
Bornkamm GW. (2007). Oncogene 27: 1618-1628 
 
